
<html lang="en"     class="pb-page"  data-request-id="8e7f2179-d7d6-4ede-ae81-a0d3ef74ac58"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm2002958;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2011.54.issue-10;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates" /></meta><meta name="dc.Creator" content="Robert Y.  Zhao" /></meta><meta name="dc.Creator" content="Sharon D.  Wilhelm" /></meta><meta name="dc.Creator" content="Charlene  Audette" /></meta><meta name="dc.Creator" content="Gregory  Jones" /></meta><meta name="dc.Creator" content="Barbara A.  Leece" /></meta><meta name="dc.Creator" content="Alexandru C.  Lazar" /></meta><meta name="dc.Creator" content="Victor S.  Goldmacher" /></meta><meta name="dc.Creator" content="Rajeeva  Singh" /></meta><meta name="dc.Creator" content="Yelena  Kovtun" /></meta><meta name="dc.Creator" content="Wayne C.  Widdison" /></meta><meta name="dc.Creator" content="John M.  Lambert" /></meta><meta name="dc.Creator" content="Ravi V. J.  Chari" /></meta><meta name="dc.Description" content="The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a nega..." /></meta><meta name="Description" content="The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a nega..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 4, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm2002958" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm2002958" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm2002958" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm2002958" /></link>
        
    
    

<title>Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm2002958" /></meta><meta property="og:title" content="Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0004.jpeg" /></meta><meta property="og:description" content="The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive N-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody–maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm2002958"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm2002958">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm2002958&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm2002958&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm2002958&amp;href=/doi/10.1021/jm2002958" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 3606-3623</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm2001585" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2002469" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+Y.++Zhao">Robert Y. Zhao</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sharon+D.++Wilhelm">Sharon D. Wilhelm</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charlene++Audette">Charlene Audette</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregory++Jones">Gregory Jones</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barbara+A.++Leece">Barbara A. Leece</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexandru+C.++Lazar">Alexandru C. Lazar</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor+S.++Goldmacher">Victor S. Goldmacher</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rajeeva++Singh">Rajeeva Singh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yelena++Kovtun">Yelena Kovtun</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wayne+C.++Widdison">Wayne C. Widdison</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Lambert">John M. Lambert</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ravi+V.+J.++Chari">Ravi V. J. Chari</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div><div class="corresp-info"><strong>*</strong>For R.Y.Z.: phone, (781) 895-0600; fax, (781) 895-0611; e-mail, <a href="/cdn-cgi/l/email-protection#a2d0cdc0c7d0d68cd8cac3cde2cbcfcfd7cccdc5c7cc8cc1cdcf"><span class="__cf_email__" data-cfemail="35475a575047411b4f5d545a755c5858405b5a52505b1b565a58">[email protected]</span></a>. For R.V.J.C.: phone, (781) 895-0600; fax, (781) 895-0611; e-mail, <a href="/cdn-cgi/l/email-protection#196b786f70377a71786b70597074746c77767e7c77377a7674"><span class="__cf_email__" data-cfemail="f98b988f90d79a91988b90b99094948c97969e9c97d79a9694">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm2002958&amp;href=/doi/10.1021%2Fjm2002958" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 3606–3623</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 25, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 March 2011</li><li><span class="item_label"><b>Published</b> online</span>4 May 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 May 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm2002958" title="DOI URL">https://doi.org/10.1021/jm2002958</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3606%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRobert%2BY.%2BZhao%252C%2BSharon%2BD.%2BWilhelm%252C%2BCharlene%2BAudette%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D10%26contentID%3Djm2002958%26title%3DSynthesis%2Band%2BEvaluation%2Bof%2BHydrophilic%2BLinkers%2Bfor%2BAntibody%25E2%2580%2593Maytansinoid%2BConjugates%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3623%26publicationDate%3DMay%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm2002958"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5808</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">134</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm2002958" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Y. Zhao&quot;},{&quot;first_name&quot;:&quot;Sharon&quot;,&quot;last_name&quot;:&quot;D. Wilhelm&quot;},{&quot;first_name&quot;:&quot;Charlene&quot;,&quot;last_name&quot;:&quot;Audette&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;A. Leece&quot;},{&quot;first_name&quot;:&quot;Alexandru&quot;,&quot;last_name&quot;:&quot;C. Lazar&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;S. Goldmacher&quot;},{&quot;first_name&quot;:&quot;Rajeeva&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Yelena&quot;,&quot;last_name&quot;:&quot;Kovtun&quot;},{&quot;first_name&quot;:&quot;Wayne&quot;,&quot;last_name&quot;:&quot;C. Widdison&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Lambert&quot;},{&quot;first_name&quot;:&quot;Ravi&quot;,&quot;last_name&quot;:&quot;V. J. Chari&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;3606-3623&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm2002958&quot;},&quot;abstract&quot;:&quot;The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive N-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody–maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2002958&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2002958" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2002958&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2002958" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2002958&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2002958" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm2002958&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2002958&amp;href=/doi/10.1021/jm2002958" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm2002958" /></input><a href="/doi/pdf/10.1021/jm2002958" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm2002958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm2002958%26sid%3Dliteratum%253Aachs%26pmid%3D21517041%26genre%3Darticle%26aulast%3DZhao%26date%3D2011%26atitle%3DSynthesis%2Band%2BEvaluation%2Bof%2BHydrophilic%2BLinkers%2Bfor%2BAntibody%25E2%2580%2593Maytansinoid%2BConjugates%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D10%26spage%3D3606%26epage%3D3623%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292002" title="Hydrophilicity">Hydrophilicity</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jmcmar.2011.54.issue-10/production/jmcmar.2011.54.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive <i>N</i>-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody–maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The efficacy of chemotherapeutic drugs is often limited by their side effects on normal tissues such as, for example, acute bone marrow or mucosal toxicity, or chronic cardiac and neurological toxicity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Since the discovery of monoclonal antibodies (mAb) 3 decades ago,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> treatments for a few types of tumors, notably non-Hodgkin’s lymphoma and HER2-positive breast cancer, have advanced considerably because of the development of mAbs that selectively target tumor-associated antigens expressed in their malignancies. The antitumor activity of these antibodies, coupled with their favorable pharmacodynamic and pharmacokinetic properties, and the lack of serious nontargeted toxicities have led to their becoming mainstays in the treatment of NHL and HER2-positive breast cancers.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Antibodies have been extensively explored as vehicles for delivery of various cytotoxic agents: first as conjugates with radionuclides for imaging and cancer therapy,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> later as conjugates with bacterial and plant toxins,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and currently, with small-molecule cytotoxic compounds.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The small-molecule cytotoxic compounds, a new class of anticancer agents termed antibody–drug conjugates (ADCs),<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> are in various stages of preclinical and clinical development. These include ADCs prepared with highly potent cytotoxic agents such as maytansinoids (DM1 and DM4),<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> calicheamicin derivatives,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> CC-1065 derivatives,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> and auristatins.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> As these studies progress, emerging clinical data are beginning to validate the potential of the ADC technology platform as an important modality in the future of cancer treatment where targeted therapy becomes the norm.<a onclick="showRef(event, 'ref10 ref15'); return false;" href="javascript:void(0);" class="ref ref10 ref15">(10, 15)</a></div><div class="NLM_p">The link between the antibody and the cell-killing agent plays a critical role in the development of ADCs, as the nature of the linker significantly affects the potency, selectivity, and the pharmacokinetics of the resulting conjugate.<a onclick="showRef(event, 'ref9 ref13 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref9 ref13 ref16 ref17 ref18 ref19 ref20">(9, 13, 16-20)</a> ADCs are thought to act via a multistep sequence of events: binding to the cell surface, endocytosis, trafficking (within an endosome) to a lysosome, proteolytic degradation of the conjugate, and diffusion of the released cytotoxic agent across the lysosomal or endosomal membrane toward its intracellular target and its interaction with the target, which ultimately causes cell death. Therefore, the linker should be sufficiently stable while in circulation to allow delivery of the intact ADC to the tumor sites but, on the other hand, sufficiently labile to allow release of the cytotoxic effector from the ADC once inside the targeted tumor cell. Four types of linkers (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) have been used for preparation of antibody–drug conjugates that have currently entered the clinic: (a) acid-labile linkers, exploiting the acidic endosomal and lysosomal intracellular microenvironment;<a onclick="showRef(event, 'ref17 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref20">(17, 20)</a> (b) linkers cleavable by lysosomal proteases;<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16, 18)</a> (c) chemically stable thioether linkers that release a lysyl adduct after proteolytic degradation of the antibody inside the cell;<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> and (d) disulfide-containing linkers,<a onclick="showRef(event, 'ref7 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref9">(7, 9)</a> which are cleaved upon exposure to an intracellular thiol.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Structures of Some Antibody–Cytotoxic Drug Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>The linkers used for each drug are indicated in parentheses, and the labile bonds are in circles.</p></p></figure><div class="NLM_p">One common feature of many linkers used to prepare ADCs is their hydrophobicity. For example, the commercially available cross-linkers SMCC and SPDP are hydrophobic. Typically, ADCs reported in the literature contain no more than 3–4 drug molecules per antibody molecule.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Attempts to attain higher drug/antibody ratios (DAR) often failed, particularly if both the cytotoxic agent and the linker were hydrophobic, because of ADC aggregation,<a onclick="showRef(event, 'ref13 ref18 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref13 ref18 ref23 ref24">(13, 18, 23, 24)</a> loss of affinity for the target antigen,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and rapid clearance from circulation.<a onclick="showRef(event, 'ref18 ref26'); return false;" href="javascript:void(0);" class="ref ref18 ref26">(18, 26)</a> Conjugates with high DAR could be beneficial in situations where the target antigen density on the cell surface is low and offers a means of boosting potency.</div><div class="NLM_p">Another factor that may limit the activity of ADCs is the emergence of drug resistant tumor cells.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> The occurrence of multidrug resistance (MDR) cancer is often attributed to the increased expression or activity of drug transporters, most often P-glycoprotein (Pgp),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> which facilitate efflux of certain, mostly hydrophobic, compounds. It would be desirable to develop a linker that would reduce such transporter-mediated efflux of the effector drug.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p last">Herein we describe the synthesis and properties of highly water-soluble hydrophilic linkers suitable for conjugation of a thiol-containing cytotoxic agent. These linkers contain either a negatively charged α-sulfonic acid group or a polar short polyethylene glycol (PEG) chain to increase their solubility. The chemically reactive groups in these linkers are <i>N</i>-hydroxysuccinimide (NHS) ester on one end and a (pyridin-2-yl)disulfanyl, (nitropyridin-2-yl)disulfanyl group, or maleimido group on the other end. The NHS ester reacts with amino groups of lysine residues on an antibody to form a stable amide bond. The (pyridin-2-yl)disulfanyl group or maleimido group of the linker reacts with the sulfhydryl group of the cytotoxic agent, forming a conjugate containing a disulfide or a thioether, respectively. These novel linkers enabled us to construct antibody-maytansinoid conjugates (AMCs) with a DAR of up to 9, that did not aggregate, that retained the affinity of the antibody, and that were markedly more potent than conjugates with DAR of 3–4. In addition, conjugates with a standard DAR load of 3–4 made using these hydrophilic linkers showed superior activity toward Pgp-expressing MDR cells in vitro than conjugates with standard nonhydrophilic linkers.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of Hydrophilic Linkers</h3><div class="NLM_p">The formation of protein aggregates poses a significant problem during the preparation of ADCs, especially when both the linker and cytotoxic agent are hydrophobic.<a onclick="showRef(event, 'ref13 ref23'); return false;" href="javascript:void(0);" class="ref ref13 ref23">(13, 23)</a> Even with relatively hydrophilic cytotoxic agents, such as DM1 and DM4, the AMCs made with the somewhat hydrophobic linkers SPDB and SMCC<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> could only be prepared at a DAR of up to 4–5 depending on the antibody. When AMCs with higher maytansinoid loads were attempted, such conjugates tended to form aggregates, resulting in precipitation. We set out to make and evaluate hydrophilic linkers to test if similar conjugates made with such linkers would maintain monomeric homogeneity at higher maytansinoid loads. To this end, we synthesized two sets of hydrophilic linkers, one set comprising cleavable disulfide linkers containing either a negatively charged sulfonate group or a noncharged PEG group and the other set comprising noncleavable maleimido-bearing linkers containing either a negatively charged sulfonate group or a noncharged PEG group.</div><div class="NLM_p">The first approach was to attempt synthesis of a simple hydrophilic linker containing a sulfonate anion using α-lipoic acid (<b>1</b>) as the starting material (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). It has been reported that α-lipoic acid (<b>1</b>) can be oxidized with hydrogen peroxide in acetone to form the cyclic thiosulfonate (<b>3</b>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We hypothesized that following antibody modification with compound <b>6</b>, the exchange reaction between the disulfide of the linker and the free thiol of the cytotoxic agent would generate a conjugate bearing a sulfonate anion (<b>7</b>). However, NMR and MS analyses of crude reaction mixtures formed by oxidation of lipoic acid (<b>1</b>) by peroxides indicated the presence of a range of oxidized compounds, such as disulfoxide (<b>2</b>) and sulfone–sulfoxide (<b>4</b>), with less than 10% of the desired thiosulfonate (<b>3</b>). Attempts to optimize the reaction conditions by varying the amount of oxidants and solvents were unsuccessful.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Original Strategy for Synthesis of the Sulfonate Hydrophilic Linker Starting from Lipoic Acid<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) [O]; (b) NHS/EDC; (c) mAb; (d) drug–SH.</p></p></figure><div class="NLM_p">This result prompted us to devise a different synthetic strategy (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) where the desired products would be stable and isolable during the synthetic process. The first α-sulfonate heterobifunctional linker <b>14</b> was developed, starting from <b>10</b> and <b>11</b> which were synthesized from the readily available dibromide <b>8</b>. The key to this strategy was the difference in substitution reaction rates for the thioacetate with the α-bromo and γ-bromo substituent of starting material <b>8</b>. A practical, reproducible, and readily scalable synthetic route and efficient purification of all precursor molecules of linker <b>14</b> were then developed, as shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The selective displacement of the α-bromo substituent by 1 equiv of thioacetic acid in THF with DIPEA at −20 °C gave methyl 2-(acetylthio)-4-bromobutanoate (<b>9</b>) in nearly quantitative yield. Oxidation of compound <b>9</b> with hydrogen peroxide in acetic acid at room temperature provided the sulfonic acid <b>10</b> in over 90% yield after crystallization. The γ-bromo moiety of the sulfonic acid <b>10</b> was then substituted with thioacetic acid using DIPEA in THF/DMA at higher temperatures (room temperature to 50 °C) to afford compound <b>11</b> in over 90% yield. Hydrolysis of the two ester groups of compound <b>11</b> by sodium hydroxide, followed by the addition of an excess of 2,2′-dithiobis(5-nitropyridine) gave the expected 4-((5′-nitropyridin-2′-yl)disulfanyl)-2-sulfobutanoic acid (<b>12</b>) in over 75% yield following reverse phase chromatography. The desired nitropyridinyl linker <b>14</b> was prepared by condensing the sulfobutanoic acid <b>12</b> with <i>N</i>-hydroxysuccimide in DMA using the carbodiimide coupling agent EDC to give an 82% yield after silica chromatography and crystallization.</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Disulfide-Linked Antibody–Cytotoxic Agent Conjugates via a Sulfonate Soluble Linker<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) HSAc, DIPEA, THF, −20 °C, 96%; (b) H<sub>2</sub>O<sub>2</sub>/HOAc, 90%; (c) HSAc, DIPEA, DMA, 90%; (d) NaOH; (e) (SPyR)<sub>2</sub>, pH 7.5; (f) NHS, EDC, DMA, 82%; (g) antibody; (h) maytansinoid–SH.</p></p></figure><div class="NLM_p">We also synthesized a similar linker bearing a pyridyldithio group <b>15</b> which was expected to have a different reaction rate toward thiol–disulfide exchange and higher stability in mildly basic conditions. The synthesis was similar to that of the nitropyridin-2-yldisulfanyl linker <b>14</b>. The two ester groups of compound <b>11</b> were subsequently hydrolyzed by 1 M NaOH, followed by neutralization to pH 7.5 with H<sub>3</sub>PO<sub>4</sub> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). The free thiol was reacted with 2,2′-dithiodipyridine to afford the pyridyl disulfide compound <b>13</b> in 80% overall yield. The final linker <b>15</b> was transformed into the NHS ester by EDC coupling in DMA in 83% yield after silica gel chromatography and crystallization.</div><div class="NLM_p">We also synthesized a linker wherein the hydrophilic element was a short PEG for use in the formation of AMCs. The PEG-containing linker <b>19</b> was synthesized from commercially available 1-mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid <b>17</b>. Compound <b>17</b> was readily converted to the pyridin-2-yldisulfanyl compound <b>18</b> with 2,2′-dithiodipyridine in 1,2-dimethoxyethane in 64%, followed by transformation of compound <b>18</b> to the NHS ester compound <b>19</b> by EDC-mediated coupling with <i>N</i>-hydroxysuccinimide in DCM in 38% yield (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of AMC Bearing a PEGylated Disulfide Linker, 15-(2-Pyridyldithio)-4,7,10,13-tetraoxapentadecanoic Acid <i>N</i>-Hydroxysuccinimide Ester <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) (SPy)<sub>2</sub>, DME, 64%; (b) NHS, EDC, DCM, 38%; (c) antibody; (d) maytansinoid–SH.</p></p></figure><div class="NLM_p">The maleimido-bearing linker <b>26</b> which would offer a thioether linked noncleavable AMC was synthesized as outlined in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. The synthesis started from the bromide <b>10</b>, which was converted to the azido compound <b>21</b> using sodium azide in DMA, resulting in a 90% yield. Hydrolysis of the ester with 1 M HCl at 100 °C provided the carboxylic acid compound <b>22</b> in 95% yield. Hydrogenation of the azido group in water afforded the amino compound <b>23</b> in quantitative yield which was used directly for next step without purification. The amino group of compound <b>23</b> was coupled with maleic anhydride in DMA to provide compound <b>24</b> in 90% yield. The maleic acid <b>24</b> was then treated with hexamethyldisilazane (HMDS) and a Lewis acid (ZnCl<sub>2</sub>) in a mixture of toluene and DMA at 100–120 °C for 8 h using a Dean–Stark trap to remove the byproduct water. Addition of a few drops of 1 M HCl in methanol afforded 85% of the desired maleimido acid <b>25</b>. The proposed mechanism of this step is depicted in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. In the first step, both the carboxylic acid and the sulfonic acid groups of compound <b>24</b> reacted with HMDS using a Lewis acid to form the TMS esters <b>25a</b>. However, the amido group preferentially attacked the enamido TMS ester <b>25b</b> to form a five-membered maleimido ring <b>25c</b> upon coordination with ZnCl<sub>2</sub>. The addition of HCl in methanol resulted in hydrolysis of the TMS esters to form the desired compound <b>25</b>. We applied the previously reported Ac<sub>2</sub>O/AcOH/reflux,<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> EDC/HOBt,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and cyanuric chloride<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> methods to complete the desired maleimido ring formation; however, all these methods resulted in poor yields and the generation of several inseparable cyclic ring or linear byproducts, which probably arose from reaction with the acid groups of compound <b>24</b>. The HMDS/ZnCl<sub>2</sub> methodology gave the maleimido compound <b>25</b> in reasonably high yields. The final linker <b>26</b> was prepared through coupling of the carboxylic acid <b>25</b> to <i>N</i>-hydroxysuccinimide with EDC in DMA and purified by silica gel chromatography. Unexpectedly, the modification reaction of <b>26</b> with the antibody’s lysine ε-amino groups under neutral conditions (pH 6.5–7.5) was very slow and had to be conducted over 24 h, resulting in extensive NHS ester hydrolysis. Modification under mildly basic conditions (pH 8.0) accelerated the reaction, but some hydrolysis of the maleimide was observed. Therefore, the sulfonate group of linker <b>26</b> was moved further away from the carbonyl group to the third carbon position of the linker (<b>36</b>).</div><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of a Noncleavable Charged Linker and AMC<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) NaN<sub>3</sub>, DMA, 90%; (b) 1 M HCl, HAc, 100 °C, 95%; (c) H<sub>2</sub>/Pd/C, H<sub>2</sub>O, 95%; (d) maleic anhydride, DMA, 83%; (e) HMDS, ZnCl, DMA, Tol; (f) CH<sub>3</sub>OH, HCl (cat.), 85%; (g) NHS, EDC, DMA, 80%; (h) antibody; (i) maytansinoid–SH.</p></p></figure><figure id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Mechanism of the Formation of Five-Membered Ring of Maleimic Compound <b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a> outlines the synthesis of the noncleavable linker <b>36</b> bearing a 3-sulfonate group. The synthesis started from commercially available (<i>E</i>)-methyl 4-bromobut-2-enoate <b>28</b>, which was reacted with sodium azide in DMA to give (<i>E</i>)-methyl 4-azidobut-2-enoate <b>29</b> in 80% yield. Michael addition of thioacetic acid to the azido compound <b>29</b> in the presence of DIPEA in THF afforded compound <b>30</b> in 81% yield. Oxidation of <b>30</b> with hydrogen peroxide in acetic acid provided compound <b>31</b> in 93% yield, which was followed by de-esterification at reflux in 1 M HCl and HOAc to give the acid compound <b>32</b> in 85% yield. Hydrogenation of compound <b>32</b> in water produced amino compound <b>33</b>, which was readily reacted with maleic anhydride in DMA to afford the enoic acid compound <b>34</b> in 83% yield over two steps. Similar to the mechanism outlined in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>, the five-membered maleimido ring of compound <b>35</b> was formed in 75% yield when compound <b>34</b> was treated with excess HMDS and ZnCl<sub>2</sub> in a mixture of DMA and toluene, with the aid of a Dean–Stark trap, followed by hydrolysis in acidic methanol. The final coupling of compound <b>35</b> with NHS in the presence of EDC in DMA gave succinimidyl 4-<i>N</i>-maleimido-3-sulfobutyrate <b>36</b> in 75% yield.</div><figure id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Succinimidyl 4-<i>N</i>-Maleimido-3-sulfobutyrate <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) NaN<sub>3</sub>, DMF, 0 °C, 80%; (b) HSAc, Et<sub>3</sub>N, THF, 81%; (c)H<sub>2</sub>O<sub>2</sub>, HAc, 93%; (d) HCl, HAc, 110 °C, 85%; (e) Pd/C/H<sub>2</sub>, 90%; (f) maleic anhydride, DMA, 83%; (g) HMDS, ZnCl, DMA, Tol; (h) CH<sub>3</sub>OH, HCl (cat.), 75%; (i) NHS, EDC, DMA, 75%.</p></p></figure><div class="NLM_p">An alternative synthesis of the enoic acid compound <b>34</b> is depicted in Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>. Michael addition of the commercially available (<i>Z</i>)-ethyl 3-cyanoacrylate <b>37</b> with HSAc in the presence of DIPEA in THF gave ethyl 3-(acetylthio)-3-cyanopropanoate (<b>38)</b> in 65% yield. Oxidation of compound <b>38</b> with hydrogen peroxide in acetic acid afforded 93% of the ethyl 3-(acetylthio)-3-cyanopropanoate (<b>39)</b>. Reduction of compound <b>39</b> with Raney Ni generated the unstable 1-amino-3-ethoxy-3-oxopropane-1-sulfonic acid, which was readily converted in 85% yield in situ to 1-(<i>tert</i>-butoxycarbonylamino)-4-ethoxy-4-oxobutane-2-sulfonic acid <b>40</b> in the presence of BOC anhydride. De-esterification of compound <b>40</b> with LiOH gave 90% of the acid <b>41</b>. Removal of the BOC group of compound <b>41</b> in a 4:1 (v/v) mixture of concentrated hydrochloric acid and dioxane followed by coupling with maleic anhydride in DMA provided 83% of the enoic acid compound <b>34</b> in two steps. This synthetic route gave an overall yield of 38%, the same as that of Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>.</div><figure id="sch8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of (<i>Z</i>)-4-(3-Carboxy-2-sulfopropylamino)-4-oxobut-2-enoic Acid <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) HSAc, DIPEA, THF, 0 °C, 65%; (b) H<sub>2</sub>O<sub>2</sub>, HAc, 93%; (c) Raney Ni, H<sub>2</sub>, BOC<sub>2</sub>O, DMA, 85%; (d) LiOH, 90%; (e) 20% HCl, dioxane; (f) maleic anhydride, DMA, 83%.</p></p></figure><div class="NLM_p">In the practice of conjugation, an ideal method is direct (“one step”) reaction of the maytansinoid-linker moieties with an antibody. Therefore, compounds <b>43</b>, <b>44</b>, <b>48</b>, <b>50</b>, and <b>51</b> are preferred to be isolated (Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>), when the thiol-bearing maytansinoids are first reacted with the sulfhydryl-reactive groups of the hydrophilic linkers (<b>15</b>, <b>19</b>, <b>36</b>, and <b>42</b>), respectively, under mild acidic conditions (pH 4.0–6.5). Initial attempts to isolate the “one-step” maytansinoid (DM4) linker reagents <b>43</b>, <b>44</b>, and <b>48</b> were not successful because the thiol–disulfide exchange reactions between the hindered thiol of DM4 and the linker <b>15</b>, <b>19</b>, or <b>36</b> under mild acidic conditions (pH 4.0–6.5) were slow (required at least 2 h), and were accompanied by hydrolysis of NHS on the linker. Therefore, the sulfonate compound <b>43</b> and <b>44</b>, prepared from reaction of linkers <b>15</b> and <b>36</b> with an excess of maytansinoids (1.5 equiv) in a pH 6.0 buffer, were used directly without isolation for conjugation with an antibody in a pH 8.0 buffer. Compound <b>48</b> could be prepared through coupling DM4 and PEG acid <b>18</b> to generate compound <b>47</b>, followed by esterification with NHS and chromatographic purification.</div><figure id="sch9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0014.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Maytansinoid–Linkers for One-Step Antibody Conjugation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) drug–SH (DM4), pH 4.0–6.5; (b) mAb, pH 6.5–8.0; (c) <b>18</b>, DME, 4-methylmorpholine; (d) NHS/EDC, 54%; (e) DM1 or DM4, pH 4.0–6.5.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Conjugation Using Hydrophilic Linkers</h3><div class="NLM_p">Three antibodies, huC242, huMy9-6, and B38.1, were used to evaluate the utility of the linkers in conjugation with maytansinoids. The first two are humanized IgG1 antibodies that target CanAg expressed on the surface of human colorectal, pancreatic, and gastric cancer cells, and CD33 expressed on myeloid leukemia cells, respectively. B38.1 is a chimeric human IgG1 targeting EpCAM expressed in various malignancies. The different targets were chosen to represent a wide range of antigen expression, expressed as antigen molecules bound per cell (ABC, or antibody binding capacity). CD33 is expressed at low levels (10000–20000 ABC), EpCAM at moderate levels (typically 500000–900000 ABC), and CanAg at very high levels (≥4 × 10<sup>6</sup> ABC). Two maytansinoids, DM1 and DM4,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> were used in the evaluation. The conjugation of DM1 and DM4 via these linkers to these three antibodies generally was accomplished by the previously reported two-step procedure.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> First, the monoclonal antibody was reacted with the linker, resulting in displacement of the <i>N</i>-hydroxysuccinimidyl group of the linker by lysine residues on the antibody under aqueous conditions to introduce a sulfhydryl-reactive group. The modified antibody was then treated with a thiol-bearing maytansinoid, resulting in either disulfide exchange with the pyridyldithio group of linkers <b>14</b>, <b>15</b>, and <b>26</b> or reaction with the maleimido moiety of linkers <b>26</b>, <b>36</b>, or <b>42</b> in a Michael-type addition reaction to form a stable thioether bond. Since the α-sulfonate group presented steric constraints, the modification reaction with linkers <b>14</b>, <b>15</b>, and <b>26</b> was performed at pH 8. At this pH both the nitropyridinyl disulfides of linker <b>14</b> and maleimide of linker <b>26</b> were unstable; therefore, linkers <b>15</b> (2-sulfo-SPDB linkage) and <b>36</b> (3-sulfo-Mal linkage) were preferred for use in conjugation. Linker <b>15</b> was preferred for conjugation because of its ability to readily modify the antibody at pH 8 without any loss of the thiopyridyl group over 12 h.</div><div class="NLM_p">Alternatively, the “one-step” procedure was used for AMCs with these hydrophilic linkers <b>15</b>, <b>19</b>, <b>36</b>, and <b>42</b>. AMCs with sulfonate linker <b>15</b> or <b>36</b> were made via first reaction of the linker <b>15</b> or <b>36</b> with an excess (1.5 equiv) of the thiol-bearing maytansinoids (DM1 or DM4) under mild acid condition (pH 4.0–6.5) for 1–2 h, followed by direct addition of an antibody at an adjusted pH 7.5–8.0 buffer. AMCs bearing PEG linker <b>19</b> or <b>42</b> were made through direct addition of <b>48</b>, <b>50</b>, or <b>51</b> to a buffer (pH ∼7.5) containing an antibody, respectively. AMCs obtained by this “one-step” method showed, by MS, the expected profile with no evidence of unconjugated linkers appended on the antibody (data not shown).</div><div class="NLM_p">Antibody conjugates of the maytansinoids DM1 and DM4 using these hydrophilic linkers with DAR varying from 1.2 to 9.1 were obtained through careful control of the linker and maytansinoid excess used in two-step conjugations or through control of the molar ratios of the one-step reagents (up to 14) in the one-step conjugation. All these conjugates consisted predominantly (more than 95%) of the monomeric species, as assessed by analytical ultracentrifugation (AUC) and by size-exclusion chromatography (SEC). The amount of maytansinoid in the final conjugate in the free form (or noncovalently associated with the antibody) was very low (≤0.1% of the total maytansinoid) or was undetectable, as determined by precipitation of the protein with acetone, followed by analyses of the supernatants by UV, HPLC, or LC–MS. Mass spectrometric characterization of conjugates prepared using these linkers gave the expected molar DAR distribution profile,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and the average maytansinoid load correlated with that determined spectrophotometrically by UV absorbance. Importantly, all AMCs prepared with these linkers (<b>15</b>, <b>19</b>, <b>36</b>, and <b>42</b>) retained the binding affinity of the antibody moiety to its target antigen. A typical example is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>: huC242-DMx conjugates prepared with maytansinoids using the linker <b>36</b> or <b>42</b>, with DAR of 3.6–7.3, comparable to that of the huC242-DMx conjugates made with SPDB and SMCC at DAR of 3.3–3.9, retained similar affinity of the antibody, all with apparent <i>K</i><sub>d</sub> between 0.6 to 1.0 nM.</div><figure id="fig1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0015.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Binding of huC242-DMx conjugates analysis by flow cytometry on COLO 205 cells at 10 000 cells/well in 3 h at 0 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vitro Activity of Maytansinoid Conjugates with Different Linkers</h3><div class="NLM_p">First, we compared the cytotoxicity of various conjugates of the anti-CD33 antibody (huMy9-6) with DM4 for the CD33-positive HL60 QC cells (about 15 000 ABC) and for the CD33-negative Ramos cells. These conjugates were made with various linkers: two previously used linkers, the disulfide-containing linker SPDB and the noncleavable linker SMCC, and four linkers with increased hydrophilicity, two disulfide-containing linkers, <b>15</b> (2-Sulfo-SPDB) and <b>19</b> (PEG<sub>4</sub>-SPDB), and two noncleavable linkers, <b>36</b> (3-Sulfo-Mal) and <b>42</b> (PEG<sub>4</sub>-Mal). Conjugates with various DAR values were made. Conjugates with high DAR values could only be made with the hydrophilic linkers <b>15</b>, <b>19</b>, <b>36</b>, and <b>42</b>.The results of these experiments are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> as IC<sub>50</sub> values. Several conclusions can be drawn from the data presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>: (i) All conjugates killed antigen-expressing HL60/QC cells in an antigen-dependent manner, since their cytotoxicity toward the antigen-negative Ramos cells was much lower. (ii) The potency of the conjugates made with each hydrophilic linker increased with an increase of DAR. For instance, the IC<sub>50</sub> of huMy9-6-2-sulfo-SPDB-DM4 decreased from 4 nM at 1.2 DAR to 0.5 nM at 3.4 DAR to 0.03 nM at 6.2 DAR (here and below, concentrations given are those of the antibody moiety). (iii) The specificity ((IC<sub>50</sub> for killing antigen-negative cells)/(IC<sub>50</sub> for killing antigen-positive cells)) of these conjugates has improved dramatically from 4- to 6-fold at DAR below 2, to 500 or higher at DAR above 6. (iv) The conjugates made with the hydrophilic linkers in the MAR range from 3 to 4, had a better specificity window, and in general, had a higher potency than similar conjugates made with either SPDB or SMCC. In this system, the conjugates are ranked by their potencies as follows: PEG4-Mal (<b>42</b>) > PEG4-SPDB (<b>19</b>) ≥ 2-sulfo-SPDB (<b>15</b>) > SMCC ≥ SPDB > 3-sulfo-Mal (<b>36</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cytotoxicity of huMy9-6-DMx Conjugates with Different Maytansinoid/Ab Ratios (DAR) for HL60/QC Cells (Ag+) and Ramos Cells (Ag−)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> vs HL60/QC</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">linker–DMx</th><th class="colsep0 rowsep0" align="center" char=".">DAR</th><th class="colsep0 rowsep0" align="center">concn of the antibody moiety (pM)</th><th class="colsep0 rowsep0" align="center">concn of the DM4 moiety (pM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> vs Ramos<br /></br>concn of the antibody moiety (pM)</th><th class="colsep0 rowsep0" align="center">specificity ratio<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2-sulfo-SPDB (<b>15</b>)-DM4</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="left">4200 ± 800</td><td class="colsep0 rowsep0" align="left">5040 ± 940</td><td class="colsep0 rowsep0" align="left">>25000 ± 2900</td><td class="colsep0 rowsep0" align="left">>6*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="left">1500 ± 400</td><td class="colsep0 rowsep0" align="left">3800 ± 900</td><td class="colsep0 rowsep0" align="left">>20000 ± 1400</td><td class="colsep0 rowsep0" align="left">>13*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="left">560 ± 300</td><td class="colsep0 rowsep0" align="left">1820 ± 870</td><td class="colsep0 rowsep0" align="left">>17000 ± 1400</td><td class="colsep0 rowsep0" align="left">>30*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="left">260 ± 100</td><td class="colsep0 rowsep0" align="left">999.4 ± 160</td><td class="colsep0 rowsep0" align="left">>17000 ± 1200</td><td class="colsep0 rowsep0" align="left">>68*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="left">150 ± 40</td><td class="colsep0 rowsep0" align="left">643.0 ± 147</td><td class="colsep0 rowsep0" align="left">>17000 ± 1200</td><td class="colsep0 rowsep0" align="left">>118**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="left">70 ± 20</td><td class="colsep0 rowsep0" align="left">346.9 ± 77.4</td><td class="colsep0 rowsep0" align="left">>15000 ± 1200</td><td class="colsep0 rowsep0" align="left">>210**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">40 ± 3</td><td class="colsep0 rowsep0" align="left">231.9 ± 15.4</td><td class="colsep0 rowsep0" align="left">15500 ± 1000</td><td class="colsep0 rowsep0" align="left">390*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="left">31 ± 2</td><td class="colsep0 rowsep0" align="left">191.6 ± 9.3</td><td class="colsep0 rowsep0" align="left">15500 ± 600</td><td class="colsep0 rowsep0" align="left">500*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="left">27 ± 1</td><td class="colsep0 rowsep0" align="left">184.1 ± 7.9</td><td class="colsep0 rowsep0" align="left">15500 ± 600</td><td class="colsep0 rowsep0" align="left">573*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="left">23 ± 1</td><td class="colsep0 rowsep0" align="left">180.2 ± 8.5</td><td class="colsep0 rowsep0" align="left">14300 ± 400</td><td class="colsep0 rowsep0" align="left">620*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="left">22 ± 1</td><td class="colsep0 rowsep0" align="left">200.2 ± 10.9</td><td class="colsep0 rowsep0" align="left">5200 ± 400</td><td class="colsep0 rowsep0" align="left">235*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PEG4-SPDB (<b>19</b>)-DM4</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="left">5350 ± 510</td><td class="colsep0 rowsep0" align="left">9630 ± 920</td><td class="colsep0 rowsep0" align="left">>25500 ± 1000</td><td class="colsep0 rowsep0" align="left">>5*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="left">1230 ± 250</td><td class="colsep0 rowsep0" align="left">6910 ± 560</td><td class="colsep0 rowsep0" align="left">25500 ± 1000</td><td class="colsep0 rowsep0" align="left">21*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="left">95.5 ± 20.3</td><td class="colsep0 rowsep0" align="left">439.3 ± 93.4</td><td class="colsep0 rowsep0" align="left">11000 ± 600</td><td class="colsep0 rowsep0" align="left">115*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">41.4 ± 3.2</td><td class="colsep0 rowsep0" align="left">236.2 ± 18.2</td><td class="colsep0 rowsep0" align="left">8700 ± 500</td><td class="colsep0 rowsep0" align="left">210*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">34.7 ± 7.1</td><td class="colsep0 rowsep0" align="left">208.2 ± 42.6</td><td class="colsep0 rowsep0" align="left">8200 ± 500</td><td class="colsep0 rowsep0" align="left">238*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="left">27.4 ± 2.2</td><td class="colsep0 rowsep0" align="left">178.1 ± 14.3</td><td class="colsep0 rowsep0" align="left">9300 ± 1000</td><td class="colsep0 rowsep0" align="left">340*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="left">18.5 ± 2.1</td><td class="colsep0 rowsep0" align="left">125.8 ± 14.</td><td class="colsep0 rowsep0" align="left">4500 ± 700</td><td class="colsep0 rowsep0" align="left">242*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="left">14.1 ± 2.0</td><td class="colsep0 rowsep0" align="left">100.1 ± 14.2</td><td class="colsep0 rowsep0" align="left">4300 ± 700</td><td class="colsep0 rowsep0" align="left">303*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3-sulfo-Mal (<b>36</b>)-DM1</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="left">2020 ± 1010</td><td class="colsep0 rowsep0" align="left">6930 ± 3420</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">20**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">155 ± 40</td><td class="colsep0 rowsep0" align="left">914.5 ± 236</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">111**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PEG4-Mal (<b>42</b>)-DM1</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="left">90.0 ± 26.0</td><td class="colsep0 rowsep0" align="left">369 ± 106.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">115**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="left">18.0 ± 4.2</td><td class="colsep0 rowsep0" align="left">151.2 ± 35.3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">237**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SPDB-DM4</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">389 ± 102</td><td class="colsep0 rowsep0" align="left">1510 ± 400</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">16**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMCC-DM1</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">320 ± 240</td><td class="colsep0 rowsep0" align="left">1250 ± 940</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">14**</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Definition of specificity ratio: (∗) IC<sub>50</sub> of the ADC vs Ramos (Ag−)/IC<sub>50</sub> of the ADC vs HL60/QC (Ag+); (∗∗) (IC<sub>50</sub> of the ADC vs HL60/QC with the presence of 1 μM of unconjugated My9-6)/(IC<sub>50</sub> of the ADC vs HL60/QC).</p></div></div></div><div class="NLM_p">Next, we examined the potency of maytansinoid conjugates of the chimeric IgG1 anti-EpCAM antibody B38.1 toward three different colon cancer cell lines, COLO 205 (∼900000 ABC), a transfected COLO 205 that expresses p-glycoprotein (mdr), and HCT-15 (∼700000 ABC) that naturally express P-glycoprotein (Pgp). As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, the AMCs bearing the three reducible disulfide linkers (SPDB, <b>15</b>, and <b>19</b>) or the three nonreducible thioether linkers (SMCC, <b>36</b>, and <b>42</b>) showed comparable potency toward COLO 205 cells (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a) with IC<sub>50</sub> of ∼100 pM. When tested against two different multidrug-resistant cell lines, COLO 205/MDR and HCT-15 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>b and Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>c), the AMC made using the hydrophilic sulfo-SPDB linker <b>15</b> displayed 10- to 20-fold higher potency than the conjugate made with <b>19</b> or the SPDB linker. Among the nonreducible thioether linked conjugates, AMCs made with hydrophilic linkers <b>36</b> and <b>42</b> were 4-fold more potent than the AMC prepared with the SMCC linker against COLO 205/MDR cells. In the MDR HCT-15 cell line, the AMC made with hydrophilic linker <b>42</b> resulted in 2- and 3-fold greater potency when compared to conjugates prepared with <b>36</b> and SMCC linkers, respectively. Notably, the IC<sub>50</sub> (∼100 pM) of the AMC having linker <b>42</b> on the two multidrug resistant cell lines was similar to the IC<sub>50</sub> of all the AMCs on the COLO 205 cell line that does not express Pgp. Overall, AMCs made with linker <b>36</b> displayed the highest potency among all of the AMCs tested, in particular against MDR cells. AMCs containing a reducible PEG<sub>4</sub> linkage (<b>19</b>) in B38.1-DM4 conjugates did not show an activity advantage against MDR cell lines possibly because the disulfide group in the hydrophilic metabolite is readily reduced by an intracellular thiol, such as glutathione, to release the hydrophobic maytansinoid thiol.</div><figure id="fig2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0001.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Activity of reducible (left) and nonreducible (right) anti-EpCAM-DMx conjugates prepared with hydrophilic linkers from the hydrophilic linker series with similar ∼3.5 ratio of DMx/mAb.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Finally, we assessed the potency of maytansinoid conjugates of the huC242 antibody which binds to CanAg expressed in very high amounts on the COLO 205 colon cancer cell line (estimated to be ≥4 × 10<sup>6</sup> ABC). AMCs utilizing all linkers, and at a range of DAR values from 3.3 to 7.3, had similar potency on COLO205 cells with IC<sub>50</sub> of about 10 pM (data not shown). Assays were performed under conditions simulating lower antigen density by addition of an excess of nonconjugated antibody to the AMC. For example, adding a 50-fold excess of nonconjugated huC242 antibody to each preparation of AMC would simulate a binding curve to COLO 205 cells that saturates at about 80 000 rather than 4 × 10<sup>6</sup> conjugate molecules bound per cell. Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> show the results of cytotoxicity studies done with AMCs made with the two hydrophilic linkers (<b>36</b> and <b>42)</b> and two standard linkers (the SPDB cleavable linker and the SMCC noncleavable linker) for comparison. Under the simulated low-antigen conditions (50-fold excess of nonconjugated antibody), the huC242-AMCs prepared with DAR of 5.6–7.3 with hydrophilic linkers <b>36</b> and <b>42</b> were highly potent with IC<sub>50</sub> of about 10 pM. By comparison, the huC242-SMCC-DM1 conjugate had an IC<sub>50</sub> of 27 pM, while the huC242-SPDB-DM4 conjugate had an IC<sub>50</sub> of 237 pM. These conjugates had DAR of 3.3 and 3.9, respectively, and as mentioned above, because of their hydrophobicity, AMCs with higher DAR in the range of 6–7 could not be made successfully with these linkers. An AMC with linker <b>36</b> was made with a DAR of 3.6; its potency was similar to that of huC242-SMCC-DM1 at a similar DAR (both noncleavable linker). Thus, the 2- to 3-fold improvement in potency for the conjugates with higher maytansinoid loading is likely due to the 2- to 3-fold greater amount of maytansinoid delivered per binding event.</div><figure id="fig3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0002.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vitro cytotoxicity of the huC242-DM1 conjugates (3.3–7.3 DAR) toward (a) COLO205 and (b) COLO205-MDR cells upon dilution with 50-fold excess unconjugated huC242 antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cytotoxicity of huC242-DMx Conjugates with Different Maytansinoid/Ab Ratios (DAR) against COLO205 and COLO205-MDR Cells upon Dilution with 50-Fold Excess Unconjugated huC242 Antibody</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">linker–DMx</th><th class="colsep0 rowsep0" align="center">DAR</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> vs COLO205 (pM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> vs COLO205MDR + 50-fold mAb (pM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3-sulfo-Mal (<b>36</b>)-DM1</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">28.1</td><td class="colsep0 rowsep0" align="left">12.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">8.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left">7.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PEG4-Mal (<b>42</b>)-DM1</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">10.6</td><td class="colsep0 rowsep0" align="left">18.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">17.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SPDB-DM4</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">237</td><td class="colsep0 rowsep0" align="left">>5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMCC-DM1</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">26.7</td><td class="colsep0 rowsep0" align="left">3000</td></tr></tbody></table></div></div><div class="NLM_p last">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b shows the results of potency assays done under the same conditions (simulated low-antigen expression) with the same set of AMCs on the COLO205 cell line that had been transfected with the P-glycoprotein gene. The two conjugates made with the hydrophobic linkers SPDB and SMCC showed little activity (IC<sub>50</sub> not reached at 3000 pM), whereas the AMCs made with hydrophilic linkers <b>36</b> and <b>42</b> were still highly active on this multidrug resistant cell line, with IC<sub>50</sub> in the range 7–20 pM.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Activity of Maytansinoid Conjugates with Different Linkers</h3><div class="NLM_p">The therapeutic effects of AMCs prepared via traditional SPDB, SPDP, and SMCC linkers have been previously reported.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The established COLO 205 MDR human tumor xenograft model in SCID mice was used to examine the in vivo antitumor activity of huB38.1-DMx conjugates prepared with the hydrophilic linkers <b>15</b> and <b>42</b> in comparison with two of the previously reported hydrophobic linkers. Animals were inoculated with COLO 205/MDR cells, and tumor xenografts were allowed to grow to a mean tumor volume of 138 + 20 mm<sup>3</sup> (8 days). All AMCs used in this study had DAR of approximately 3.5, and animals were dosed with a single injection of 10 mg/kg (antibody dose) (∼170 μg/kg conjugated DMx). In the absence of treatment, the mean tumor volume increased to 500 mm<sup>3</sup> in 17 days and 1200 mm<sup>3</sup> in 43 days. Treatment with the hydrophilic linker conjugates B38.1-PEG<sub>4</sub>-Mal-DM1 (noncleavable linker) and B38.1-2-sulfo-SPDB-DM4 (cleavable linker) profoundly suppressed the in vivo tumor growth for 20 and 30 days, respectively, as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. In contrast, conjugates using the nonhydrophilic linkers B38.1-SPDB-DM4 (cleavable linker) and B38.1-SMCC-DM1 (noncleavable linker) were less effective in this multidrug resistant model, only slowing the rate of tumor growth for a net tumor growth delay of about 16 and 14 days, respectively.</div><figure id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0003.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo efficacy of anti-EpCAM-DMx conjugates (∼3.5 DMx/Ab) against multidrug resistant COLO205-MDR tumors in SCID mice (single iv injection, 170 μg/kg DMx based dose (10 mg/kg mAb dose)).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51126" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51126" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the design of antibody–drug conjugates, the linker connecting the cytotoxic agent to the targeting antibody plays a critical role in conjugate potency and efficacy.<a onclick="showRef(event, 'ref7 ref12 ref17 ref21'); return false;" href="javascript:void(0);" class="ref ref7 ref12 ref17 ref21">(7, 12, 17, 21)</a> Over the past 2 decades, linkers have been designed with the goal of achieving high stability in the extracellular environment, yet able to readily release the cell-killing agent upon internalization of the conjugate into the target tumor cell.<a onclick="showRef(event, 'ref21 ref36'); return false;" href="javascript:void(0);" class="ref ref21 ref36">(21, 36)</a> However, conjugation of hydrophobic cytotoxic drugs using linkers that are themselves hydrophobic can lead to conjugate aggregation or loss in the binding affinity of the antibody, particularly at higher (>5 D/A) drug loads.<a onclick="showRef(event, 'ref7 ref13 ref23'); return false;" href="javascript:void(0);" class="ref ref7 ref13 ref23">(7, 13, 23)</a> We reasoned that enhancing the hydrophilicity of the linkers would enable preparation of ADCs with higher drug loads, resulting in a greater concentration of the cytotoxic agent delivered to the target cell and thus improved antitumor activity.</div><div class="NLM_p">In these novel linkers, a charged sulfonate group or a short polyethyleneglycol spacer was introduced to enhance their hydrophilicity. The synthesis of linkers containing a sulfonic acid substituent at the C2 position was achieved by taking advantage of the preferred substitution reaction of the α-bromo over the γ-bromo substituent in starting material <b>8</b> by thioacetate. Although the reaction rate for displacement of the α-bromo substituent by nucleophiles to give the desired product is known to be considerably faster than that of the γ-bromo substituent,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> conducting the reaction at cold temperature (−20 °C) ensured that the desired product was exclusively obtained. In the next step, the oxidation reaction of the thioacetate group proceeded smoothly with the γ-bromo substituent and the methyl ester being unaffected under the reaction conditions in a mixture of water and acetic acid at room temperature. The subsequent displacement reaction of the γ-bromo substituent by thioacetate proceeded best under warm temperature and mild basic conditions. Higher temperature (>60 °C) or strong basic conditions (pH > 11) resulted in a competing elimination reaction instead of substitution. The other key step was the synthesis of sulfonated maleimido linkers <b>26</b> and <b>36</b> wherein the formation of the five-membered maleimido ring was aided by coordination of the Lewis acid, ZnCl<sub>2</sub> (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). The competing cyclization reaction, involving the second carboxylic group and the sulfonic acid group in this molecule, was prevented by addition of excess of HMDS and DIPEA which served to stabilize the coordination reaction. Coordination of the maleic acid group by Zn<sup>2+</sup> rendered it more electrophilic and facilitated nucleophilic attack by the amide nitrogen, resulting in intramolecular cyclization and formation of the maleimide ring. With this strategy for the construction of the maleimide, two different approaches for the precursor <b>34</b> starting from <b>28</b> or <b>37</b> for the synthesis of 3-sulfo-Mal linker <b>36</b> were explored (Schemes <a class="ref internalNav" href="#sch7" aria-label="7">7</a> and <a class="ref internalNav" href="#sch8" aria-label="8">8</a>). Both approaches provided reasonable yields. In the last NHS ester formation step, the possibility of ester formation on both the sulfonate and carboxyl groups had to be considered. We exploited the difference in p<i>K</i><sub>a</sub> values of the sulfonic acid and the carboxylic acid moieties (1.8 and 4.8, respectively) and conducted the coupling reaction with NHS under mildly acidic conditions. These conditions maximized the difference in the coupling rates and gave predominantly the carboxylic acid ester. Thus, the precursors <b>12</b>, <b>13</b>, <b>25</b>, and <b>35</b> were prepared in their protonated carboxylic acid forms (purified with C-18 column eluted with acidic solution followed by crystallization), avoiding the need to add an acid catalyst in the NHS ester formation reactions, although the time to achieve complete reaction was long (>6 h). Addition of a catalyst, such as DIPEA or DMAP, to speed up the reaction resulted in the formation of the undesired sulfonate NHS.</div><div class="NLM_p">These hydrophilic linkers bearing either a short PEG spacer or a sulfonate substituent (e.g., <b>15</b>, <b>19</b>, <b>36</b>, and <b>42</b>) have enabled the preparation of conjugates with as many as nine maytansinoids linked per antibody molecule without affecting the monomer content or the binding affinity of the conjugate to the target antigen. AMCs prepared with the hydrophilic disulfide linkers <b>15</b> and <b>19</b> showed a greater than stoichiometric enhancement of in vitro potency with increasing maytansinoid loading under conditions of low target density on the cell surface. For example, the potency of the huMy9-6-DM4 conjugates was increased over 10-fold when DAR was doubled from 3 to 6, without a concomitant increase in nonspecific cytotoxicity (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Although the correlation between drug loading and cellular cytotoxicity is known, only a stoichiometric increase in potency has been reported.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> For example, Hamblett and co-workers compared the activities of antiCD30 antibody-MMAE (monomethyl auristatin E) conjugates with DAR of 2, 4, and 8 found that the potency was directly dependent on drug loading, the potency increasing about 2-fold (range 1- to ∼3-fold) when doubling the DAR.</div><div class="NLM_p">An important advantage of the incorporation of hydrophilic linkers in AMCs is their potential to overcome multidrug resistance (MDR). The active efflux of a broad range of anticancer drugs by MDR proteins can seriously limit the efficacy of cancer chemotherapy.<a onclick="showRef(event, 'ref28 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref30">(28, 30)</a> Chemotherapeutic drugs are exported in both ATP-dependent and ATP-independent manners and even against significant concentration gradients.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The ATP-dependent group belongs to the ATP-binding cassette (ABC) transporter family, which includes Pgp, MRP, BCRP, among others.<a onclick="showRef(event, 'ref28 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref28 ref39 ref40">(28, 39, 40)</a> All of these MDR proteins are involved in diverse physiological processes and are responsible for the uptake and efflux of a multitude of substances from cancer cells. Since the early 1990s, several inhibitors of MDR transporters have been developed for coadministration with cancer therapeutic agents in clinical trials: examples include verapamil, cyclosporine, valspodar (PSC-833), and others.<a onclick="showRef(event, 'ref28 ref39'); return false;" href="javascript:void(0);" class="ref ref28 ref39">(28, 39)</a> Unfortunately, most of them had unfavorable pharmacological properties (poor specificity, low bioavailability at tumor site); many of them were also potassium and calcium channel blockers, and such agents also inhibit clearance of the cytotoxic drug by the efflux pumps in normal cells, thus increasing toxicity. These limitations have precluded their use in the clinic.</div><div class="NLM_p">Here, we explored whether AMCs with hydrophilic linkers could overcome multidrug resistance. Previous reports have shown that AMCs are efficiently metabolized in cells to generate a lysine–linker–maytansinoid metabolite, wherein the lysine residue is derived from lysosomal degradation of the antibody component of the conjugate.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Thus, AMCs with hydrophilic linkers are expected to generate a more polar lysine–hydrophilic linker–maytansinoid metabolite inside the cell, which would be anticipated to be a poor substrate for MDR efflux pumps. Our results indicate that AMCs with hydrophilic linkers are indeed more potent toward MDR cells in vitro and in vivo compared to AMCs with standard hydrophobic linkers. For example, incorporation of the sulfonate moiety enhances the activity of AMCs with reducible (<b>15</b>) and nonreducible (<b>36)</b> linkages in B38.1-DM1 conjugates against MDR cell lines (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), suggesting that the polar lysine–sulfo-linker–maytansinoid metabolites generated inside the target cells either are poor MDR protein substrates or have limited accessibility to an MDR transporter (the binding of a substrate to MDR protein occurs only after diffusion of the substrate into the lipid bilayer of the plasma membrane).<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> B38.1-DMx conjugates with a nonreducible hydrophilic PEG<sub>4</sub> linker (<b>42</b>) also displayed enhanced potency toward MDR cells. A recent report indicates that the hydrophilic maytansinoid metabolite derived with an AMC with the PEG<sub>4</sub> linker is retained to a greater extent inside MDR cells compared to an AMC with a standard linker, which provides an explanation for the higher activity of the former versus the latter.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">The enhancement of activity toward MDR cell lines, as well as the opportunity afforded by hydrophobic linkers to increase potency of an AMC in cases where the target antigen has relatively low expression (∼10000–100000 ABC), was further demonstrated with a third antibody/antigen target system utilizing the huC242 antibody that targets CanAg. Incorporation of the sulfonate or PEG functionalities into the nonreducible linkers <b>36</b> and <b>42</b> resulted in as much as a 100-fold greater cytotoxicity (compared with huC242-DMx conjugates prepared with SPDB and SMCC linkers) against both COLO 205 and COLO 205/MDR cells under experimental conditions to stimulate a relatively low maximal ABC value of ∼80000 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><div class="NLM_p">The results from the in vivo studies further support the findings in vitro. Conjugates prepared with either the sulfonate (<b>15</b>) or PEG linkers (<b>42</b>) demonstrated enhanced conjugate efficacy against the COLO205MDR xenograft model as exemplified by using the B38.1 antibody targeting EpCAM expressed on this multidrug resistant colon cancer cell line. Taken together, the results of in vitro and in vivo studies utilizing three different antibody/target antigen systems suggest that incorporating hydrophilic linkers into AMCs provides two benefits. First, the ability to deliver a higher concentration of maytansinoid into target cells per antibody binding event using AMCs with high DAR is made possible by using hydrophilic linkers. The increase in potency can be superstoichiometric, since just doubling the maytansinoid load from 3.4 to 6.6 with the sulfo-SPDB linker (<b>15</b>) increases the specific potency of the CD33-targeting AMC by 10-fold (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), and in the case of the sulfo-Mal nonreducible linker (<b>36</b>), AMC potency can be increased by greater than 100-fold upon increasing the DAR from 3.4 to 5.9. Such superstoichiometric enhancement of potency may be important in cases where the target antigen density is low (such as is the case for CD33). Second, AMCs with hydrophilic linkers generate metabolites that may be poorly effluxed out of the tumor cells by MDR transporters, resulting in greater activity toward multidrug resistant cells. The biological mechanisms have been further explored for linker <b>42</b>, confirming that resistance to pgp-enhanced efflux is the mechanism by which increased potency of the linked maytansinoid was obtained.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p last">Although the ideal linker for all antibody–drug conjugates may not exist, we believe the modifications for functionality of the linker in ADCs can have a significant impact on conjugate activity, especially in enhancing the therapeutic index and mitigating the systemic toxicity. We have developed a broad portfolio of novel linkers with differing chemical attributes for evaluation of the optimal linker–drug combination for a given antibody/target antigen pair. Following these principles, there are ongoing efforts toward the evaluation and development of hydrophilic linkers in the design of antibody–drug conjugates with the goal of achieving better efficacy against a broad range of tumor cell lines.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Materials and Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All other reagents were obtained from the Aldrich Chemical Co., unless otherwise stated. Melting points were determined on an Electrothermal melting point apparatus. Proton magnetic resonance (<sup>1</sup>H NMR) spectra were obtained on a Bruker Avance spectrometer operating at 400 MHz. The chemical shifts are reported in values relative to that of an internal tetramethylsilane (Me<sub>4</sub>Si) standard. UV spectra were recorded on a Beckman DU-640 spectrophotometer. Optical rotations were determined using a Rudolph AUTOPOL IV polarimeter. Low resolution mass spectra were obtained on a Bruker Daltonics ion-trap mass spectrometer, and high resolution mass spectra were obtained by continuous infusion electrospray mass spectrometry using a Waters QTOF-API-US mass spectrometer. Before HRMS analysis, the samples were mixed with calibration solution containing NaI and CsI in 50% isopropanol. For measurements, several spectra were summed; the summed spectra were smoothed and centered using a lock mass value from the calibration standard peaks that were close to the <i>m</i>/<i>z</i> value of the analyte. Elemental analysis was performed by Micro-Analysis, Inc. (Wilmington, DE). High performance liquid chromatography (HPLC) was performed on either a Beckman or Varian instrument (analytical or preparative scale) equipped with a diode array detector. The linkers used for antibody conjugation were over 95% pure as indicated by HPLC (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Methyl 2-(Acetylthio)-4-bromobutyrate (<b>9</b>)</h3><div class="NLM_p last">To a solution of methyl 2,4-dibromobutyrate (<b>8</b>) (10.0 g, 38.4 mmol) in 100 mL of dry THF at −20 °C was added dropwise a mixture of thioacetic acid (2.75 mL, 38.5 mmol) and DIPEA (8.50 mL, 48.9 mmol) in 50 mL of dry THF in 1.5 h. After being stirred overnight at −20 °C, then at 0 °C for 2 h under Ar, the mixture was concentrated, diluted with EtOAc/hexane, washed with 1.0 M NaH<sub>2</sub>PO<sub>4</sub>, dried over MgSO<sub>4</sub>, filtered, evaporated, and purified by SiO<sub>2</sub> chromatography (1:12 to 1:10 EtOAc/hexane) to afford 9.5 g (96%) of the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>) 4.38 (1H, t, <i>J</i> = 7.1 Hz), 3.74 (s, 3H), 3.40 (m, 2H), 2.57–2.47 (m, 1H), 2.37 (s, 3H), 2.36–2.21 (m, 1H); <sup>13</sup>C NMR 193.24, 171.36, 53.15, 44.45, 34.67, 30.46, 29.46; ESI MS <i>m</i>/<i>z</i>+ 276.9 (M + Na), 278.9 (M + 2 + Na); HRMS <i>m</i>/<i>z</i>+ (C<sub>7</sub>H<sub>11</sub>BrO<sub>3</sub>S + Na), calcd 276.9510, found 276.9521.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>R</i>,<i>S-</i>Methyl 4-Bromobutyrate 2-Sulfonic Acid (<b>10</b>)</h3><div class="NLM_p last">A solution of methyl 2-(acetylthio)-4-bromobutyrate (<b>9</b>) (9.20 g, 36.3 mmol) in acetic acid (80 mL) was treated with hydrogen peroxide (40 mL, 30% in water). The mixture was stirred overnight, evaporated, and coevaporated with water, diluted with water, neutralized with NaHCO<sub>3</sub> to pH 5, and washed with 1:1 hexane/EtOAc. The aqueous solution was evaporated, dissolved in ethanol, concentrated, and crystallized with ethanol/toluene/hexane to afford 8.6 g (90% yield) of the title compound. Mp = 275–283 (dec); <sup>1</sup>H NMR (D<sub>2</sub>O) 4.12 (dd, 1H, <i>J</i> = 4.8, 9.3 Hz), 3.83 (s, 3H), 3.64 (m, 1H), 3.53 (m, 1H), 2.54 (m, 2H); <sup>13</sup>C NMR 172.16, 66.73, 55.66, 33.39, 32.70; ESI MS <i>m</i>/<i>z</i>– 260.8 (M – 1); HRMS calcd for (C<sub>5</sub>H<sub>9</sub>BrO<sub>5</sub>S – H) 258.9276, found 258.9268.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 4-(Acetylthio)-1-methoxy-1-oxobutane-2-sulfonic Acid (or Methyl 4-(Acetylthio)-2-sulfobutyrate) (<b>11</b>)</h3><div class="NLM_p last">To methyl 2-sulfo-4-bromobutyrate (<b>10</b>) (5.0 g, 19.2 mmol) in a mixture of DMA (20 mL) and THF (60 mL) were added thioacetic acid (3.0 mL, 40.2 mmol) and DIPEA (9.0 mL, 51.7 mmol) in THF (50 mL). The mixture was stirred overnight at 35 °C, evaporated, and coevaporated with 3 × 100 mL of water, then neutralized to pH 6.5 with NaHCO<sub>3</sub>. The mixture was redissolved in methanol, filtered through Celite, concentrated, and purified by SiO<sub>2</sub> chromatography, eluent CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>/HCOOH 37.5:250:1 to 50:250:1), to afford 4.4 g (90% yield) of the title compound. <sup>1</sup>H NMR(D<sub>2</sub>O) 3.95 (dd, 1H, <i>J</i> = 4.1, 10.3 Hz), 3.83 (s, 3H), 3.74 (m, 2H), 3.22 (dd, 2H, <i>J</i> = 7.4, 14.9 Hz), 2.39 (s, 3H); <sup>13</sup>C NMR 203.88, 172.91, 67.32, 56.17, 29.04, 20.61; ESI MS <i>m</i>/<i>z</i>– 254.8 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>7</sub>H<sub>12</sub>O<sub>6</sub>S<sub>2</sub> – H) calcd 254.9997, found 255.004.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4-((5-Nitropyridin-2-yl)disulfanyl)-2-sulfobutanoic Acid (<b>12</b>)</h3><div class="NLM_p last">To 4-(acetylthio)-1-methoxy-1-oxobutane-2-sulfonic acid (<b>11</b>) (3.0 g, 11.7 mmol) in water (100 mL) was added NaOH (3 M, 50 mL). After being stirred under argon for 3 h, the mixture was neutralized with 1 M H<sub>3</sub>PO<sub>4</sub> to pH 7.2 under Ar and then added dropwise to a solution of 1,2-bis(5-nitropyridin-2-yl)disulfane (15.0 g, 48.3 mmol) in DMA (200 mL). After being stirred for 4 h under argon the mixture was concentrated, diluted with water, filtered, evaporated, and purified by loading onto a C-18 4.0 cm × 20 cm column, eluted with water/methanol (98:2), and then crystallized with EtOH/hexane to afford 3.1 g (75% yield) of the title compound. Mp = 288–291 °C (dec); <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>) 9.29 (d, 1H, <i>J</i> = 2.2 Hz), 8.63 (dd, 1H, <i>J</i> = 2.7, 8.9 Hz), 8.17 (d, 1H, <i>J</i> = 8.9 Hz), 3.73 (t, 1H, <i>J</i> = 7.2 Hz), 3.22–3.17 (m, 1H), 3.15–3.10 (m, 1H), 2.41–2.33 (m, 2H); <sup>13</sup>C NMR 170.92, 169.10, 146.04, 143.67, 133.65, 120.72, 64.22, 37.82, 29.26; ESI MS <i>m</i>/<i>z</i>– 352.8 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>9</sub>H<sub>10</sub>N2O<sub>7</sub>S<sub>3</sub> – H) calcd 352.9572, found 352.9576.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 4-(Pyridin-2-yldisulfanyl)-2-sulfobutanoic Acid (<b>13</b>)</h3><div class="NLM_p last">To 4-(acetylthio)-1-methoxy-1-oxobutane-2-sulfonic acid (<b>11</b>) (1.50 g, 5.85 mmol) was added an aqueous solution of NaOH (0.5 M, 100 mL). After being stirred under Ar for 3 h, the mixture was concentrated to ∼50 mL and neutralized with 1 M H<sub>3</sub>PO<sub>4</sub> to pH 7.2 under Ar. The mixture was added dropwise to a solution of 2,2′-dithiodipyridine (5.0 g, 22.65 mmol) in DMA (60 mL). After being stirred for 4 h under Ar, the mixture was concentrated, diluted with water, filtered, evaporated, and purified on a C-18 4.0 cm × 20 cm column eluted with water/methanol (99:1 to 90:10) to afford 1.32 g (73% yield) of the title compound. <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>) 8.39 (dd, 1H, <i>J</i> = 3.5, 4.8 Hz), 7.86 (m, 2H), 7.25 (m, 1H), 3.59 (dd, 1H, <i>J</i> = 5.2, 9.4 Hz), 2.90 (m, 2H), 2.28 (m, 2H); <sup>13</sup>C NMR 172.60, 159.16, 148.93, 138.09, 121.03, 119.38, 67.49, 36.39, 28.666; ESI MS <i>m</i>/<i>z</i>– 307.8 (M – H). HRMS <i>m</i>/<i>z</i>– (C<sub>9</sub>H<sub>11</sub>NO<sub>5</sub>S<sub>3</sub> – H) calcd 307.9721, found 307.9727.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 1-(2,5-Dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic Acid (or Succinimidyl 4-(5-Nitropyridin-2-yl)disulfanyl)-2-sulfobutyrate (<b>14</b>))</h3><div class="NLM_p last">To 4-((5-nitropyridin-2-yl)disulfanyl)-2-sulfobutanoic acid (<b>12</b>) (220 mg, 0.62 mmol) in DMA (15 mL) was added NHS (100 mg, 0.87 mmol) and EDC (480 mg, 2.50 mmol). The mixture was stirred under argon overnight, evaporated, and purified by SiO<sub>2</sub> chromatography, eluting with CH<sub>2</sub>CH<sub>2</sub>/CH<sub>3</sub>OH/HCOOH (10000:1000:1 to 10000:1500:1) to afford 227 mg (82% yield) of the title compound. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) 9.25 (d, 1H, <i>J</i> = 5.2 Hz), 8.57 (dd, 1H, <i>J</i> = 2.5, 8.9 Hz), 8.04 (t, 1H, <i>J</i> = 8.0 + 8.9 Hz), 3.86 (dd, 1H, <i>J</i> = 4.9, 9.7 Hz), 3.13–3.12 (m, 2H), 2.76 (s, 4H), 2.36–2.30 (m, 1H), 2.25–2.21 (m, 1H); <sup>13</sup>C NMR 166.96, 165.01, 144.93, 142.26, 132.63, 119.61, 61.00, 35.03, 29.30, 25.39; ESI MS <i>m</i>/<i>z</i>– 449.8 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>O<sub>9</sub>S<sub>3</sub> – H) calcd 449.9736, found 449.9739. Anal. Calcd for C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>O<sub>9</sub>S<sub>3</sub>: C, 34.59; H, 2.90; N, 9.31. Found: C, 34.80; H, 3.17; N, 9.30.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Succinimidyl 4-(Pyridin-2-yl)disulfanyl)-2-sulfobutyrate (<b>15</b>)</h3><div class="NLM_p last">To 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid (<b>13</b>) (680 mg, 2.20 mmol) in DMA (50 mL) were added NHS (300 mg, 2.60 mmol) and EDC (1.35 g, 7.03 mmol). The mixture was stirred under Ar overnight, evaporated, and purified by SiO<sub>2</sub> chromatography, eluting with CH<sub>2</sub>CH<sub>2</sub>/CH<sub>3</sub>OH/HCOOH (10000:1000:1 to 10000:1500:1) to afford 720 mg (80% yield) of the title compound. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) 8.40 (dd, 1H, <i>J</i> = 3.5, 4.7 Hz), 7.85 (m, 2H), 7.24 (m, 1H), 3.58 (dd, 1H, <i>J</i> = 5.1, 9.4 Hz), 2.94–2.90 (m, 2H), 2.74 (s, 4H), 2.31–2.27 (m, 2H); <sup>13</sup>C NMR 168.16, 161.11, 147.91, 139.22, 121.63, 119.31, 66.80, 36.30, 28.36, 25.42; ESI MS <i>m</i>/<i>z</i>– 404.8 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>7</sub>S<sub>3</sub> – H) calcd 404.9885, found 404.9881. Anal. Calcd for C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>7</sub>S<sub>3</sub>: C, 38.41; H, 3.47; N, 6.89. Found: C, 38.57; H, 3.52; N, 6.99.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 15-(2-Pyridyldithio)-4,7,10,13-tetraoxapentadecanoic Acid (<b>18</b>)</h3><div class="NLM_p last">To a solution of aldrithiol-2 (1.17 g, 5.31 mmol) in 5.0 mL of 1,2-dimethoxyethane was added a solution of 3-(2-thiotetraethylene glycol)propionic acid (17) (Quanta Biodesign, 490 mg, 1.73 mmol) dissolved in 1.0 mL of 1,2-dimethoxyethane. The reaction mixture was stirred at room temperature for 3.5 h and then concentrated and purified by silica chromatography, eluting with 5% methanol in methylene chloride, to yield 431.6 mg (63.7% yield) of the desired product. <sup>1</sup>H NMR (CDCl<sub>3</sub>) 2.615 (2H, t), 2.986 (2H, t), 3.569–3.626 (4H, m), 3.634 (8H, d, <i>J</i> = 3.2 Hz), 3.738 (4H, dt), 7.101 (1H, m), 7.667 (1H, m), 7.781 (1H, d, <i>J</i> = 8.4 Hz), and 8.466 ppm (1H, m); HRMS <i>m</i>/<i>z</i>– (C<sub>16</sub>H<sub>25</sub>NO<sub>6</sub>S<sub>2</sub> + Na) calcd 414.1021, found 414.1049.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 15-(2-Pyridyldithio)-4,7,10,13-tetraoxapentadecanoic Acid <i>N</i>-Hydroxysuccinimide Ester (<b>19</b>)</h3><div class="NLM_p last">A 10 mL round bottomed flask was charged with 15-(2-pyridyldithio)-4,7,10,13-tetraoxapentadecanoic acid (431 mg, 1.10 mmol), methylene chloride (50 mL), <i>N</i>-hydroxysuccinimide (3.6 mg, 0.31 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (6.8 mg, 0.036 mmol), and the reaction was allowed to proceed for 2 h at room temperature with stirring. The product was purified by silica chromatography, eluting with 7% 1,2-dimethoxyethane in methylene chloride to give 206.3 mg (38.4% yield) of the desired product. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.81 (4H, s), 2.86 (2H, t, <i>J</i> = 6.4 Hz), 2.98 (2H, t, <i>J</i> = 6.3 Hz), 3.53–3.55 (2H, m), 3.59–3.60 (m, 2H), 3.61 (10H, d, <i>J</i> = 2.5 Hz), 3.62 (2H, t, <i>J</i> = 6.2 Hz), 3.81 (2H, t, <i>J</i> = 6.4 Hz), 7.10 (1H, dd, <i>J</i> = 5.0, 7.2 Hz), 7.71 (1H, dt, <i>J</i> = 15.5, 8.0, and 1.5 Hz), 7.81 (1H, d, <i>J</i> = 8.0 Hz), 8.43 (1H, dd, <i>J</i> = 4.1, 0.7 Hz); <sup>13</sup>C NMR 25.79, 32.37, 38.82, 53.62, 65.93, 68.99, 70.64, 70.70, 70.87, 70.94, 120.41, 121.01, 148.79, 160.49, 166.91, 169.11; ESI MS: <i>m</i>/<i>z</i>+ 511.1 (M + Na)<sup>+</sup>; HRMS <i>m</i>/<i>z</i>– (C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>8</sub>S<sub>2</sub> + Na) calcd 511.1185, found 511.1182. Anal. Calcd for C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>8</sub>S<sub>2</sub>: C, 49.17; H, 5.78; N, 5.73. Found: C, 49.19; H, 5.91; N, 5.77.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Methyl 4-Azido-2-sulfobutyrate (<b>21</b>)</h3><div class="NLM_p last">A mixture of methyl 4-bromo-2-sulfobutyrate (<b>10</b>) (1.07 g, 4.11 mmol) and sodium azide (0.70 g (10.7 mmol) in DMF (50 mL) was stirred overnight. The mixture was evaporated and purified by silica chromatography and eluted with 1:5:0.01 CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>/HAc and crystallized with CH<sub>3</sub>OH/toluene/hexane to afford 1.00 g (95%) of the title compound. Mp = 267 −272 °C (dec). <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>): 12.06 (br, 1H), 3.65 (s, 3H), 3.59 (dd, 1H, <i>J</i> = 5.4, 8.9 Hz), 3.47 (m, 2H), 2.24 (m, 2H). <sup>13</sup>C NMR 171.10, 64.29, 52.24, 50.64, 21.35. ESI MS <i>m</i>/<i>z</i>+ 267.9 (M + 2Na–H), <i>m</i>/<i>z</i>– 222.0 (M – H). HRMS <i>m</i>/<i>z</i>– (C<sub>5</sub>H<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S – H) calcd 222.0185, found 222.0179.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-Azido-2-sulfobutyric Acid (<b>22</b>)</h3><div class="NLM_p last">Methyl 4-azido-2-sulfobutyrate (<b>21</b>) (1.00 g, 4.08 mmol) in a mixture of HCl (50 mL, 1.0 M) and HOAc (5 mL) was heated at 100 °C for 6 h. The mixture was evaporated and coevaporated with 3 × 50 mL of water and crystallized with water/acetone to afford 1.0 g (99%) of the title compound. <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>): 3.60 (m, 2H), 3.52 (m, 1H), 2.24 (m, 2H). <sup>13</sup>C NMR 170.96, 63.04, 50.66, 29.12. ESI MS <i>m</i>/<i>z</i>– 207.7 (MW – H); HRMS <i>m</i>/<i>z</i>– (C<sub>4</sub>H<sub>7</sub>N<sub>3</sub>O<sub>5</sub>S – H) calcd 208.0028, found 208.0021.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-Amino-2-sulfobutyric Acid (<b>23</b>)</h3><div class="NLM_p last">4-Azido-2-sulfobutyric acid (<b>22</b>) (500 mg, 2.40 mmol), water (20 mL), and Pd/C (110 mg, 10% Pd, 50% water based) were placed into a 250 mL hydrogenation shaking bottle. After evacuation, 20 psi of hydrogen was let into the bottle. The mixture was shaken for 8 h, then filtered through Celite, washed with DMF, evaporated, and coevaporated with dry DMF to afford 476 mg (91% HCl salt) of the title product. ESI MS <i>m</i>/<i>z</i>– 181.8 (MW – H). This product was used directly without further purification.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>Z</i>)-4-(3-Carboxy-3-sulfopropylamino)-4-oxobut-2-enoic Acid (<b>24</b>)</h3><div class="NLM_p last">The above 4-amino-2-sulfobutyric acid, HCl salt (<b>23</b>) (476 mg, 2.16 mmol) in dry DMF (20 mL) was treated with maleic anhydride (232 mg, 2.36 mmol). The mixture was stirred under argon overnight, evaporated, and purified on a self-packed C-18, 1.0 cm × 25 cm column, eluted with water. The fractions containing product were pooled, evaporated, and crystallized with H<sub>2</sub>O/acetone to afford 552 mg (83%, in two steps) of the title product. <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>): 9.70 (br, 1H), 6.73 (d, 1H, <i>J</i> = 12.8 Hz), 6.32 (d, 1H, <i>J</i> = 12.8 Hz), 3.69 (m, 1H), 3.47 (m, 2H), 2.27 (m, 2H). <sup>13</sup>C NMR 171.47, 167.32, 165.87, 135.44, 133.07, 63.82, 39.13, 27.62. ESI MS <i>m</i>/<i>z</i>– 279.8 (MW – H); HRMS <i>m</i>/<i>z</i>– (C<sub>8</sub>H<sub>11</sub>NO<sub>8</sub>S – H) calcd 280.0127, found 280.0111.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-<i>N</i>-Maleimido-2-sulfobutanoic Acid (<b>25</b>)</h3><div class="NLM_p last">(<i>Z</i>)-4-(3-Carboxy-3-sulfopropylamino)-4-oxobut-2-enoic acid (<b>24</b>) (310 mg, 1.10 mmol) in a mixture of dry DMA (5 mL) and dry toluene (20 mL) was heated. After the temperature reached 80 °C, HMDS (hexamethyldisilazane) (1.40 mL, 6.71 mmol) and ZnCl<sub>2</sub> (1.85 mL, 1.0 M in diethyl ether, 1.85 mmol) were added. The mixture was continually heated to 115–125 °C, and toluene was collected through Dean–Stark trap. The reaction mixture was fluxed at 120 °C for 6 h. During this period, 2 × 20 mL of dry toluene was added to keep the mixture volume around 8–10 mL. Then the mixture was cooled, and 1 mL of 1:10 HCl (conc)/CH<sub>3</sub>OH was added. The mixture was evaporated, and the sample was purified by silica chromatography and eluted with CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>/HAc (1:5:0.01 to 1:4:0.01) to afford 245 mg (85%) of the title product. <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>): 10.83(br, 1H), 6.95 (s, 2H), 3.65 (m, 1H), 3.54 (m, 2H), 2.27 (m, 2H). <sup>13</sup>C NMR 173.61, 172.04, 135.47, 64.18, 37.1, 27.89. ESI MS <i>m</i>/<i>z</i>– 261.8 (MW – H). HRMS <i>m</i>/<i>z</i>– (C<sub>8</sub>H<sub>9</sub>NO<sub>7</sub>S – H) calcd 262.0021, found 262.0037.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Succinimidyl 4-<i>N</i>-Maleimido-2-sulfobutyrate (<b>26</b>)</h3><div class="NLM_p last">4-<i>N</i>-Maleimido-2-sulfobutanoic acid (<b>25</b>) (240 mg, 0.91 mmol) in DMA (10 mL) was added to NHS (220 mg, 1.91 mmol) and EDC (500 mg, 2.60 mmol). The mixture was stirred under argon overnight, evaporated, and purified on SiO<sub>2</sub> chromatography, eluting with CH<sub>2</sub>CH<sub>2</sub>/CH<sub>3</sub>OH/HAc (10000:1000:1 to 10000:2000:1), then crystallized with DMA/EtOAc/hexane to afford 262 mg (80% yield) of the title compound. <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>) 6.99 (s, 1H), 3.83 (m, 1H), 3.64 (m, 2H), 2.75 (s, 4H), 2.34 (m, 2H); <sup>13</sup>C NMR 171.97, 171.82, 166.64, 135.58, 62.00, 36.66, 26.62; ESI MS <i>m</i>/<i>z</i>– 358.9 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>9</sub>S – H) calcd 359.0185, found 359.0171. Anal. Calcd for C<sub>12</sub>H<sub>12</sub>N <sub>2</sub>O<sub>9</sub>S: C, 40.00; H, 3.36; N, 7.78. Found: C, 40.22; H, 3.42; N, 7.87.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>E</i>)-Methyl 4-Azidobut-2-enoate (<b>29</b>)</h3><div class="NLM_p last">To the solution of NaN<sub>3</sub> (2.80 g, 43.01 mmol) in 100 mL of DMF at 0 °C was added methyl 4-bromocrotonate (<b>28</b>) (5.00 mL, 85%, 36.10 mmol). After being stirred at 0 °C for 30 min, the mixture was stirred at room temperature for 4 h, evaporated, suspended with EtOAc/hexane (1:1), filtered, evaporated, and chromatographically purified on a silica column, eluting with ethyl acetate/hexane (1:25 to 1:10) afforded 4.08 g (80% yield) of the title product. <sup>1</sup>H NMR (CDCl<sub>3</sub>) 6.88 (m, 1H), 6.06 (ddd, 1H, <i>J</i> = 1.7, 3.4, 15.6 Hz), 3.97 (dd, 2H, <i>J</i> = 1.2, 4.96 Hz), 3.73 (s, 3H); <sup>13</sup>C NMR 166.23, 140.86, 123.49, 51.95, 51.36; ESI MS <i>m</i>/<i>z</i>+ 182.5 (M + Na + H<sub>2</sub>O), 305.5 (2M + Na); HRMS <i>m</i>/<i>z</i>+ (C<sub>5</sub>H<sub>7</sub>N<sub>3</sub>O<sub>2</sub>S + Na + H<sub>2</sub>O) calcd 182.0542, found 182.0555.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Methyl 3-(Acetylthio)-4-azidobutanoate (<b>30</b>)</h3><div class="NLM_p last">To the solution of (<i>E</i>)-methyl 4-azidobut-2-enoate (<b>29</b>) (4.00 g, 28.37 mmol) in 60 mL of THF at 0 °C were added a mixture of thioacetic acid (3.0 mL, 42.09 mmol) and DIPEA (8.0 mL, 45.92 mmol) in 60 mL of THF over 20 min. After being stirred at 0 °C for 1 h, the mixture was allowed to warm to room temperature, then stirred at room temperature overnight, and evaporated to dryness. The residue was redissolved in CH<sub>2</sub>Cl<sub>2</sub>, washed with NaHCO<sub>3</sub> (sat.) and 1 M NaH<sub>2</sub>PO<sub>4</sub>/NaCl (sat.), pH 4, successively, dried over MgSO<sub>4</sub>, filtered, evaporated, and chromatographed on silica. The product eluted with an ethyl acetate/hexane gradient (1:8 to 1:4) to afford 4.98 g (81%) of the title product. <sup>1</sup>H NMR (CDCl<sub>3</sub>) 3.66 (m, 1H), 3.62 (s, 3H), 3.40 (dd, 1H, <i>J</i> = 7.5, 12.7 Hz), 3.31 (m, 1H), 2.78 (m, 1H), 2.60 (m, 1H), 2.32 (s, 3H); <sup>13</sup>C NMR (DMF-<i>d</i><sub>7</sub>) 192.20, 172.48, 56.56, 53.60, 51.31, 34.58, 30.56; ESI MS <i>m</i>/<i>z</i>+ 240.0 (M + Na), 255.9 (M + K); HRMS <i>m</i>/<i>z</i>+ (C<sub>7</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub>S + Na) calcd 240.0419, found 240.0406.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Azido-4-methoxy-4-oxobutane-2-sulfonic Acid (<b>31</b>)</h3><div class="NLM_p last">To methyl 3-(acetylthio)-4-azidobutanoate (<b>30</b>) (4.00 g, 18.43 mmol) in acetic acid (75 mL) was added 30% H<sub>2</sub>O<sub>2</sub> (25 mL). The mixture was stirred overnight, evaporated, and coevaporated with EtOH/toluene, and purified on SiO<sub>2</sub>, eluting with CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>/HAc (100:800:1 to 100:500:1) to afford 3.85 (93%) g of the title compound. <sup>1</sup>H NMR (CD<sub>3</sub>OD) 3.78 (dd, 1H, <i>J</i> = 5.0, 12.7 Hz), 3.62 (s, 3H), 3.44 (dd, 1H, <i>J</i> = 7.5, 12.7 Hz), 3.33 (m, 1H), 2.84 (dd, 1H, <i>J</i> = 5.6, 16.5 Hz), 2.57 (dd, 1H, <i>J</i> = 7.5, 16.5 Hz); <sup>13</sup>C NMR (DMF-<i>d</i><sub>7</sub>) 173.37, 57.31, 52.54, 52.49, 34.51; ESI MS <i>m</i>/<i>z</i>– 221.7 (M + H); HRMS <i>m</i>/<i>z</i>– (C<sub>5</sub>H<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S – H) calcd 222.0185, found 222.0176.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-Azido-3-sulfobutanoic Acid (<b>32</b>)</h3><div class="NLM_p last">Azido-4-methoxy-4-oxobutane-2-sulfonic acid (3.80 g, 17.04 mmol) in a mixture of 1.0 M HCl (150 mL) and acetic acid (8 mL) was refluxed at 120 °C overnight, evaporated, and successively coevaporated with water and ethanol/toluene, and purified on SiO<sub>2</sub>, eluting with CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>/HOAc (100:500:1 to 100:400:1) to afford 3.02 (85%) g of the title compound. <sup>1</sup>H NMR (CD<sub>3</sub>OD) 3.77 (dd, 1H, <i>J</i> = 5.1, 12.8 Hz), 3.45 (dd, 1H, <i>J</i> = 7.0, 12.8 Hz), 3.31 (m, 1H), 2.86 (dd, 1H, <i>J</i> = 4.7, 16.7 Hz), 2.51 (dd, 1H, <i>J</i> = 8.4, 16.7 Hz); <sup>13</sup>C NMR (DMF-<i>d</i><sub>7</sub>) 173.98, 67.50, 59.78, 27.82; ESI MS <i>m</i>/<i>z</i>– 207.7 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>4</sub>H<sub>7</sub>N<sub>3</sub>O<sub>5</sub>S – H) calcd 208.0028, found 208.0055.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 4-Amino-3-sulfobutanoic Acid (<b>33</b>)</h3><div class="NLM_p last">In a 500 mL hydrogenation bottle were placed 4-azido-3-sulfobutanoic acid (<b>32</b>) (3.00 g, 14.35 mmol) in methanol (150 mL) and 0.32 g of Pd/C (10% Pd, 50% wet). After evacuating the air, 30 psi of H<sub>2</sub> was introduced, and the mixture was shaken overnight, filtered through Celite, evaporated, and coevaporated with dry EtOH to afford about 2.50 g (95%) of 4-amino-3-sulfobutanoic acid. <sup>1</sup>H NMR (CD<sub>3</sub>OD) 3.24 (m, 1H), 3.17 (m, 1H), 2.90 (dd, 1H, <i>J</i> = 2.6, 16.5 Hz), 2.33 (dd, 1H, <i>J</i> = 10.1, 16.5 Hz); ESI MS <i>m</i>/<i>z</i>– 181.60 (M – H). The resulting compound was unstable and was used directly without further purification.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>Z</i>)-4-(3-Carboxy-2-sulfopropylamino)-4-oxobut-2-enoic Acid (<b>34</b>)</h3><div class="NLM_p last">To the solution of 4-amino-3-sulfobutanoic acid (<b>33</b>) (∼2.50 g, 13.66 mmol) in 100 mL of DMA was added maleic anhydride (1.48 g, 15.10 mmol), and the mixture was stirred overnight, evaporated, purified on C-18 column (2 cm × 30 cm) eluted with 1% HOAc in water and crystallized with MeOH/acetone/toluene to afford 3.34 g (83%) of (<i>Z</i>)-4-(3-carboxy-2-sulfopropylamino)-4-oxobut-2-enoic acid. <sup>1</sup>H NMR (CD<sub>3</sub>OD) 6.33 (d, 1H, <i>J</i> = 12.6 Hz), 6.10 (d, 1H, <i>J</i> = 12.6 Hz), 3.64 (dd, 1H, <i>J</i> = 5.8, 14.0 Hz), 3.54 (m, 1H), 3.30 (m, 1H), 2.78 (dd, 1H, <i>J</i> = 4.9, 16.8 Hz), 2.39 (m, 1H); <sup>13</sup>C NMR 173.52, 168.68, 167.98, 135.59, 127.79, 57.31, 40.56, 34.52; ESI MS <i>m</i>/<i>z</i>– 279.7 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>8</sub>H<sub>11</sub>NO<sub>8</sub>S – H) calcd 280.0127, found 208.0169.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)-3-sulfobutanoic Acid (<b>35</b>)</h3><div class="NLM_p last">(<i>Z</i>)-4-(3-Carboxy-2-sulfopropylamino)-4-oxobut-2-enoic acid (<b>34</b>) (450 mg, 1.60 mmol) in a mixture of 10 mL of dry DMA and 50 mL of dry toluene was heated. After the temperature reached 80 °C, HMDS (hexamethyldisilazane, 1.80 mL, 8.63 mmol) and ZnCl<sub>2</sub> (3.2 mL, 1.0 M in diethyl ether) were added. The mixture was heated to 115–125 °C, and toluene was collected through a Dean–Stark trap. The reaction mixture was fluxed at 120 °C for 6 h. During this period, 2 × 20 mL of dry toluene was added to keep the mixture volume around 8–10 mL. Then the mixture was cooled, 1 mL of 1:10 HCl (conc)/CH<sub>3</sub>OH was added, evaporated, and purified on SiO<sub>2</sub> eluted with 1:5:0.01 CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>/HAc to afford 315 mg (75%) of the title product. <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>) 6.96 (s, 2H), 4.04 (dd, 1H, <i>J</i> = 4.3, 13.8 Hz), 3.47 (m, 1H), 3.23 (dd, 1H, <i>J</i> = 7.4, 14.7 Hz), 2.99 (dd, 1H, <i>J</i> = 3.3, 16.8 Hz), 2.35 (dd, 1H, <i>J</i> = 8.1, 16.9 Hz); <sup>13</sup>C NMR 173.58, 172.18, 135.54, 54.61, 40.24, 32.43; ESI MS <i>m</i>/<i>z</i>– 261.70 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>8</sub>H<sub>9</sub>NO<sub>7</sub>S – H) calcd 262.0021, found 262.0040.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 1-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)-4-(2,5-dioxopyrrolidin-1-yloxy)-4-oxobutane-2-sulfonic Acid (<b>36</b>)</h3><div class="NLM_p last">4-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)-3-sulfobutanoic acid (<b>35</b>) (110 mg, 0.418 mmol), EDC (240 mg, 1.25 mmol), and <i>N</i>-hydroxysuccinimide (58 mg, 0.504 mmol) were stirred in 10 mL of DMA overnight and then evaporated and purified on SiO<sub>2</sub>, eluting with CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>/HAc (100:900:1 to 100: 600:1) to afford 112 mg (75%) of the title product. <sup>1</sup>H NMR (DMF-<i>d</i><sub>7</sub>) 6.93 (s, 2H), 4.06 (dd, 1H, <i>J</i> = 4.8, 13.1 Hz), 3.80 (dd, 1H, <i>J</i> = 10.7, 13.9 Hz), 3.35 (dd, 1H <i>J</i> = 3.3, 17.8 Hz), 3.25 (m, 1H), 3.10 (dd, 1H, <i>J</i> = 2.2, 16.4 Hz), 2.87 (m, 4H); <sup>13</sup>C NMR 172.27, 170.88, 169.29, 135.55, 55.28, 40.22, 32.69, 26.66; ESI MS <i>m</i>/<i>z</i>– 261.70 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>9</sub>S – H) calcd 359.0185, found 359.0208. Anal. Calcd for C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>9</sub>S: C, 40.00; H, 3.36; N, 7.78. Found: C, 40.36; H, 3.27; N, 7.67.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Ethyl 3-(Acetylthio)-3-cyanopropanoate (<b>38</b>)</h3><div class="NLM_p last">To (<i>Z</i>)-ethyl 3-cyanoacrylate (<b>37</b>) (5.01 g, 40.00 mmol) in 80 mL of THF at −20 °C was added a solution of thioacetic acid (5.0 mL, 70.15 mmol) and DIPEA (16.0 mL, 92.03 mmol) in 20 mL of THF in 30 min. The mixture was kept at −20 °C for 4 h and then at room temperature overnight. The mixture was concentrated, diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with saturated NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered, evaporated, and purified by SiO<sub>2</sub> chromatography (1:4 EtOAc/hexane) to afford 5.22 g (65%) of the title compound. <i>R<sub>f</sub></i> = 0.25 (1:4 EtAC/hexane); <sup>1</sup>H NMR (CDCl<sub>3</sub>), 4.44 (m, 1H), 4.11 (dd, 2H, <i>J</i> = 7.1, 14.3 Hz), 3.38 (m, 1H), 3.15 (m, 1H), 2.17 (s, 3H), 1.19 (t, 3H, <i>J</i> = 7.2 Hz); <sup>13</sup>C NMR 194.12, 173.21, 119.82, 61.35, 33.52, 30.08, 14.62; MS <i>m</i>/<i>z</i>+ 225.9 (M + Na), <i>m</i>/<i>z</i>– 201.7 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>8</sub>H<sub>11</sub>NO<sub>3</sub>S + Na) calcd 224.0357, found 224.0262.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Cyano-3-ethoxy-3-oxopropane-1-sulfonic Acid (<b>39</b>)</h3><div class="NLM_p last">Ethyl 3-(acetylthio)-3-cyanopropanoate (<b>38</b>) (2.00 g, 9.95 mmol) in acetic acid (40 mL) was treated with H<sub>2</sub>O<sub>2</sub> (12 mL, 30%). The mixture was stirred overnight, evaporated, and purified on silica gel chromatography, eluting with methanol/dichloromethane/acetic acid (1:8:0.01 to 1:5:0.01) to afford 1.72 g (84%) of the title compound. <sup>1</sup>H NMR (DMSO), 4.63 (m, 1H), 4.12 (dd, 2H, <i>J</i> = 7.1, 14.3 Hz), 3.27 (m, 1H), 3.05 (m, 1H), 1.28 (t, 3H, <i>J</i> = 7.2 Hz); <sup>13</sup>C NMR 173.15, 113.85, 61.38, 48.32, 26.33, 14.15; ESI MS <i>m</i>/<i>z</i>– 205.8 (MW – H); HRMS <i>m</i>/<i>z</i>– (C<sub>6</sub>H<sub>9</sub>NO<sub>5</sub>S – H) calcd 206.0123, found 206.0151.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 1-(<i>tert</i>-Butoxycarbonylamino)-4-ethoxy-4-oxobutane-2-sulfonic Acid (<b>40</b>)</h3><div class="NLM_p last">In a hydrogenation bottle was added cyano-3-ethoxy-3-oxopropane-1-sulfonic acid (<b>39</b>) (2.50 g, 12.06 mmol), ethanol (80 mL), fresh filtered Raney Ni (0.40 g), and BOC anhydride (3.30 g, 15.12 mmol). After the air inside the bottle was evacuated by vacuum, 20 psi of hydrogen was introduced into the bottle. The bottle was shaken overnight, and the reaction mixture was filtered through Celite, evaporated, and purified on silica gel, eluting with methanol/dichloromethane/acetic acid (1:6:0.01) to afford 3.18 g (85%) of the title compound. <sup>1</sup>H NMR (DMSO), 6.82 (s, 1H), 4.26 (m, 1H), 4.11 (dd, 2H, <i>J</i> = 7.1, 14.3 Hz), 3.53 (dd, 1H, <i>J</i> = 4.2, 13.4 Hz), 3.36 (m, 1H), 2.86 (m, 1H), 2.51 (m, 1H), 1.38 (s, 9H), 1.22 (t, 3H, <i>J</i> = 7.2 Hz); <sup>13</sup>C NMR 173.35, 155.72, 80.44, 62.05, 52.55, 41.61, 34.50, 28.85, 14.52; ESI MS <i>m</i>/<i>z</i>– 309.8 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>11</sub>H<sub>21</sub>NO<sub>7</sub>S – H) calcd 310.0960, found 310.0904.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-(<i>tert</i>-Butoxycarbonylamino)-3-sulfobutanoic Acid (<b>41</b>)</h3><div class="NLM_p last">To 1-(<i>tert</i>-butoxycarbonylamino)-4-ethoxy-4-oxobutane-2-sulfonic acid (<b>40</b>) (402 mg, 1.29 mmol) in a mixture of THF/H<sub>2</sub>O (1:2, 60 mL) was added lithium hydroxide monohydrate (2.0 g, 47.6 mmol). The mixture was stirred under Ar overnight, concentrated, and purified on C-18 column (2 cm × 30 cm), eluting with a gradient from 100% water to 10% methanol in water to afford 328 mg (90%) of the title compound. <sup>1</sup>H NMR (DMSO), 6.78 (s, 1H), 4.03 (m, 1H), 3.57 (dd, 1H, <i>J</i> = 4.2, 13.4 Hz), 3.41 (m, 1H), 2.89 (m, 1H), 2.61 (m, 1H), 1.39 (s, 9H); <sup>13</sup>C NMR 174.21, 155.82, 79.85, 59.95, 42.06, 32.52, 28.88, 14.55; ESI MS 281.8 (M – H); HRMS <i>m</i>/<i>z</i>– (C<sub>9</sub>H<sub>17</sub>NO<sub>7</sub>S – H) calcd 282.0647, found 282.0630.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>Z</i>)-4-(3-Carboxy-2-sulfopropylamino)-4-oxobut-2-enoic Acid (<b>34</b>)</h3><div class="NLM_p last">4-(<i>tert</i>-Butoxycarbonylamino)-3-sulfobutanoic acid (<b>41</b>) (321 mg, 1.13 mmol) was stirred in a mixture of HCl (conc)/dioxane (1:4, 15 mL) for 30 min, evaporated, and coevaporated with ethanol/toluene (1:1, 4 × 20 mL) to dryness. To the dried material were added maleic anhydride (121 mg, 1.23 mmol) and DMA (20 mL), and the mixture was stirred overnight, evaporated, and run through a C-18 column eluted with water, and crystallized with EtOH/hexane to afford 263 mg (83%) of the title compound. ESI MS 279.8 (M – H). The NMR data are the same through the route with 4-azido-3-sulfobutanoic acid (<b>32</b>).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Succinimidyl-[(<i>N</i>-maleimidopropionamido)tetraethyleneglycol] Ester (<b>42</b>, NHS-PEG<sub>4</sub>-maleimide)</h3><div class="NLM_p last">An amount of 100 mg of the compound purchased from Quanta Biodesign was coevaporated with CH<sub>2</sub>Cl<sub>2</sub> and benzyne (1:2, 2 × 50 mL) to remove the water before being checked by NMR and elemental analysis. <sup>1</sup>H NMR (CDCl<sub>3</sub>) 2.47 (2H, t, <i>J</i> = 7.0 Hz), 2.80 (s, 4H), 2.85 (2H, t, <i>J</i> = 6.4 Hz), 3.36–3.39 (m, 2H), 3.49 (2H, t, <i>J</i> = 5.2 Hz), 3.56–3.64 (m, 12H), 3.78 – 3.82 (m, 4H), 6.66 (2H, s); <sup>13</sup>C NMR 25.77, 32.32, 34.49, 34.69, 39.44, 65.89, 69.82, 70.39, 70.62, 70.65, 70.68, 70.79, 70.88, 134.38, 166.92, 169.20, 169.95, 170.69; HRMS <i>m</i>/<i>z</i>+ (C<sub>22</sub>H<sub>32</sub>N<sub>3</sub>O<sub>11</sub>) calcd 514.2037, found 514.2018. Anal. Calcd for C<sub>22</sub>H<sub>31</sub>N<sub>3</sub>O<sub>11</sub>·<sup>1</sup>/<sub>3</sub>H<sub>2</sub>O): C, 50.86; H, 6.14; N, 8.09. Found: C, 50.75; H, 6.16; N, 7.92.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 15-(DM4-dithio)-4,7,10,13-tetraoxapentadecanoic Acid (<b>47</b>)</h3><div class="NLM_p last">A solution of <i>N</i><sup>2′</sup>-deacetyl-<i>N</i><sup>2′</sup>-(4-mercapto-4-methyl-1-oxopentyl)maytansine (DM4, 18.6 mg, 0.0239 mmol) and 15-(2-pyridyldithio)-4,7,10,13-tetraoxapentadecanoic acid (14.0 mg, 0.0358 mmol) was prepared in 0.75 mL of 1,2-dimethoxyethane. 4-Methylmorpholine (6.0 mg, 0.0597 mmol) was added to the reaction vessel, and the reaction proceeded for 24 h at room temperature with stirring. Upon reaction completion, the crude reaction mixture was dried in vacuo and used without further purification.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 15-(DM4-dithio)-4,7,10,13-tetraoxapentadecanoic Acid <i>N</i>-Hydroxysuccinimide Ester (<b>48</b>)</h3><div class="NLM_p last">The crude 15-(DM4-dithio)-4,7,10,13-tetraoxapentadecanoic acid was dissolved in 2.0 mL of methylene chloride and combined with <i>N</i>-hydroxysuccinimide (3.6 mg, 0.31 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (6.8 mg, 0.036 mmol). The mixture was stirred for 2.5 h, and the product was purified by silica chromatography, eluting with 4% methanol in methylene chloride. The solvent was removed under vacuum to give 15.0 mg (54.2% yield) of the desired product. ESI MS: <i>m</i>/<i>z</i> found, 1179.3 (M + Na)<sup>+</sup>; calcd, 1179.4.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 23-(2,5-Dioxopyrrolidin-1-yloxy)-2,3-dimethyl-4,23-dioxo-11,14,17,20-tetraoxa-7,8-dithia-3-azatricosan-1-oic Acid, Maytansinol Ester. DM1-MAL-PEG<sub>4</sub>-NHS (<b>50</b>)</h3><div class="NLM_p last">A solution of <i>N</i><sup>2′</sup>-deacetyl-<i>N</i><sup>2′</sup>-(3-mercapto-1-oxopropyl)maytansine (DM1, 28.1 mg, 0.0381 mmol) was prepared in 0.50 mL of THF, and succinimidyl-[(<i>N</i>-maleimidopropionamido)tetraethyleneglycol] ester (<b>42</b>, NHS-PEG<sub>4</sub>-maleimide, Quanta Biodesign, 39.1 mg, 0.0762 mmol) was added in 1.5 mL of 2:1 potassium phosphate buffer (50 mM, pH 6) and THF. The reaction proceeded for 1 h with stirring at room temperature, and TLC analysis indicated that the reaction was complete. The crude reaction mixture was purified by silica chromatography, eluting with 6% ethanol in methylene chloride. The solvent was removed under vacuum to give 9.6 mg (20.1% yield) of the desired product. <sup>1</sup>H NMR (CDCl<sub>3</sub>, reference 7.26 ppm) δ 0.792 (3H, s), 1.192–1.274 (3H, m), 1.290 (3H, s), 1.311 (2H, d, <i>J</i> = 2.4 Hz), 1.452 (1H, m), 1.560 (1H, d, <i>J</i> = 13.6 Hz), 1.631 (3H, s), 2.167 (1H, dd, <i>J</i> = 11.6 and 2.6 Hz), 2.351 (1H, dd, <i>J</i> = 14.8 and 3.8 Hz), 2.437 (2H, m), 2.565–2.639 (2H, m), 2.787–2.902 (10H, m), 2.919–3.142 (5H, m), 3.192 (3H, s), 3.348 (3H, d, <i>J</i> = 1.6 Hz), 3.399 (2H, m), 3.484 (1H, d, <i>J</i> = 8.8), 3.523 (2H, m), 3.645 (13H, m), 3.708 (2H, m), 3.767 (1H, m), 3.833 (2H, t), 3.980 (3H, s), 4.272 (1H, t), 4.770 (1H, d, <i>J</i> = 12 Hz), 5.354 (1H, m), 5.644 (1H, m), 6.236 (1H, s), 6.362 (1H, broad s), 6.415 (1H, dd, <i>J</i> = 11.2 and 4 Hz), 6.625 (1H, s), 6.658 (1H, dd, <i>J</i> = 6.4 and 4.6 Hz), and 6.822 (1H, dd, <i>J</i> = 4 and 1.6 Hz). ESI MS: <i>m</i>/<i>z</i> found, 1273.5 (M + Na)<sup>+</sup>, calcd 1273.5. HRMS: found, 1273.4637 (M + Na)<sup>+</sup>; calcd, 1273.4605.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 24-(2,5-Dioxopyrrolidin-1-yloxy)-2,3,7,7-tetramethyl-4,24-dioxo-12,15,18,21-tetraoxa-8,9-dithia-3-azatetracosan-1-oic Acid, Maytansinol Ester. DM4-MAL-PEG<sub>4</sub>-NHS (<b>51</b>)</h3><div class="NLM_p last">In a 10 mL round-bottom flask, DM4 (340.8 mg, 0.437 mmol) and Mal-PEG<sub>4</sub>-NHS (<b>42</b>) (247 mg, 0.480 mmol) were combined and dissolved in <i>N</i>,<i>N</i>-dimethylacetamide (2 mL). The reaction flask was equipped with a stir bar and the solution stirred as the reactants went into solution. <i>N</i>,<i>N</i>-Diisopropylethylamine (0.076 mL, 0.437 mmol) was then added. The flask was equipped with a septa, and the mixture was stirred at room temperature for ∼30 min. The crude reaction mixture appeared clear and dark orange. Upon reaction completion (as determined by HPLC) the reaction volume was reduced in vacuo to give a crude orange oil. No further workup was performed. The crude material was dissolved in a minimal volume of CH<sub>2</sub>Cl<sub>2</sub> and purified by SiO<sub>2</sub> chromatography, eluting with 6% EtOH in CH<sub>2</sub>Cl<sub>2</sub>. Then 5 mL fractions were collected and checked for product by TLC. Pure-product-containing fractions were combined and concentrated in vacuo under a high vacuum (using an individual pump). <sup>1</sup>H NMR (CDCl<sub>3</sub>, reference 7.26 ppm) δ 0.796 (3H, s), 1.200–1.360 (14H, m), 1.424–1.489 (1H, m), 1.578 (1H, d, <i>J</i> = 13.6 Hz), 1.633 (3H, s), 1.798–2.094 (2H, m), 2.171 (1H, d, <i>J</i> = 13.2), 2.259–2.326 (1H, m), 2.426–2.472 (2H, m), 2.520 (1H, m), 2.577 (1H, m), 2.836 (4H, s), 2.879–2.906 (5H, m), 3.010 (1H, dd, <i>J</i> = 6 and 3.6 Hz), 3.073–3.167 (2H, m), 3.205 (3H, m), 3.345 (3H, s), 3.399 (2H, m), 3.486 (1H, d, <i>J</i> = 9.2 Hz), 3.536 (2H, t), 3.643 (12H, s), 3.648 (3H, s), 3.769 (2H, m), 3.838 (2H, t, <i>J</i> = 6.4 Hz), 3.978 (3H, s), 4.277 (1H, t, <i>J</i> = 10.4 Hz), 4.775 (1H, m), 5.345 (1H, m), 5.657 (1H, m), 6.246 (1H, s), 6.418 (2H, m), 6.646 (1H, dd, <i>J</i> = 1.2 and 6 Hz), 6.696 (1H, s), and 6.824 (1H, s). ESI MS: found 1315.6 (M + Na)<sup>+</sup>, calcd 1315.5; found 1329.4 (M + Cl)<sup>−</sup>, calcd 1329.3. HRMS: found 1315.5103 (M + Na)<sup>+</sup>, calcd 1513.5075.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Preparation of Conjugates</h3><div class="NLM_p last">Three antibodies, huC242, huMy9-6, and B38.1, were used to evaluate the utility of the linkers in conjugation with maytansinoids. The first two are humanized IgG1 antibodies that target CanAg expressed on the surface of human colorectal, pancreatic, and gastric cancer cells and CD33 expressed on myeloid leukemia cells, respectively. B38.1 is a chimeric human IgG1 targeting EpCAM expressed on various malignancies. The linker (<b>14</b>, <b>15</b>, <b>20</b>, <b>26</b>, <b>36</b>, or <b>42</b>) was dissolved in DMA (<i>N</i>,<i>N</i>-dimethylacetamide) at approximately 20 mM. For the antibody modification reaction, a solution of an antibody (8 mg/mL) was treated with 5–50 equiv of linker in a sodium phosphate buffer (pH 8.0 for linker <b>14</b>, <b>15</b>, and <b>26</b>; pH 6.5–7.0 for <b>20</b>, <b>36</b>, and <b>42</b>) with stirring in the presence of 5% (v/v) DMA. The reaction was allowed to proceed at ambient temperature for 10 min to 24 h. Unreacted linker was removed from the antibody by gel filtration using a Sephadex G25 column equilibrated in 150 mM potassium phosphate buffer containing 100 mM NaCl at pH 6.5 or pH 7.4. The extent of incorporation of S-Py linker was assessed by release of pyridine-2-thione using 50 mM DTT and measuring the absorbance at 343 nm as described below (ε<sub>343</sub> = 8080 M<sup>–1</sup> cm<sup>–1</sup> for free pyridine-2-thione). For the S-Py-NO<sub>2</sub> linker, modification was assessed directly by measuring the absorbance at 325 nm (ε<sub>325</sub> = 10 964 M<sup>–1</sup> cm<sup>–1</sup> for the 4-nitropyridyl-2-dithio group linked to antibody). For the conjugation reaction, thiol-containing maytansinoid (either DM1 or DM4) was dissolved in DMA at approximately 10 mM. The maytansinoid (0.8- to 1.7-fold molar excess relative to the number of linker molecules) was slowly added with stirring to the antibody which was at 2.5 mg/mL in sodium phosphate (pH 6.5–7.0) in a final concentration of 3% (v/v) DMA. The reaction was allowed to proceed at ambient temperature for 2–12 h. Conjugated antibody was purified using a Sephadex G25 column equilibrated with sodium phosphate buffer (pH 6.5). The number of molecules of maytansinoid incorporated per antibody molecule was assessed by measuring <i>A</i><sub>252</sub> and <i>A</i><sub>280</sub> of the conjugate as described below.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Measurement of Releasable Pyridine-2-Thione and Antibody Concentration of Linker-Modified Antibodies</h3><div class="NLM_p last">The molar ratio of pyridine-2-thione linked per mole of antibody is determined by measuring the <i>A</i><sub>280</sub> of the modified antibody and then the increase at <i>A</i><sub>343</sub> following the addition of DTT (50 μL of 1 M DTT/mL of sample). The concentration of DTT-released pyridine-2-thione is then calculated using an ε<sub>343</sub> of 8080 M<sup>–1</sup> cm<sup>–1</sup>. The concentration of antibody can then be calculated using an ε<sub>280</sub> of 194 712 M<sup>–1</sup> cm<sup>–1</sup> after subtracting the contribution of pyridine-2-thione absorbance at 280 nm (<i>A</i><sub>343nm</sub> post-DTT × 5100/8080) from the total <i>A</i><sub>280nm</sub> measured before DTT addition. The molar ratio of pyridine-2-thione/antibody can then be calculated. The mg/mL (g/L) concentration of antibody is calculated using a molecular weight of 147 000 g/mol.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Measurement of Antibody-Linked 5-Nitropyridyl-2-dithio Groups and Antibody Concentration of a Linker Modified Antibody<u class="uu">.</u></h3><div class="NLM_p last">The molar ratio of the 4-nitropyridyl-2-dithio groups linked per mole of antibody is calculated by measuring the <i>A</i><sub>280</sub> and <i>A</i><sub>325</sub> of the modified antibody without DTT treatment. The number of antibody-bound 4-nitropyridyl-2-dithio groups is calculated using an ε<sub>325nm</sub> of 10 964 M<sup>–1</sup> cm<sup>–1</sup>. The concentration of antibody can then be calculated using an ε<sub>280nm</sub> of 194 712 M<sup>–1</sup> cm<sup>–1</sup> after subtracting the contribution of the 5-nitropyridyl-2-dithio group absorbance at 280 nm (<i>A</i><sub>325nm</sub> × 3344/10964) from the total <i>A</i><sub>280 nm</sub> measured. The molar ratio of 4-nitropyridyl-2-dithio groups/antibody can then be calculated. The mg/mL (g/L) concentration of antibody is calculated using a molecular weight of 147 000 g/mol</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Calculating Antibody and DMx Component Concentrations of an AMC<u class="uu">.</u></h3><div class="NLM_p last">The antibody and DMx both absorb at the two wavelengths used to measure each component separately, i.e., 280 and 252 nm. The components are quantified using the following algebraic expressions which account for the contribution of each component at each wavelength (<i>C</i><sub>Ab</sub> is the molar concentration of antibody, and <i>C</i><sub>D</sub> is the molar concentration of DM1):<span class="NLM_disp-formula" id="eq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/jm-2011-002958_m001.gif" alt="" /></img><span class="labelSpan">(1)</span></span><span class="NLM_disp-formula" id="eq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/jm-2011-002958_m002.gif" alt="" /></img><span class="labelSpan">(2)</span></span>Each equation is solved for <i>C</i><sub>Ab</sub>:<span class="NLM_disp-formula" id="eq3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/jm-2011-002958_m003.gif" alt="" /></img><span class="labelSpan">(1a)</span></span><span class="NLM_disp-formula" id="eq4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/jm-2011-002958_m004.gif" alt="" /></img><span class="labelSpan">(2a)</span></span>An equality is set up (eq <a class="ref internalNav" href="#eq3" aria-label="1a">1a</a> = eq <a class="ref internalNav" href="#eq4" aria-label="2a">2a</a>) and solved for <i>C</i><sub>D</sub>:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/jm-2011-002958_m005.gif" alt="" /></img></span>Once the <i>C</i><sub>D</sub> is calculated, the value is used to solve for <i>C</i><sub>Ab</sub> in eq <a class="ref internalNav" href="#eq3" aria-label="1a">1a</a> (or eq <a class="ref internalNav" href="#eq4" aria-label="2a">2a</a>) above. The ratio of DMx/antibody (DAR) can then be calculated. The mg/mL (g/L) concentration of antibody is calculated using a molecular weight of 147 000 g/mol. The concentration of DM1 is calculated using a molecular weight of 736.5 g/mol (linked DM1), and the concentration of DM4 is calculated using a molecular weight of 778.5 g/mol (linked DM1).</div></div><div id="sec4_37_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> General One-Step Conjugation Procedure</h3><div class="NLM_p last">An amount of 1.0 equiv of linker (<b>14</b>, <b>15</b>, <b>26</b>, or <b>36</b>, ∼2 mM) in DMA was added to PBS buffer (pH 6.0) containing 1.5 equiv of DM1 or DM4, and the mixtures were incubated for 45–120 min at 4–20 °C. Then 0.1–0.25 equiv of mAb in a buffer solution (∼pH 8) was added to the linker–drug mixture and the final pH adjusted to 7.0–8.0. After incubating for 2–24 h at room temperature, the mixture was purified using a Sephadex G25 column equilibrated with PBS, pH 6.5. The number of maytansinoid molecules incorporated was determined as described above. For conjugation of AMC with PEG linkers, the maytansinoid–linker moiety (<b>48</b>, <b>50</b>, or <b>51</b>, 2–10 equiv) was added to a PBS solution (pH ∼7) containing an antibody. After incubating for 2–24 h at room temperature, the mixture was purified using a Sephadex G25 column equilibrated with PBS, pH 6.5.</div></div><div id="sec4_37_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Analytical (MS) Assay of the Conjugate</h3><div class="NLM_p last">AMCs at 1 mg/mL were deglycosylated with PNGase F (New England BioLabs, Ipswitch, MA) using 2 units/μg of protein. The samples were incubated overnight at 37 °C, after which they were analyzed using a TSK gel Super 3000 SW size-exclusion column (4.6 mm × 30 cm, 4 μm particle size, 250 Å pore size) from Tosoh Biosciences (Montgomeryville, PA), installed on a UPLC chromatographic system (Waters, Milford, MA). The column was maintained at 60 °C and operated with a mobile phase composition of 50% acetonitrile, 1% formic acid, 0.02% TFA with a flow rate of 0.25 mL/min. The outlet of the column was split and <sup>1</sup>/<sub>5</sub> of the flow was directed toward the electrospray source of a LCT time-of-flight mass spectrometer (Waters). The raw mass spectra were acquired using an <i>m</i>/<i>z</i> range between 1000 and 4500. The spectra originating from the immunoconjugates were summed and deconvoluted using MaxEnt1 deconvolution algorithm (Waters).</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> In Vitro Cytotoxicity Assays.</h3><div class="NLM_p">The cell lines used in the cytotoxicity assays were HCT-15 (ATCC CCL-225), a human colon tumor multidrug resistant cell line; HL60/QC, a variant of the human promyelocytic leukemia cell line HL60; COLO 205 (ATCC CCL-222), a human colon tumor cell line; Ramos (ATCC CRL-1923), a human Burkitt’s lymphoma cell; and COLO205/MDR, a clone of the COLO 205 cell line retrovirally transduced with the mdr1 gene.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> HCT-15 cells were grown in RPMI-1640 (catalog no. 30-2001, ATCC, Manassas, VA) supplemented with 10% fetal bovine serum and gentamycin. All other cell lines were grown in RPMI-1640 (catalog no. 11875-085, Invitrogen), supplemented with 10% fetal bovine serum and gentamycin. The cells were maintained at 37 °C in a humidified atmosphere that contained 6% CO<sub>2</sub>.</div><div class="NLM_p last">The cytotoxicity study was performed using a WST-8 dye-based cell survival assay as previously described.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> In Vivo Evaluation</h3><div class="NLM_p last">SCID mice were inoculated subcutaneously in the right flank with COLO 205/MDR cells (1.5 × 10<sup>6</sup> cells/mouse) in 0.1 mL of serum-free medium. The tumors were grown for 8 days to an average size of about 100 mm<sup>3</sup>, and the animals were then randomly divided into several groups (5–6 animals per group). The first group of mice served as the control group and was treated with the phosphate-buffered saline vehicle. The remaining groups were treated with a single injection of the following conjugates at a maytansinoid dose of 170 μg/kg: (a) B38.1-SMCC-DM1, (b) B38.1-PEG4-Mal-DM1, (c) B38.1-SPDB-DM4, and (d) B38.1-2-sulfo-SPDB-DM4 administered intravenously. Tumor sizes were measured twice weekly, and the tumor volumes were calculated using the formula tumor volume = <sup>1</sup>/<sub>2</sub>(length × width × height). The weight of the animals was also measured twice per week.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/jm2002958">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">HPLC purity data and UV chromatographic profiles for target compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2002958/suppl_file/jm2002958_si_001.pdf">jm2002958_si_001.pdf (244.7 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm2002958" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Y. Zhao</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#44362b262136306a3e2c252b042d2929312a2b23212a6a272b29643625322d6a272c25362d042d2929312a2b23212a6a272b29"><span class="__cf_email__" data-cfemail="1c6e737e796e683266747d735c7571716972737b7972327f7371">[email protected]</span> <span class="__cf_email__" data-cfemail="2a584b5c430449424b58436a4347475f44454d4f4404494547">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ravi V. J. Chari</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#aedcc1cccbdcda80d4c6cfc1eec7c3c3dbc0c1c9cbc080cdc1c38edccfd8c780cdc6cfdcc7eec7c3c3dbc0c1c9cbc080cdc1c3"><span class="__cf_email__" data-cfemail="d9abb6bbbcabadf7a3b1b8b699b0b4b4acb7b6bebcb7f7bab6b4">[email protected]</span> <span class="__cf_email__" data-cfemail="176576617e39747f76657e577e7a7a6279787072793974787a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharon D. Wilhelm</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charlene Audette</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory Jones</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara A. Leece</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexandru C. Lazar</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor S. Goldmacher</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajeeva Singh</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yelena Kovtun</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wayne C. Widdison</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Lambert</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank former collegues, Dapeng Sun (now at New England Biolabs, Shanghai, China), Michele Mayo (now at AstraZeneca, Waltham, MA), and Brenda Kellogg for their contributions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i63" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i63"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i64" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i64"> Abbreviations Used</h2><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–cytotoxic drug conjugate</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">DAR or D/A</td><td class="NLM_def"><p class="first last">drug/antibody ratio</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMx</td><td class="NLM_def"><p class="first last">DM1 and/or DM4</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">ε</td><td class="NLM_def"><p class="first last">molar absorbance coefficient</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">reduced glutathione</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">MOAT</td><td class="NLM_def"><p class="first last">multispecific organic anion transporter</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">NHS</td><td class="NLM_def"><p class="first last"><i>N</i>-hydroxysuccinimide</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">Pgp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">SMCC</td><td class="NLM_def"><p class="first last">succinimidyl 4-(<i>N</i>-maleimidomethyl)cyclohexane-1-carboxylate</p></td></tr><tr><td class="NLM_term">SPDB</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl 4-(2-pyridyldithio)butanoate</p></td></tr><tr><td class="NLM_term">SPDP</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl 4-(2-pyridyldithio)propanoate</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76837" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76837" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Verstappen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimans, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoekman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postma, T. J.</span><span> </span><span class="NLM_article-title">Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1549</span><span class="NLM_x">–</span> <span class="NLM_lpage">1563</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1549-1563&author=C.+C.+Verstappenauthor=J.+J.+Heimansauthor=K.+Hoekmanauthor=T.+J.+Postma&title=Neurotoxic+complications+of+chemotherapy+in+patients+with+cancer%3A+clinical+signs+and+optimal+management"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstappen%26aufirst%3DC.%2BC.%26aulast%3DHeimans%26aufirst%3DJ.%2BJ.%26aulast%3DHoekman%26aufirst%3DK.%26aulast%3DPostma%26aufirst%3DT.%2BJ.%26atitle%3DNeurotoxic%2520complications%2520of%2520chemotherapy%2520in%2520patients%2520with%2520cancer%253A%2520clinical%2520signs%2520and%2520optimal%2520management%26jtitle%3DDrugs%26date%3D2003%26volume%3D63%26spage%3D1549%26epage%3D1563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Kohler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milstein, C.</span><span> </span><span class="NLM_article-title">Continuous cultures of fused cells secreting antibody of predefined specificity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">497</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2F256495a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=1172191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1975&pages=495-497&author=G.+Kohlerauthor=C.+Milstein&title=Continuous+cultures+of+fused+cells+secreting+antibody+of+predefined+specificity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous cultures of fused cells secreting antibody of predefined specificity</span></div><div class="casAuthors">Kohler G; Milstein C</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5517</span>),
    <span class="NLM_cas:pages">495-7</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLHx9X4gieguxsqfvU0ziafW6udTcc2eZnULW-ygKq0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D&md5=b5003f0bd9ce2870718bc392c40b89eb</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F256495a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F256495a0%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DG.%26aulast%3DMilstein%26aufirst%3DC.%26atitle%3DContinuous%2520cultures%2520of%2520fused%2520cells%2520secreting%2520antibody%2520of%2520predefined%2520specificity%26jtitle%3DNature%26date%3D1975%26volume%3D256%26spage%3D495%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etessami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span> </span><span class="NLM_article-title">Principal therapeutic uses of monoclonal antibodies in oncology</span> <span class="citation_source-journal">Cancer Radiother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">24s</span><span class="NLM_x">–</span> <span class="NLM_lpage">28s</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=24s-28s&issue=Suppl.+1&author=F.+Penault-Llorcaauthor=A.+Etessamiauthor=J.+Bourhis&title=Principal+therapeutic+uses+of+monoclonal+antibodies+in+oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DEtessami%26aufirst%3DA.%26aulast%3DBourhis%26aufirst%3DJ.%26atitle%3DPrincipal%2520therapeutic%2520uses%2520of%2520monoclonal%2520antibodies%2520in%2520oncology%26jtitle%3DCancer%2520Radiother.%26date%3D2002%26volume%3D6%26issue%3DSuppl.%25201%26spage%3D24s%26epage%3D28s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0ljDYkFFvxViyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span> </span><span class="NLM_article-title">Realizing the full potential of immunotoxins</span> <span class="citation_source-journal">Cancer Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=2701364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1989&pages=50-55&author=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=V.+S.+Goldmacher&title=Realizing+the+full+potential+of+immunotoxins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Realizing the full potential of immunotoxins</span></div><div class="casAuthors">Blattler, Walter A.; Lambert, John M.; Goldmacher, Victor S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cells (1989)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">50-5</span>CODEN:
                <span class="NLM_cas:coden">CCELER</span>;
        ISSN:<span class="NLM_cas:issn">1042-2196</span>.
    </div><div class="casAbstract">A review with 51 refs. discussing some of the insights that have come from detailed analyses of the so-called first-generation immunotoxins, and how these insights have prompted ideas for more effective design of second-generation immunotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0w_MAoEvYArVg90H21EOLACvtfcHk0ljDYkFFvxViyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWis7w%253D&md5=b751d65874356ab81be011049a79aa8c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26atitle%3DRealizing%2520the%2520full%2520potential%2520of%2520immunotoxins%26jtitle%3DCancer%2520Cells%26date%3D1989%26volume%3D1%26spage%3D50%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Targeted cancer therapy: conferring specificity to cytotoxic drugs</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700108g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=98-107&author=R.+V.+Chari&title=Targeted+cancer+therapy%3A+conferring+specificity+to+cytotoxic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs</span></div><div class="casAuthors">Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Most anticancer drugs in clin. use today display poor tumor specificity, resulting in high systemic toxicity.  Monoclonal antibodies that recognize specific markers on the surface of tumor cells offer an alternative therapy that is tumor-specific and, thus, less toxic.  Although highly selective, very few monoclonal antibodies are therapeutically useful because they only display modest cell-killing activity.  The tumor selectivity of monoclonal antibodies can be exploited for the targeted delivery of highly cytotoxic drugs that are otherwise too toxic to be used on their own.  This Account provides a brief history of the development of antibody-drug conjugates, followed by a review of recent advances, wherein highly cytotoxic drugs have been linked to tumor-reactive antibodies.  Linkers have been designed such that these monoclonal antibody-drug conjugates are stable in circulation and are virtually nontoxic until they bind to the tumor cell through the antibody component.  Upon binding to the tumor cell and internalization, lysosomal processing releases the potent cytotoxic agents inside the cell.  These conjugates display high target-specific cytotoxicity in vitro and antitumor activity that is superior to that of the antibodies alone or the std. anticancer drugs in human tumor xenograft models.  Several conjugates from this new class of tumor-targeted anticancer agents are currently undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHel9bmmcerVg90H21EOLACvtfcHk0ljDYkFFvxViyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D&md5=83bb7694ba47151534d9fd5c626edfc2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Far700108g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700108g%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520conferring%2520specificity%2520to%2520cytotoxic%2520drugs%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D98%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2FS0169-409X%2897%2900095-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=10837619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlOjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=89-104&author=R.+V.+Chari&title=Targeted+delivery+of+chemotherapeutics%3A+tumor-activated+prodrug+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy</span></div><div class="casAuthors">Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">89-104</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with 66 refs.  The potential of targeted delivery of chemotherapeutic drugs for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic concns. to the target site.  While in vivo studies in animal tumor models have produced very encouraging results, clin. studies with antibody-drug conjugates have been less successful.  This paper will review the current status of the targeted delivery approach and analyze some of the reasons for the lack of success so far.  Starting with a historical perspective, this review will end with a description of newer, more potent and specific antibody-drug conjugates, which behave like tumor-activated prodrugs that may yet fulfil the promise of the targeted delivery approach for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Bgt9D72i97Vg90H21EOLACvtfcHk0lga3awaY3mqqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlOjsrg%253D&md5=c401d630c51432f2f1933644c0b84e51</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2897%2900095-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252897%252900095-1%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DTargeted%2520delivery%2520of%2520chemotherapeutics%253A%2520tumor-activated%2520prodrug%2520therapy%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1998%26volume%3D31%26spage%3D89%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Potent antibody drug conjugates for cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2Fj.cbpa.2009.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=19414278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=235-244&author=P.+D.+Senter&title=Potent+antibody+drug+conjugates+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in the past few years in the area of antibody drug conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors.  Early work in this field incorporated clin. approved drugs and mouse monoclonal antibodies (mAbs), which had modest activities, and were generally immunogenic.  The results of these studies prompted investigation that led to the identity of several key parameters that influenced activity and tolerability.  These included the antigen target, the use of non-immunogenic mAb carriers, the incorporation of highly potent drugs and novel conditionally stable linker technologies, and the specific methods used to attach drugs to mAbs.  As a result of these investigations, new agents with pronounced clin. activities have been developed.  These include SGN-35, an ADC directed against the CD30-pos. malignancies such as Hodgkin's disease and anaplastic large cell lymphoma, and trastuzumab-DM1 which has shown activity in metastatic breast carcinoma.  This review details many of the technol. advancements, and provides examples of promising ADCs that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomJSUUPIrcbVg90H21EOLACvtfcHk0lga3awaY3mqqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D&md5=3cf72b412351bae075fab1159c49d8c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DPotent%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanagh, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Semisynthetic maytansine analogues for the targeted treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Blattlerauthor=R.+V.+Chari&title=Semisynthetic+maytansine+analogues+for+the+targeted+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0lga3awaY3mqqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DSemisynthetic%2520maytansine%2520analogues%2520for%2520the%2520targeted%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Lambert, J. M.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates: a new strategy for the treatment of cancer</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1358%2Fdof.2010.035.06.1497487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFChur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=471-480&author=J.+M.+Lambert&title=Antibody%E2%80%93maytansinoid+conjugates%3A+a+new+strategy+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer</span></div><div class="casAuthors">Lambert, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">471-480</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Early clin. development in the field of targeted delivery of cytotoxic drugs to tumors using antibodies failed to achieve effective, well-tolerated anticancer products.  In recent years, several new highly potent cell-killing agents, such as thiol derivs. of the potent antimitotic microtubule agent maytansine, developed by ImmunoCen, are being utilized to make a new generation of antibody-drug conjugates (ADCs).  Several antibody-maytansinoid conjugates (AMCs) have shown encouraging efficacy in clin. trials, including trastuzumab-DM1 (T-DM1), which targets HER2+ breast cancer, SAR-3419, which targets CD19 expressed on B-cell malignancies, and IMGN-901, which targets CD56 expressed on both solid tumors (small cell lung cancer and other neuroendocrine tumor types) and hematol. tumors, including multiple myeloma.  Besides their demonstrated efficacy in phase I and/or phase II clin. studies, these AMCs are well tolerated, with no clin. significant myelosuppression, suggesting that AMC compds. are well suited for evaluation in combination treatment regimens.  Maytansinoids are payloads for antibody-mediated delivery that are realizing the promise of ADCs for improved targeted therapy in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwoNcf49xdQrVg90H21EOLACvtfcHk0lgmgy494pPSJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFChur3N&md5=b878b5e78355f1e057e25eea9f00c94d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.06.1497487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.06.1497487%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%253A%2520a%2520new%2520strategy%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DDrugs%2520Future%26date%3D2010%26volume%3D35%26spage%3D471%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Damle, N. K.</span><span> </span><span class="NLM_article-title">Tumour-targeted chemotherapy with immunoconjugates of calicheamicin</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">–</span> <span class="NLM_lpage">1452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1517%2F14712598.4.9.1445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=15335312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFOmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1445-1452&author=N.+K.+Damle&title=Tumour-targeted+chemotherapy+with+immunoconjugates+of+calicheamicin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-targeted chemotherapy with immunoconjugates of calicheamicin</span></div><div class="casAuthors">Damle, Nitin K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1445-1452</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Antibody-targeted chemotherapy is a therapeutic strategy in cancer therapy that involves a monoclonal antibody specific for a tumor-assocd. antigen, covalently linked via a suitable linker to a potent cytotoxic agent.  Tumor-targeted delivery of a cytotoxic agent in the form of an immunoconjugate is expected to improve its antitumor activity and safety.  Calicheamicin is a cytotoxic natural product isolated from Micromonospora echinospora that is at least 1000-fold more potent than conventional cytotoxic chemotherapeutics.  Calicheamicin binds DNA in the minor groove and causes double-strand DNA breaks, leading to cell death.  Immunoconjugates of calicheamicin targeted against tumor-assocd. antigens exhibit tumor-specific cytotoxic effects and cause regression of established human tumor xenografts in nude mice.  Gemtuzumab ozogamicin is the first clin. validated cytotoxic immunoconjugate in which a humanized anti-CD33 antibody is linked to a deriv. of calicheamicin.  Gemtuzumab ozogamicin is indicated for the treatment of elderly patients with relapsed acute myeloid leukemia.  A similar conjugate, inotuzumab ozogamicin, is being evaluated at present in Phase I clin. trials in patients with non-Hodgkin's lymphoma.  A no. of tumor-targeted immunoconjugates of calicheamicin are being explored preclinically at present for their therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz7ki0LzNT5LVg90H21EOLACvtfcHk0lgmgy494pPSJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFOmtro%253D&md5=33bd35d83fa6b220a2f41b1db67efdc8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F14712598.4.9.1445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.4.9.1445%26sid%3Dliteratum%253Aachs%26aulast%3DDamle%26aufirst%3DN.%2BK.%26atitle%3DTumour-targeted%2520chemotherapy%2520with%2520immunoconjugates%2520of%2520calicheamicin%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2004%26volume%3D4%26spage%3D1445%26epage%3D1452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Hamann, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinman, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shochat, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mountain, A.</span><span> </span><span class="NLM_article-title">A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049794n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=354-360&author=P.+R.+Hamannauthor=L.+M.+Hinmanauthor=C.+F.+Beyerauthor=D.+Lindhauthor=J.+Upeslacisauthor=D.+Shochatauthor=A.+Mountain&title=A+calicheamicin+conjugate+with+a+fully+humanized+anti-MUC1+antibody+shows+potent+antitumor+effects+in+breast+and+ovarian+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A Calicheamicin Conjugate with a Fully Humanized Anti-MUC1 Antibody Shows Potent Antitumor Effects in Breast and Ovarian Tumor Xenografts</span></div><div class="casAuthors">Hamann, Philip R.; Hinman, Lois M.; Beyer, Carl F.; Lindh, Delores; Upeslacis, Janis; Shochat, Dan; Mountain, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-360</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Murine CTM01 is an internalizing murine IgG1 monoclonal antibody that recognizes the MUC1 antigen expressed on many solid tumors of epithelial origin.  Calicheamicin conjugates of this antibody have previously been shown to be potent, selective antitumor agents in preclin. models.  A conjugate has now been made with a genetically engineered human version of this antibody, hCTM01.  The hCTM01 is an IgG4 isotype, has an immunoaffinity approx. 30% higher than mCTM01 by competitive RIA, and is efficiently internalized into target cells.  The hCTM01-NAc-gamma calicheamicin DM amide conjugate, referred to as CMB-401, shows targeted killing of MUC1-expressing cells in vitro and produces pronounced dose-related antitumor effects over an 8-fold dose range against a MUC1-expressing, ovarian xenograft tumor, OvCar-3.  The specificity of CMB-401 was confirmed by comparing its antitumor effects with those of an isotype-matched nonspecific conjugate against the MX-1 breast carcinoma.  CMB-401, given either i.p. or iv, was highly active in these models in single and multiple dose regimens and gave complete regressions at the highest doses examd. with good overall therapeutic ratios.  CMB-401 also gave good antitumor effects at similar doses with a cisplatin-resistant MUC1-expressing cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpohk2Pfsj8-rVg90H21EOLACvtfcHk0lgmgy494pPSJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7Y%253D&md5=24504bade5fee83d49b9a7431c37c1ac</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fbc049794n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049794n%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DBeyer%26aufirst%3DC.%2BF.%26aulast%3DLindh%26aufirst%3DD.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DShochat%26aufirst%3DD.%26aulast%3DMountain%26aufirst%3DA.%26atitle%3DA%2520calicheamicin%2520conjugate%2520with%2520a%2520fully%2520humanized%2520anti-MUC1%2520antibody%2520shows%2520potent%2520antitumor%2520effects%2520in%2520breast%2520and%2520ovarian%2520tumor%2520xenografts%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D354%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Zhao, R. Y.; Sun, D.; Cavanagh, E.; Miller, M.; Leece, B.; Erickson, H.; Singh, R.; Kovtun, Y.; Goldmacher, V.; Chari, R.</span><span> </span><span class="NLM_article-title">Design and Synthesis of PEG-Containing CC-1065 Analogs for Targeted Therapy of Cancer</span>. Presented at the 233rd National Meeting of the American Chemical Society, Chicago, IL, U.S.,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>No. 38, Medicinal Chemistry Section.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+Y.+Zhao&author=D.+Sun&author=E.+Cavanagh&author=M.+Miller&author=B.+Leece&author=H.+Erickson&author=R.+Singh&author=Y.+Kovtun&author=V.+Goldmacher&author=R.+Chari&title=Design+and+Synthesis+of+PEG-Containing+CC-1065+Analogs+for+Targeted+Therapy+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%2BY.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520PEG-Containing%2520CC-1065%2520Analogs%2520for%2520Targeted%2520Therapy%2520of%2520Cancer%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourret, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derr, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadayoni, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattocks, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span> </span><span class="NLM_article-title">Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4079</span><span class="NLM_x">–</span> <span class="NLM_lpage">4084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=7545085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK2MXotV2mtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=4079-4084&author=R.+V.+Chariauthor=K.+A.+Jackelauthor=L.+A.+Bourretauthor=S.+M.+Derrauthor=B.+M.+Tadayoniauthor=K.+M.+Mattocksauthor=S.+A.+Shahauthor=C.+Liuauthor=W.+A.+Blattlerauthor=V.+S.+Goldmacher&title=Enhancement+of+the+selectivity+and+antitumor+efficacy+of+a+CC-1065+analogue+through+immunoconjugate+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of the selectivity and antitumor efficacy of a CC-1065 analog through immunoconjugate formation</span></div><div class="casAuthors">Chari, Ravi V. J.; Jackel, Kristine A.; Bourret, Lizabeth A.; Derr, Susan M.; Tadayoni, B. Mitra; Mattocks, Kristin M.; Shah, Sudhir A.; Liu, Changnian; Blattler, Walter A.; Goldmacher, Victor S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4079-84</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Bis-indolyl-(seco)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one compds. are synthetic analogs of CC-1065 that are highly cytotoxic toward a broad spectrum of tumor cell lines.  One of these compds., called DC1 (I), was conjugated to antibodies via novel cleavable disulfide linkers.  Conjugates of DC1 with murine mAbs anti-B4 and N901 directed against tumor-assocd. antigens CD19 and CD56, resp., proved to be extremely potent and antigen selective in killing target cells in culture.  DC1 conjugates with humanized versions of anti-B4 and N901 antibodies were also constructed and demonstrated to be as cytotoxic and selective as the resp. murine antibody conjugates.  The anti-B4-DC1 conjugate showed antitumor efficacy in an aggressive metastatic human B-cell lymphoma survival model in SCID mice and completely cured animals bearing large tumors.  Anti-B4-DC1 was considerably more effective in this tumor model than doxorubicin, cyclophosphamide, etoposide, or vincristine at their max. tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfKcvk5pnoe7Vg90H21EOLACvtfcHk0lghIIhAlo5YbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotV2mtrY%253D&md5=0ce1107615cef0d96494217ef4281864</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DJackel%26aufirst%3DK.%2BA.%26aulast%3DBourret%26aufirst%3DL.%2BA.%26aulast%3DDerr%26aufirst%3DS.%2BM.%26aulast%3DTadayoni%26aufirst%3DB.%2BM.%26aulast%3DMattocks%26aufirst%3DK.%2BM.%26aulast%3DShah%26aufirst%3DS.%2BA.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26atitle%3DEnhancement%2520of%2520the%2520selectivity%2520and%2520antitumor%2520efficacy%2520of%2520a%2520CC-1065%2520analogue%2520through%2520immunoconjugate%2520formation%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D4079%26epage%3D4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugates: targeted drug delivery for cancer</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2Fj.cbpa.2010.06.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=20643572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=529-537&author=S.+C.+Alleyauthor=N.+M.+Okeleyauthor=P.+D.+Senter&title=Antibody%E2%80%93drug+conjugates%3A+targeted+drug+delivery+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: Targeted drug delivery for cancer</span></div><div class="casAuthors">Alley, Stephen C.; Okeley, Nicole M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technol., and the stoichiometry and placement of conjugated drugs.  The underlying reason for this was obtained in pre-clin. biodistribution and pharmacokinetics studies showing that targeted delivery leads to high intratumoral free drug concns., while non-target tissues are largely spared from chemotherapeutic exposure.  Recent developments in the field have led to an increase in the no. of ADCs being tested clin., with 3 in late stage clin. trials: Brentuximab vedotin (also referred to as SGN-35) for Hodgkin lymphoma; Trastuzumab-DM1 for breast cancer; and Inotuzumab ozogamicin for non-Hodgkin lymphoma.  This review highlights the recent pre-clin. and clin. advances that have been made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-9ugy8pi8C7Vg90H21EOLACvtfcHk0lghIIhAlo5YbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D&md5=ace266066ea07d49d0e0b4338b48eeb3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.170%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%253A%2520targeted%2520drug%2520delivery%2520for%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D529%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oflazoglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc0502917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=114-124&author=S.+O.+Doroninaauthor=B.+A.+Mendelsohnauthor=T.+D.+Boveeauthor=C.+G.+Cervenyauthor=S.+C.+Alleyauthor=D.+L.+Meyerauthor=E.+Oflazogluauthor=B.+E.+Tokiauthor=R.+J.+Sandersonauthor=R.+F.+Zabinskiauthor=A.+F.+Wahlauthor=P.+D.+Senter&title=Enhanced+activity+of+monomethylauristatin+F+through+monoclonal+antibody+delivery%3A+effects+of+linker+technology+on+efficacy+and+toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity</span></div><div class="casAuthors">Doronina, Svetlana O.; Mendelsohn, Brian A.; Bovee, Tim D.; Cerveny, Charles G.; Alley, Stephen C.; Meyer, Damon L.; Oflazoglu, Ezogelin; Toki, Brian E.; Sanderson, Russell J.; Zabinski, Roger F.; Wahl, Alan F.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against antigen pos. tumor models.  MMAF is a new antimitotic auristatin deriv. with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE, most likely due to impaired intracellular access.  In vitro cytotoxicity studies indicated that mAb-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-MMAF (mAb-L1-MMAF) conjugates were >2200-fold more potent than free MMAF on a large panel of CD30 pos. hematol. cell lines.  As with cAC10-L1-MMAE, the corresponding MMAF ADC induced cures and regressions of established xenograft tumors at well tolerated doses.  To further optimize the ADC, several new linkers were generated in which various components within the L1 linker were either altered or deleted.  One of the most promising linkers contained a noncleavable maleimidocaproyl (L4) spacer between the drug and the mAb.  CAC10-L4-MMAF was approx. as potent in vitro as cAC10-L1-MMAF against a large panel of cell lines and was equally potent in vivo.  Importantly, cAC10-L4-MMAF was tolerated at >3 times the MTD of cAC10-L1-MMAF.  LCMS studies indicated that drug released from cAC10-L4-MMAF was the cysteine-L4-MMAF adduct, which likely arises from mAb degrdn. within the lysosomes of target cells.  This new linker technol. appears to be ideally suited for drugs that are both relatively cell-impermeable and tolerant of substitution with amino acids.  Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwQJyn8sp0LVg90H21EOLACvtfcHk0lghIIhAlo5YbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL&md5=92da0266f0a83c7680006ef94956c879</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fbc0502917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0502917%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DOflazoglu%26aufirst%3DE.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DEnhanced%2520activity%2520of%2520monomethylauristatin%2520F%2520through%2520monoclonal%2520antibody%2520delivery%253A%2520effects%2520of%2520linker%2520technology%2520on%2520efficacy%2520and%2520toxicity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D114%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hamann, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinman, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menendez, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durr, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span> </span><span class="NLM_article-title">An anti-MUC1 antibody–calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">353</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049795f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=346-353&author=P.+R.+Hamannauthor=L.+M.+Hinmanauthor=C.+F.+Beyerauthor=L.+M.+Greenbergerauthor=C.+Linauthor=D.+Lindhauthor=A.+T.+Menendezauthor=R.+Wallaceauthor=F.+E.+Durrauthor=J.+Upeslacis&title=An+anti-MUC1+antibody%E2%80%93calicheamicin+conjugate+for+treatment+of+solid+tumors.+Choice+of+linker+and+overcoming+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An Anti-MUC1 Antibody-Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance</span></div><div class="casAuthors">Hamann, Philip R.; Hinman, Lois M.; Beyer, Carl F.; Greenberger, Lee M.; Lin, Clara; Lindh, Delores; Menendez, Ana T.; Wallace, Rosalyn; Durr, Frederick E.; Upeslacis, Janis</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">346-353</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anti-MUC1 antibody, CTM01, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to solid tumors of epithelial origin that express this antigen.  Earlier calicheamicin conjugates relied on the attachment of a hydrazide deriv. to the oxidized carbohydrates that occur naturally on antibodies.  This produced a "carbohydrate conjugate" capable of releasing active drug by hydrolysis in the lysosomes where the pH is low.  Conjugates have now been made that are formed by reacting a calicheamicin deriv. contg. an activated ester with the lysines of antibodies.  This gives an "amide conjugate" that is stable to hydrolysis, leaving the disulfide that is present in all calicheamicin conjugates as the only likely site of drug release from the conjugate.  As previously shown for the carbohydrate conjugate, this amide conjugate of CTM01 produces complete regressions of xenograft tumors at doses of 300 μg/kg (calicheamicin equiv.) given three times.  This indicates that hydrolytic drug release is not necessary for potent, selective cytotoxicity for calicheamicin conjugates of CTM01.  Although the unconjugated calicheamicins are in general less active in cells expressing the multidrug resistance phenotype, both in vitro and in vivo results of studies reported here suggest that the efficacy of the calicheamicins toward such tumors is unexpectedly enhanced by antibody conjugation, esp. for the "amide conjugate".  These hydrolytically stable conjugates are also active toward cisplatin-resistant ovarian carcinoma cells as well.  Such studies indicate that the calicheamicin amide conjugate of CTM01 may have potential for the treatment of MUC1-pos. solid tumors, including some types of resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWx1KbzV6eYLVg90H21EOLACvtfcHk0lghIIhAlo5YbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7c%253D&md5=2a8c7e5d7d8fe237dac2de3090b06765</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc049795f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049795f%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DBeyer%26aufirst%3DC.%2BF.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLindh%26aufirst%3DD.%26aulast%3DMenendez%26aufirst%3DA.%2BT.%26aulast%3DWallace%26aufirst%3DR.%26aulast%3DDurr%26aufirst%3DF.%2BE.%26aulast%3DUpeslacis%26aufirst%3DJ.%26atitle%3DAn%2520anti-MUC1%2520antibody%25E2%2580%2593calicheamicin%2520conjugate%2520for%2520treatment%2520of%2520solid%2520tumors.%2520Choice%2520of%2520linker%2520and%2520overcoming%2520drug%2520resistance%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D346%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">King, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubowchik, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestone, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4336</span><span class="NLM_x">–</span> <span class="NLM_lpage">4343</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020149g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4336-4343&author=H.+D.+Kingauthor=G.+M.+Dubowchikauthor=H.+Mastalerzauthor=D.+Willnerauthor=S.+J.+Hofsteadauthor=R.+A.+Firestoneauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Monoclonal+antibody+conjugates+of+doxorubicin+prepared+with+branched+peptide+linkers%3A+inhibition+of+aggregation+by+methoxytriethyleneglycol+chains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibody conjugates of doxorubicin Prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains</span></div><div class="casAuthors">King, H. Dalton; Dubowchik, Gene M.; Mastalerz, Harold; Willner, David; Hofstead, Sandra J.; Firestone, Raymond A.; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4336-4343</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High mole ratio BR96 immunoconjugates were synthesized using branched peptide-doxorubicin linkers designed to liberate doxorubicin following antigen-specific internalization into lysosomes. However, these immunoconjugates are highly prone to noncovalent, dimeric aggregation.  We hypothesize that this is due to (1) the hydrophobic nature of the peptides, (2) the loss of pos. charge upon amide formation at the 3'-amino group of doxorubicin, and (3) the proximity of the peptide hydrophobic residues to form efficient intermol. stacking interactions.  By introducing a hydrophilic methoxytriethylene glycol chain onto the doxorubicin portion of the branched peptide linkers, aggregation has been eliminated or greatly reduced in the immunoconjugate products.  The methoxytriethylene glycol chain was linked to the doxorubicin moiety of the linker via a hydrazone bond that is stable at pH 7 but hydrolyzes rapidly at pH 5 to release free drug. BR96 immunoconjugates synthesized from methoxytriethylene glycol-modified branched peptide-doxorubicin linkers are highly potent and immunospecific in vitro.  The data suggest that the methoxytriethylene glycol chain hydrolyzes as designed upon antigen-specific internalization into tumor lysosomes in vitro, where enzymic degrdn. of the peptide linker releases free doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr70hWG3Du_3rVg90H21EOLACvtfcHk0ljWegGcOP_5Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVCntbs%253D&md5=2769f58125d9dcb895529a30aaa6debb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm020149g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020149g%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DH.%2BD.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DMonoclonal%2520antibody%2520conjugates%2520of%2520doxorubicin%2520prepared%2520with%2520branched%2520peptide%2520linkers%253A%2520inhibition%2520of%2520aggregation%2520by%2520methoxytriethyleneglycol%2520chains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4336%26epage%3D4343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Contribution of linker stability to the activities of anticancer immunoconjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc7004329" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=759-765&author=S.+C.+Alleyauthor=D.+R.+Benjaminauthor=S.+C.+Jeffreyauthor=N.+M.+Okeleyauthor=D.+L.+Meyerauthor=R.+J.+Sandersonauthor=P.+D.+Senter&title=Contribution+of+linker+stability+to+the+activities+of+anticancer+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates</span></div><div class="casAuthors">Alley, Stephen C.; Benjamin, Dennis R.; Jeffrey, Scott C.; Okeley, Nicole M.; Meyer, Damon L.; Sanderson, Russell J.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">759-765</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are highly active at well tolerated doses.  For maximal intratumoral drug delivery, linkers are required that are highly stable in the systemic circulation, yet allow for efficient drug release at the target site.  In this respect, amide bond-based technologies constitute a technol. advancement, since the linker half-lives in circulation (t1/2 ∼ 7 days) are much longer than earlier generation linkers that break down within 1-2 days.  The amide linkers, some of which contain peptides, are appended to the mAb carriers through thioether/maleimide adducts.  Here, we describe that use of a bromoacetamidecaproyl (bac) in place of the maleimidocaproyl (mc) increases the plasma stability of resulting thioether ADCs.  One such ADC, 1F6-C4v2-bac-MMAF, which is directed against the CD70 antigen on lymphomas and renal cell carcinoma, was prepd. contg. a bac thioether spacer between the drug (MMAF) and the mAb carrier (1F6-C4v2).  There was no measurable systemic drug release from this ADC for 2 wk postadministration in mice.  In order to assess the impact of improving linker stability beyond mc contg. ADCs, a series of mc and bac-linked 1F6-MMAF conjugates were compared for tolerability, intratumoral drug delivery, and therapeutic efficacy in nude mice with renal cell carcinoma xenografts.  There were no statistically significant efficacy differences between sets of mc and bac contg. ADCs, although the bac linker technol. led to 25% higher intratumoral drug exposure over a 7 day period compared to the corresponding mc linker.  The mechanism of drug release from maleimide-adducts likely involves a retro-Michael reaction that takes place in plasma, based on in vitro studies demonstrating that some of the released drug-maleimide deriv. became covalently bound to cysteine-34 of serum albumin.  In summary, the data indicate that new linkers can be obtained with improved in vivo stability by replacing the maleimide with an acetamide, but the resulting ADCs had similar tolerability and activity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAEuKHrhYzvrVg90H21EOLACvtfcHk0ljWegGcOP_5Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D&md5=62abdec871dda99c160a9b989c12f6f0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbc7004329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc7004329%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DContribution%2520of%2520linker%2520stability%2520to%2520the%2520activities%2520of%2520anticancer%2520immunoconjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D759%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Blättler, W. A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">B., S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">New heterobifunctional protein cross-linking reagent that forms an acid labile link</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1524</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00327a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1985&pages=1517-1524&author=W.+A.+K.+Bl%C3%A4ttlerauthor=S.+B.author=J.+M.+Lambertauthor=P.+D.+Senter&title=New+heterobifunctional+protein+cross-linking+reagent+that+forms+an+acid+labile+link"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbi00327a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00327a034%26sid%3Dliteratum%253Aachs%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%2BK.%26aulast%3DB.%26aufirst%3DS.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DNew%2520heterobifunctional%2520protein%2520cross-linking%2520reagent%2520that%2520forms%2520an%2520acid%2520labile%2520link%26jtitle%3DBiochemistry%26date%3D1985%26volume%3D24%26spage%3D1517%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody%E2%80%93cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody%25E2%2580%2593cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, P. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">4426</span><span class="NLM_x">–</span> <span class="NLM_lpage">4433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4426-4433&author=H.+K.+Ericksonauthor=P.+U.+Parkauthor=W.+C.+Widdisonauthor=Y.+V.+Kovtunauthor=L.+M.+Garrettauthor=K.+Hoffmanauthor=R.+J.+Lutzauthor=V.+S.+Goldmacherauthor=W.+A.+Blattler&title=Antibody%E2%80%93maytansinoid+conjugates+are+activated+in+targeted+cancer+cells+by+lysosomal+degradation+and+linker-dependent+intracellular+processing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DGarrett%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%2520are%2520activated%2520in%2520targeted%2520cancer%2520cells%2520by%2520lysosomal%2520degradation%2520and%2520linker-dependent%2520intracellular%2520processing%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4426%26epage%3D4433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, P. R.</span><span> </span><span class="NLM_article-title">Selection of reaction additives used in the preparation of monomeric antibody–calicheamicin conjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc700321z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yrur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=358-361&author=I.+Hollanderauthor=A.+Kunzauthor=P.+R.+Hamann&title=Selection+of+reaction+additives+used+in+the+preparation+of+monomeric+antibody%E2%80%93calicheamicin+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selection of Reaction Additives Used in the Preparation of Monomeric Antibody-Calicheamicin Conjugates</span></div><div class="casAuthors">Hollander, Irwin; Kunz, Arthur; Hamann, Philip. R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">358-361</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The formation of protein aggregates can be a major problem during the prepn. of antibody-drug conjugates.  Herein is described the methods by which reaction additives were selected, which reduce the tendency of antibodies to aggregate during the attachment of the cytotoxic agent calicheamicin to form an immunoconjugate.  Reaction conditions were delineated that produced optimized yields of monomeric conjugates.  These conditions were used in the preclin. prepns. of gemtuzumab ozogamicin (Mylotarg), the first com. available chemotherapeutic immunoconjugate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg3Cw6oqJgr7Vg90H21EOLACvtfcHk0liDwzADTKvqaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yrur3M&md5=0811ce169312ba1da792bb8d1c3655e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc700321z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc700321z%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DKunz%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26atitle%3DSelection%2520of%2520reaction%2520additives%2520used%2520in%2520the%2520preparation%2520of%2520monomeric%2520antibody%25E2%2580%2593calicheamicin%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D358%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manikumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of antibody–drug conjugates comprised of potent camptothecin analogues</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1242</span><span class="NLM_x">–</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc9001097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlKjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=1242-1250&author=P.+J.+Burkeauthor=P.+D.+Senterauthor=D.+W.+Meyerauthor=J.+B.+Miyamotoauthor=M.+Andersonauthor=B.+E.+Tokiauthor=G.+Manikumarauthor=M.+C.+Waniauthor=D.+J.+Krollauthor=S.+C.+Jeffrey&title=Design%2C+synthesis%2C+and+biological+evaluation+of+antibody%E2%80%93drug+conjugates+comprised+of+potent+camptothecin+analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues</span></div><div class="casAuthors">Burke, Patrick J.; Senter, Peter D.; Meyer, David W.; Miyamoto, Jamie B.; Anderson, Martha; Toki, Brian E.; Manikumar, Govindarajan; Wani, Mansukh C.; Kroll, David J.; Jeffrey, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1242-1250</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) were prepd. with potent camptothecin analogs attached to monoclonal antibodies (mAbs) via dipeptide or glucuronide-based linkers.  Aniline-contg. camptothecin analogs were employed to provide a site of linker attachment via carbamate bonds that would be stable in circulation.  The camptothecin analogs, 7-butyl-10-amino-camptothecin and 7-butyl-9-amino-10,11-methylenedioxy-camptothecin, are generally 10-1000 times more potent than camptothecin.  Dipeptide and glucuronide drug linkers were employed contg. self-immolative spacers that release drug following lysosomal degrdn. upon ADC internalization into antigen-pos. cell lines.  The camptothecin drug linkers were conjugated to three antibodies: chimeric BR96, chimeric AC10, and humanized 1F6, which bind to the Lewis-Y antigen on carcinomas, CD30 on hematol. malignancies, and CD70 present on hematol. malignancies and renal cell carcinoma, resp.  ADCs bearing the potent camptothecin analog, 7-butyl-9-amino-10,11-methylenedioxy-camptothecin, were highly potent and immunol. specific on a panel of cancer cell lines in vitro, and efficacious at well-tolerated doses in a renal cell carcinoma xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN96RaueGbDrVg90H21EOLACvtfcHk0ljvxiocCLqB1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlKjtro%253D&md5=c9eb87cd5a7e0e947c75f4d9a18a7503</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fbc9001097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9001097%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DManikumar%26aufirst%3DG.%26aulast%3DWani%26aufirst%3DM.%2BC.%26aulast%3DKroll%26aufirst%3DD.%2BJ.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%2520comprised%2520of%2520potent%2520camptothecin%2520analogues%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26spage%3D1242%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">King, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurgaitis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestone, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellstrom, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc980100i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK1MXht1Kisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=279-288&author=H.+D.+Kingauthor=D.+Yurgaitisauthor=D.+Willnerauthor=R.+A.+Firestoneauthor=M.+B.+Yangauthor=S.+J.+Laschauthor=K.+E.+Hellstromauthor=P.+A.+Trail&title=Monoclonal+antibody+conjugates+of+doxorubicin+prepared+with+branched+linkers%3A+a+novel+method+for+increasing+the+potency+of+doxorubicin+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates</span></div><div class="casAuthors">King, H. Dalton; Yurgaitis, Derek; Willner, David; Firestone, Raymond A.; Yang, Michael B.; Lasch, Shirley J.; Hellstroem, Karl Erik; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-288</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Immunoconjugates of monoclonal antibody BR96 and Doxorubicin have been prepd. using a novel series of branched hydrazone linkers.  Since each linker bound to the mAb carries two DOX mols., the DOX/mAb molar ratios of these conjugates were approx. 16, twice that of those previously prepd. with single-chain hydrazone linkers.  The conjugates were stable at a physiol. pH of 7, but released DOX rapidly at lysosomal pH 5.  The branched series of BR96 conjugates demonstrated antigen-specific cytotoxicity, and were more potent in vitro than the single-chain conjugate on both a DOX (4-14-fold) and mAb (7-23-fold) basis.  The results suggest that, by using the branched linker methodol., it is possible to significantly reduce the amt. of mAb required to achieve antigen-specific cytotoxic activity.  In this paper, the synthesis and in vitro biol. of branched chain immunoconjugates are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSIvOo_ta5LVg90H21EOLACvtfcHk0ljvxiocCLqB1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1Kisb8%253D&md5=3816d461f60a77f179300b0da40a2ca2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbc980100i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc980100i%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DH.%2BD.%26aulast%3DYurgaitis%26aufirst%3DD.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DM.%2BB.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DHellstrom%26aufirst%3DK.%2BE.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DMonoclonal%2520antibody%2520conjugates%2520of%2520doxorubicin%2520prepared%2520with%2520branched%2520linkers%253A%2520a%2520novel%2520method%2520for%2520increasing%2520the%2520potency%2520of%2520doxorubicin%2520immunoconjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D1999%26volume%3D10%26spage%3D279%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Hamblett, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chace, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenox, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissler, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopcha, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francisco, J. A.</span><span> </span><span class="NLM_article-title">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">7063</span><span class="NLM_x">–</span> <span class="NLM_lpage">7070</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1158%2F1078-0432.CCR-04-0789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=15501986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7063-7070&author=K.+J.+Hamblettauthor=P.+D.+Senterauthor=D.+F.+Chaceauthor=M.+M.+Sunauthor=J.+Lenoxauthor=C.+G.+Cervenyauthor=K.+M.+Kisslerauthor=S.+X.+Bernhardtauthor=A.+K.+Kopchaauthor=R.+F.+Zabinskiauthor=D.+L.+Meyerauthor=J.+A.+Francisco&title=Effects+of+drug+loading+on+the+antitumor+activity+of+a+monoclonal+antibody+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span></div><div class="casAuthors">Hamblett, Kevin J.; Senter, Peter D.; Chace, Dana F.; Sun, Michael M. C.; Lenox, Joel; Cerveny, Charles G.; Kissler, Kim M.; Bernhardt, Starr X.; Kopcha, Anastasia K.; Zabinski, Roger F.; Meyer, Damon L.; Francisco, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7063-7070</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE) conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties per mAb, was previously shown to have potent cytotoxic activity against CD30+ malignant cells.  To det. the effect of drug loading on antibody-drug conjugate therapeutic potential, we assessed cAC10 antibody-drug conjugates contg. different drug-mAb ratios in vitro and in vivo.  Coupling MMAE to the cysteines that comprise the interchain disulfides of cAC10 created an antibody-drug conjugate population, which was purified using hydrophobic interaction chromatog. to yield antibody-drug conjugates with two, four, and eight drugs per antibody (E2, E4, and E8, resp.).  Antibody-drug conjugate potency was tested in vitro against CD30+ lines followed by in vivo xenograft models.  The max.-tolerated dose and pharmacokinetic profiles of the antibody-drug conjugates were investigated in mice.  Although antibody-drug conjugate potency in vitro was directly dependent on drug loading (IC50 values E8<E4<E2), the in vivo antitumor activity of E4 was comparable with E8 at equal mAb doses, although the E4 contained half the amt. of MMAE per mAb.  E2 was also an active antitumor agent but required higher doses.  The max.-tolerated dose of E2 in mice was at least double that of E4, which in turn was twice that of E8.  MMAE loading affected plasma clearance, as E8 cleared 3-fold faster than E4 and 5-fold faster than E2.  By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCAEfk7W0KNbVg90H21EOLACvtfcHk0ljvxiocCLqB1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D&md5=2d2dd7a498d1181a57dcd3ab8b931e65</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0789%26sid%3Dliteratum%253Aachs%26aulast%3DHamblett%26aufirst%3DK.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DSun%26aufirst%3DM.%2BM.%26aulast%3DLenox%26aufirst%3DJ.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKopcha%26aufirst%3DA.%2BK.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520drug%2520loading%2520on%2520the%2520antitumor%2520activity%2520of%2520a%2520monoclonal%2520antibody%2520drug%2520conjugate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7063%26epage%3D7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Takeshita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinjo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamakage, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigeno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, R.</span><span> </span><span class="NLM_article-title">CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1111%2Fj.1365-2141.2009.07701.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=19388933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlWgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2009&pages=34-43&author=A.+Takeshitaauthor=K.+Shinjoauthor=N.+Yamakageauthor=T.+Onoauthor=I.+Hiranoauthor=H.+Matsuiauthor=K.+Shigenoauthor=S.+Nakamuraauthor=T.+Tobitaauthor=M.+Maekawaauthor=K.+Ohnishiauthor=Y.+Sugimotoauthor=H.+Kiyoiauthor=T.+Naoeauthor=R.+Ohno&title=CMC-544+%28inotuzumab+ozogamicin%29+shows+less+effect+on+multidrug+resistant+cells%3A+analyses+in+cell+lines+and+cells+from+patients+with+B-cell+chronic+lymphocytic+leukaemia+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma</span></div><div class="casAuthors">Takeshita, Akihiro; Shinjo, Kaori; Yamakage, Nozomi; Ono, Takaaki; Hirano, Isao; Matsui, Hirotaka; Shigeno, Kazuyuki; Nakamura, Satoki; Tobita, Tadasu; Maekawa, Masato; Ohnishi, Kazunori; Sugimoto, Yoshikazu; Kiyoi, Hitoshi; Naoe, Tomoki; Ohno, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analyzed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro.  The cell lines used were CD22-pos. parental Daudi and Raji, and their P-gp pos. sublines, Daudi/MDR and Raji/MDR.  Cells obtained from 19 patients with B-cell CLL or NHL were also used.  The effect of CMC-544 was analyzed by viable cell count, morphol., annexin-V staining, and cell cycle distribution.  A dose-dependent, selective cytotoxic effect of CMC-544 was obsd. in cell lines that expressed CD22.  CMC-544 was not effective on Daudi/MDR and Raji/MDR cells compared with their parental cells.  The MDR modifiers, PSC833 and MS209, restored the cytotoxic effect of CMC-544 in P-gp-expressing sublines.  In clin. samples, the cytotoxic effect of CMC-544 was inversely related to the amt. of P-gp (p = 0.003), and to intracellular rhodamine-123 accumulation (P < 0.001).  On the other hand, the effect pos. correlated with the amt. of CD22 (P = 0.010).  The effect of CMC-544 depends on the levels of CD22 and P-gp.  Our findings will help to predict the clin. effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNU682oM1owbVg90H21EOLACvtfcHk0ljeB8K2bzS5dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlWgsb0%253D&md5=a3e0b7e363b730afb39b9e6d2f57ccb7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2009.07701.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2009.07701.x%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DShinjo%26aufirst%3DK.%26aulast%3DYamakage%26aufirst%3DN.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DHirano%26aufirst%3DI.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DShigeno%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DTobita%26aufirst%3DT.%26aulast%3DMaekawa%26aufirst%3DM.%26aulast%3DOhnishi%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DOhno%26aufirst%3DR.%26atitle%3DCMC-544%2520%2528inotuzumab%2520ozogamicin%2529%2520shows%2520less%2520effect%2520on%2520multidrug%2520resistant%2520cells%253A%2520analyses%2520in%2520cell%2520lines%2520and%2520cells%2520from%2520patients%2520with%2520B-cell%2520chronic%2520lymphocytic%2520leukaemia%2520and%2520lymphoma%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2009%26volume%3D146%26spage%3D34%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Szakacs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth-Genthe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Targeting multidrug resistance in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2Fnrd1984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=16518375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=219-234&author=G.+Szakacsauthor=J.+K.+Patersonauthor=J.+A.+Ludwigauthor=C.+Booth-Gentheauthor=M.+M.+Gottesman&title=Targeting+multidrug+resistance+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting multidrug resistance in cancer</span></div><div class="casAuthors">Szakacs, Gergely; Paterson, Jill K.; Ludwig, Joseph A.; Booth-Genthe, Catherine; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy.  In most cases, multiple drugs are used, as resistance to single agents occurs almost universally.  For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chem. structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years.  Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters.  We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7LUp3JikHr7Vg90H21EOLACvtfcHk0ljeB8K2bzS5dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D&md5=67ca376f65aa58a71288167f6815a896</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrd1984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1984%26sid%3Dliteratum%253Aachs%26aulast%3DSzakacs%26aufirst%3DG.%26aulast%3DPaterson%26aufirst%3DJ.%2BK.%26aulast%3DLudwig%26aufirst%3DJ.%2BA.%26aulast%3DBooth-Genthe%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520multidrug%2520resistance%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D219%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Mechanisms of cancer drug resistance</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1146%2Fannurev.med.53.082901.103929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=11818492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2002&pages=615-627&author=M.+M.+Gottesman&title=Mechanisms+of+cancer+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cancer drug resistance</span></div><div class="casAuthors">Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">615-627</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer.  Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin.  Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.  The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance.  Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquuMAtOcoDfbVg90H21EOLACvtfcHk0ljeB8K2bzS5dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D&md5=8f442a5c749266ad76ad7c7406a4e611</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.53.082901.103929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.53.082901.103929%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DMechanisms%2520of%2520cancer%2520drug%2520resistance%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2002%26volume%3D53%26spage%3D615%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handley, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Is resistance useless? Multidrug resistance and collateral sensitivity</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2Fj.tips.2009.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=19762091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=546-556&author=M.+D.+Hallauthor=M.+D.+Handleyauthor=M.+M.+Gottesman&title=Is+resistance+useless%3F+Multidrug+resistance+and+collateral+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Is resistance useless? Multidrug resistance and collateral sensitivity</span></div><div class="casAuthors">Hall, Matthew D.; Handley, Misty D.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">546-556</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  When cancer cells develop resistance to chemotherapeutics, it is frequently conferred by the ATP-dependent efflux pump P-glycoprotein (MDR1, P-gp, ABCB1).  P-gp can efflux a wide range of cancer drugs; its expression confers cross-resistance, termed "multidrug resistance" (MDR), to a wide range of drugs.  Strategies to overcome this resistance have been actively sought for more than 30 years, yet clin. solns. do not exist.  A less understood aspect of MDR is the hypersensitivity of resistant cancer cells to other drugs, a phenomenon known as "collateral sensitivity" (CS).  This review highlights the extent of this effect for the first time, and discusses hypotheses (e.g. generation of reactive oxygen species) to account for the underlying generality of this phenomenon, and proposes exploitation of CS as a strategy to improve response to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqXXX0g-kpErVg90H21EOLACvtfcHk0lje78RHIH9wTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3J&md5=eec04be9cc6fd699383bbd1e72ea7aa6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DHandley%26aufirst%3DM.%2BD.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DIs%2520resistance%2520useless%253F%2520Multidrug%2520resistance%2520and%2520collateral%2520sensitivity%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D546%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Saito, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, S.</span><span> </span><span class="NLM_article-title">Studies on the oxidation products of lipoic acid</span> <span class="citation_source-journal">J. Vitaminol. (Kyoto)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.5925%2Fjnsv1954.13.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=4861288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaF2sXkslWgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1967&pages=115-121&author=I.+Saitoauthor=S.+Fukui&title=Studies+on+the+oxidation+products+of+lipoic+acid"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the oxidation products of lipoic acid</span></div><div class="casAuthors">Saito, Isao; Fukui, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Vitaminology</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-21</span>CODEN:
                <span class="NLM_cas:coden">JVITA5</span>;
        ISSN:<span class="NLM_cas:issn">0022-5398</span>.
    </div><div class="casAbstract">Oxidn. of α-lipoic acid (I) in CHCl3 soln. by tert.-butyl hydroperoxide (5 molar ratio) for 1 day at 40° gave a product with an Rf of 0.90 on paper with 2.8% aq. ammonia-satd. n-butanol as the developing agent.  It had an inhibitory effect upon Streptococcus faecalis 10 C 1; and by ir spectrum and chem. analyses, appeared to be the tert-butyl ester of lipoic acid sulfone.  Oxidn. of I with H2O2 (2 molar ratio) in aq. Me2CO for 1 day at room temp. produced β-lipoic acid and a lipoic acid-active product which according to ir and uv spectra, appeared to be an isomer of β-lipoic acid with the sulfoxide group in a different position.  Oxidn. of I with H2O2 (10 molar ratio) in HOAc for 2 days at 40° resulted in a white ppt., m.p. 108-110°, which by ir spectrum and elementary analysis, appeared to be lipoic acid disulfone.  It was inactive for S. faecalis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCi8PptV-7mbVg90H21EOLACvtfcHk0lje78RHIH9wTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXkslWgsr8%253D&md5=9704592478f8005d2374f5ed708ce6eb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.5925%2Fjnsv1954.13.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5925%252Fjnsv1954.13.115%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DI.%26aulast%3DFukui%26aufirst%3DS.%26atitle%3DStudies%2520on%2520the%2520oxidation%2520products%2520of%2520lipoic%2520acid%26jtitle%3DJ.%2520Vitaminol.%2520%2528Kyoto%2529%26date%3D1967%26volume%3D13%26spage%3D115%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kluger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. C.</span><span> </span><span class="NLM_article-title">Carboxylic acid participation in amide hydrolysis. Competition between acid-catalyzed dehydration and anhydride formation</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5921</span><span class="NLM_x">–</span> <span class="NLM_lpage">5925</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00197a062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1989&pages=5921-5925&author=R.+Klugerauthor=J.+C.+Hunt&title=Carboxylic+acid+participation+in+amide+hydrolysis.+Competition+between+acid-catalyzed+dehydration+and+anhydride+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fja00197a062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00197a062%26sid%3Dliteratum%253Aachs%26aulast%3DKluger%26aufirst%3DR.%26aulast%3DHunt%26aufirst%3DJ.%2BC.%26atitle%3DCarboxylic%2520acid%2520participation%2520in%2520amide%2520hydrolysis.%2520Competition%2520between%2520acid-catalyzed%2520dehydration%2520and%2520anhydride%2520formation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1989%26volume%3D111%26spage%3D5921%26epage%3D5925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Garner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandhee, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngs, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, V. O.</span><span> </span><span class="NLM_article-title">Development of an asymmetric approach to the 3,8-diazabicyclo[3.2.1]octane moiety of quinocarcin via intramolecular 1,3-dipolar cycloadditions of photochemically generated azomethine ylides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5893</span><span class="NLM_x">–</span> <span class="NLM_lpage">5903</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00020a035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1991&pages=5893-5903&author=P.+Garnerauthor=W.+B.+Hoauthor=S.+K.+Grandheeauthor=W.+J.+Youngsauthor=V.+O.+Kennedy&title=Development+of+an+asymmetric+approach+to+the+3%2C8-diazabicyclo%5B3.2.1%5Doctane+moiety+of+quinocarcin+via+intramolecular+1%2C3-dipolar+cycloadditions+of+photochemically+generated+azomethine+ylides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo00020a035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00020a035%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DP.%26aulast%3DHo%26aufirst%3DW.%2BB.%26aulast%3DGrandhee%26aufirst%3DS.%2BK.%26aulast%3DYoungs%26aufirst%3DW.%2BJ.%26aulast%3DKennedy%26aufirst%3DV.%2BO.%26atitle%3DDevelopment%2520of%2520an%2520asymmetric%2520approach%2520to%2520the%25203%252C8-diazabicyclo%255B3.2.1%255Doctane%2520moiety%2520of%2520quinocarcin%2520via%2520intramolecular%25201%252C3-dipolar%2520cycloadditions%2520of%2520photochemically%2520generated%2520azomethine%2520ylides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1991%26volume%3D56%26spage%3D5893%26epage%3D5903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Haval, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mhaske, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argade, N. P.</span><span> </span><span class="NLM_article-title">Cyanuric chloride: decent dehydrating agent for an exclusive and efficient synthesis of kinetically controlled isomaleimides</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">942</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=937-942&author=K.+P.+Havalauthor=S.+B.+Mhaskeauthor=N.+P.+Argade&title=Cyanuric+chloride%3A+decent+dehydrating+agent+for+an+exclusive+and+efficient+synthesis+of+kinetically+controlled+isomaleimides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaval%26aufirst%3DK.%2BP.%26aulast%3DMhaske%26aufirst%3DS.%2BB.%26aulast%3DArgade%26aufirst%3DN.%2BP.%26atitle%3DCyanuric%2520chloride%253A%2520decent%2520dehydrating%2520agent%2520for%2520an%2520exclusive%2520and%2520efficient%2520synthesis%2520of%2520kinetically%2520controlled%2520isomaleimides%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26spage%3D937%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lazar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amphlett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span> </span><span class="NLM_article-title">Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1806</span><span class="NLM_x">–</span> <span class="NLM_lpage">1814</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1002%2Frcm.1987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=15945030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVegt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1806-1814&author=A.+C.+Lazarauthor=L.+Wangauthor=W.+A.+Blattlerauthor=G.+Amphlettauthor=J.+M.+Lambertauthor=W.+Zhang&title=Analysis+of+the+composition+of+immunoconjugates+using+size-exclusion+chromatography+coupled+to+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry</span></div><div class="casAuthors">Lazar, Alexandru C.; Wang, Lintao; Blaettler, Walter A.; Amphlett, Godfrey; Lambert, John M.; Zhang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1806-1814</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Recombinant monoclonal antibody drug products play an increasingly important role in the treatment of various diseases.  Antibodies are large, multi-chain proteins and antibody prepns. often contain several mol. variants, which renders them heterogeneous.  The heterogeneity is further increased in immunoconjugates prepd. by covalently linking several drug mols. per antibody mol.  As part of the product characterization, the mol. wts. of the antibodies or their drug conjugates need to be measured.  Electrospray ionization mass spectrometry (ESI-MS) is well suited for the anal. of recombinant antibodies and immunoconjugates.  Sample prepn. is an important element of ESI-MS anal., in particular samples need to be freed of interfering charged species, such as salts and buffer components.  In this paper, Amicon centrifugal filters, reversed-phase high-performance liq. chromatog. (HPLC), and size-exclusion HPLC were evaluated for sample desalting.  Size-exclusion HPLC, using aq. acetonitrile as the mobile phase, directly coupled to ESI-MS provided the best performance and was optimized for the study of immunoconjugates.  The results showed that antibodies carrying covalently linked maytansinoid mols. generated charge envelope profiles that differ from those of the non-conjugated antibody.  For the detn. of the distribution of the various conjugate species in an immunoconjugate sample prepd. by randomly linking in the av. 3.6 drug mols. per antibody mol., the exptl. conditions needed to be carefully selected to allow acquisition of the whole spectrum contg. the charge envelopes of all species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruiBJzbRAMY7Vg90H21EOLACvtfcHk0liPGblwqE8duQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVegt70%253D&md5=678eee93e086e099fa72f4d2d79e6646</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Frcm.1987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1987%26sid%3Dliteratum%253Aachs%26aulast%3DLazar%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DAmphlett%26aufirst%3DG.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DAnalysis%2520of%2520the%2520composition%2520of%2520immunoconjugates%2520using%2520size-exclusion%2520chromatography%2520coupled%2520to%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2005%26volume%3D19%26spage%3D1806%26epage%3D1814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Sutherland, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreyka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span> </span><span class="NLM_article-title">Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">10540</span><span class="NLM_x">–</span> <span class="NLM_lpage">10547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=10540-10547&author=M.+S.+Sutherlandauthor=R.+J.+Sandersonauthor=K.+A.+Gordonauthor=J.+Andreykaauthor=C.+G.+Cervenyauthor=C.+Yuauthor=T.+S.+Lewisauthor=D.+L.+Meyerauthor=R.+F.+Zabinskiauthor=S.+O.+Doroninaauthor=P.+D.+Senterauthor=C.+L.+Lawauthor=A.+F.+Wahl&title=Lysosomal+trafficking+and+cysteine+protease+metabolism+confer+target-specific+cytotoxicity+by+peptide-linked+anti-CD30-auristatin+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%2BS.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DGordon%26aufirst%3DK.%2BA.%26aulast%3DAndreyka%26aufirst%3DJ.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DT.%2BS.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DLaw%26aufirst%3DC.%2BL.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26atitle%3DLysosomal%2520trafficking%2520and%2520cysteine%2520protease%2520metabolism%2520confer%2520target-specific%2520cytotoxicity%2520by%2520peptide-linked%2520anti-CD30-auristatin%2520conjugates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D10540%26epage%3D10547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Drake, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvain, S. M.</span><span> </span><span class="NLM_article-title">The reaction of organic halides with piperidine. IV. Bromo esters</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1934</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja01318a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1934&pages=697-700&author=W.+V.+Drakeauthor=S.+M.+McElvain&title=The+reaction+of+organic+halides+with+piperidine.+IV.+Bromo+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja01318a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01318a050%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DW.%2BV.%26aulast%3DMcElvain%26aufirst%3DS.%2BM.%26atitle%3DThe%2520reaction%2520of%2520organic%2520halides%2520with%2520piperidine.%2520IV.%2520Bromo%2520esters%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1934%26volume%3D56%26spage%3D697%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Awasthi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhal, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saini, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandya, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pikula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandorowicz-Pikula, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimniak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awasthi, Y. C.</span><span> </span><span class="NLM_article-title">Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">9327</span><span class="NLM_x">–</span> <span class="NLM_lpage">9334</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi992964c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=9327-9334&author=S.+Awasthiauthor=J.+Chengauthor=S.+S.+Singhalauthor=M.+K.+Sainiauthor=U.+Pandyaauthor=S.+Pikulaauthor=J.+Bandorowicz-Pikulaauthor=S.+V.+Singhauthor=P.+Zimniakauthor=Y.+C.+Awasthi&title=Novel+function+of+human+RLIP76%3A+ATP-dependent+transport+of+glutathione+conjugates+and+doxorubicin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi992964c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi992964c%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DSinghal%26aufirst%3DS.%2BS.%26aulast%3DSaini%26aufirst%3DM.%2BK.%26aulast%3DPandya%26aufirst%3DU.%26aulast%3DPikula%26aufirst%3DS.%26aulast%3DBandorowicz-Pikula%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DS.%2BV.%26aulast%3DZimniak%26aufirst%3DP.%26aulast%3DAwasthi%26aufirst%3DY.%2BC.%26atitle%3DNovel%2520function%2520of%2520human%2520RLIP76%253A%2520ATP-dependent%2520transport%2520of%2520glutathione%2520conjugates%2520and%2520doxorubicin%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D9327%26epage%3D9334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0liPGblwqE8duQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambudkar, S. V.</span><span> </span><span class="NLM_article-title">Overview: ABC transporters and human disease</span> <span class="citation_source-journal">J. Bioenerg. Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1023%2FA%3A1012866803188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=11804186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=453-458&author=M.+M.+Gottesmanauthor=S.+V.+Ambudkar&title=Overview%3A+ABC+transporters+and+human+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Overview: ABC transporters and human disease</span></div><div class="casAuthors">Gottesman, Michael M.; Ambudkar, Suresh V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-458</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">A review.  ABC transporters are found in all known organisms, and approx. 1,100 different transporters belonging to this family have been described in the literature.  The family is defined by homol. within the ATP-binding cassette (ABC) region, which extends outside of the more typical Walker motifs found in all ATP-binding proteins.  Most family members also contain transmembrane domains involved in recognition of substrates, which are transported across, into, and out of cell membranes, but some members utilize ABCs as engines to regulate ion channels.  There are approx. 50 known ABC transporters in the human, and there are currently 13 genetic diseases assocd. with defects in 14 of these transporters.  The most common genetic disease conditions include cystic fibrosis, Stargardt disease, age-related macular degeneration, adrenoleukodystrophy, Tangier disease, Dubin-Johnson syndrome and progressive familial intrahepatic cholestasis.  At least 8 members of this family are involved in the transport of a variety of amphipathic compds., including anticancer drugs, and some appear to contribute to the resistance of cancer cells to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMu6ktbmOQNLVg90H21EOLACvtfcHk0lhxz9l-T9aj8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVymuw%253D%253D&md5=86de63d7320866aee7f6e8dd57b9a1de</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012866803188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012866803188%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26atitle%3DOverview%253A%2520ABC%2520transporters%2520and%2520human%2520disease%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2001%26volume%3D33%26spage%3D453%26epage%3D458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Raviv, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggemann, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">3975</span><span class="NLM_x">–</span> <span class="NLM_lpage">3980</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2FS0021-9258%2819%2939690-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=1968065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK3cXhslWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1990&pages=3975-3980&author=Y.+Ravivauthor=H.+B.+Pollardauthor=E.+P.+Bruggemannauthor=I.+Pastanauthor=M.+M.+Gottesman&title=Photosensitized+labeling+of+a+functional+multidrug+transporter+in+living+drug-resistant+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells</span></div><div class="casAuthors">Raviv, Yossef; Pollard, Harvey B.; Bruggemann, Edward P.; Pastan, Ira; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3975-80</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A 170,000-Da glycoprotein (P170 multidrug transporter) becomes specifically labeled in multidrug-resistant human KB carcinoma cells by the photolabile lipophilic membrane probe 5-[125I]iodonaphthalene-1-azide ([125I]INA) when photoactivation of the probe is triggered by energy transfer from intracellular doxorubicin or rhodamine 123.  In contrast, in drug-sensitive cells, drug-induced specific labeling of membrane proteins with [125I]INA was not obsd.  Instead, multiple membrane proteins became labeled in a nonspecific manner.  This phenomenon of drug-induced specific labeling of P170 by [125I]INA is obsd. only in living cells, but not in purified membrane vesicles or lysed cells.  It is generated by doxorubicin and rhodamine 123, drugs that are chromophores and to which the cells exhibit resistance; but it is not obsd. with other drugs or dyes.  Verapamil, a calcium channel blocker which reverses resistance to doxorubicin, also abolishes doxorubicin-induced specific [125I]INA labeling of P170.  These results reveal that a specific interaction between P170 and doxorubicin takes place in living cells and demonstrate that P170 is directly involved in the mechanism of drug resistance in vivo.  They also provide a possible means to label functional domains in the multidrug transporter.  The results demonstrate that photosensitized [125I]INA labeling is a technique which provides sufficient spatial and time resoln. to detect specific intracellular interactions between chromophores and proteins in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphFkvZS77SHbVg90H21EOLACvtfcHk0lhxz9l-T9aj8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslWrtbc%253D&md5=20c20a46b0b6b90acb1c2893e3bf55fd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2939690-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252939690-5%26sid%3Dliteratum%253Aachs%26aulast%3DRaviv%26aufirst%3DY.%26aulast%3DPollard%26aufirst%3DH.%2BB.%26aulast%3DBruggemann%26aufirst%3DE.%2BP.%26aulast%3DPastan%26aufirst%3DI.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DPhotosensitized%2520labeling%2520of%2520a%2520functional%2520multidrug%2520transporter%2520in%2520living%2520drug-resistant%2520tumor%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1990%26volume%3D265%26spage%3D3975%26epage%3D3980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates designed to bypass multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2528-2537&author=Y.+V.+Kovtunauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=G.+E.+Jonesauthor=H.+Dohertyauthor=E.+K.+Maloneyauthor=H.+K.+Ericksonauthor=X.+Sunauthor=S.+Wilhelmauthor=O.+Abauthor=K.+C.+Laiauthor=W.+C.+Widdisonauthor=B.+Kelloggauthor=H.+Johnsonauthor=J.+Pinkasauthor=R.+J.+Lutzauthor=R.+Singhauthor=V.+S.+Goldmacherauthor=R.+V.+Chari&title=Antibody%E2%80%93maytansinoid+conjugates+designed+to+bypass+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DDoherty%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKellogg%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DH.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%2520designed%2520to%2520bypass%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 134 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yu J. Cao, Xuechun Wang, Zhidong Wang, Lijun Zhao, Shuhong Li, Zhuxia Zhang, Xiaoyi Wei, Hwayoung Yun, Sei-hyun Choi, Zhong Liu, Lili Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Stephanie A. Kazane</span>. </span><span class="cited-content_cbyCitation_article-title">Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. </span><span class="cited-content_cbyCitation_journal-name">ACS Synthetic Biology</span><span> <strong>2021,</strong> <em>10 </em>
                                    (5)
                                     , 1176-1183. <a href="https://doi.org/10.1021/acssynbio.1c00007" title="DOI URL">https://doi.org/10.1021/acssynbio.1c00007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acssynbio.1c00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facssynbio.1c00007%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Synthetic%2520Biology%26atitle%3DSwitchable%252BCAR-T%252BCells%252BOutperformed%252BTraditional%252BAntibody-Redirected%252BTherapeutics%252BTargeting%252BBreast%252BCancers%26aulast%3DCao%26aufirst%3DYu%2BJ.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05012021%26date%3D15042021%26volume%3D10%26issue%3D5%26spage%3D1176%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kimberly S. Taylor, Chen Zhang, Evgenia Glukhov, William H. Gerwick, <span class="NLM_string-name hlFld-ContribAuthor">Takashi L. Suyama</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis of Laucysteinamide A, a Monomeric Congener of Somocystinamide A. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2021,</strong> <em>84 </em>
                                    (3)
                                     , 865-870. <a href="https://doi.org/10.1021/acs.jnatprod.0c01317" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.0c01317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.0c01317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.0c01317%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DTotal%252BSynthesis%252Bof%252BLaucysteinamide%252BA%25252C%252Ba%252BMonomeric%252BCongener%252Bof%252BSomocystinamide%252BA%26aulast%3DTaylor%26aufirst%3DKimberly%2BS.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D07122020%26date%3D26022021%26volume%3D84%26issue%3D3%26spage%3D865%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nai-Shu Hsu, Cheng-Chung Lee, Wen-Chih Kuo, Ya-Wen Chang, Shin-Yi Lo, <span class="NLM_string-name hlFld-ContribAuthor">Andrew H.-J. Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Versatile and Modular Linker for Antibody–Drug Conjugates Based on Oligonucleotide Strand Pairing. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (7)
                                     , 1804-1811. <a href="https://doi.org/10.1021/acs.bioconjchem.0c00281" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.0c00281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.0c00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.0c00281%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DDevelopment%252Bof%252Ba%252BVersatile%252Band%252BModular%252BLinker%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BBased%252Bon%252BOligonucleotide%252BStrand%252BPairing%26aulast%3DHsu%26aufirst%3DNai-Shu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04052020%26date%3D08062020%26date%3D25062020%26date%3D11062020%26volume%3D31%26issue%3D7%26spage%3D1804%26epage%3D1811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mateusz Adam Krzyscik, Małgorzata Zakrzewska, <span class="NLM_string-name hlFld-ContribAuthor">Jacek Otlewski</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1). </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (7)
                                     , 2734-2748. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00419" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00419%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSite-Specific%25252C%252BStoichiometric-Controlled%25252C%252BPEGylated%252BConjugates%252Bof%252BFibroblast%252BGrowth%252BFactor%252B2%252B%252528FGF2%252529%252Bwith%252BHydrophilic%252BAuristatin%252BY%252Bfor%252BHighly%252BSelective%252BKilling%252Bof%252BCancer%252BCells%252BOverproducing%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B1%252B%252528FGFR1%252529%26aulast%3DKrzyscik%26aufirst%3DMateusz%2BAdam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18042020%26date%3D05062020%26date%3D05062020%26date%3D16062020%26date%3D05062020%26volume%3D17%26issue%3D7%26spage%3D2734%26epage%3D2748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shinichi Sato, Masaki Matsumura, Tetsuya Kadonosono, Satoshi Abe, Takafumi Ueno, Hiroshi Ueda, <span class="NLM_string-name hlFld-ContribAuthor">Hiroyuki Nakamura</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Selective Protein Chemical Modification of Exposed Tyrosine Residues Using Tyrosine Click Reaction. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (5)
                                     , 1417-1424. <a href="https://doi.org/10.1021/acs.bioconjchem.0c00120" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.0c00120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.0c00120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.0c00120%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSite-Selective%252BProtein%252BChemical%252BModification%252Bof%252BExposed%252BTyrosine%252BResidues%252BUsing%252BTyrosine%252BClick%252BReaction%26aulast%3DSato%26aufirst%3DShinichi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01032020%26date%3D30032020%26date%3D13042020%26date%3D30032020%26volume%3D31%26issue%3D5%26spage%3D1417%26epage%3D1424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicholas C. Yoder, Chen Bai, Daniel Tavares, Wayne C. Widdison, Kathleen R. Whiteman, Alan Wilhelm, Sharon D. Wilhelm, Molly A. McShea, Erin K. Maloney, Olga Ab, Lintao Wang, Shan Jin, Hans K. Erickson, Thomas A. Keating, <span class="NLM_string-name hlFld-ContribAuthor">John M. Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (9)
                                     , 3926-3937. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00529" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00529%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DA%252BCase%252BStudy%252BComparing%252BHeterogeneous%252BLysine-%252Band%252BSite-Specific%252BCysteine-Conjugated%252BMaytansinoid%252BAntibody-Drug%252BConjugates%252B%252528ADCs%252529%252BIllustrates%252Bthe%252BBenefits%252Bof%252BLysine%252BConjugation%26aulast%3DYoder%26aufirst%3DNicholas%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15052019%26date%3D09072019%26date%3D03072019%26date%3D31072019%26date%3D09072019%26volume%3D16%26issue%3D9%26spage%3D3926%26epage%3D3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jennifer
A. Fulcher, Kyle Tamshen, Alexander L. Wollenberg, Valerie A. Kickhoefer, Jan Mrazek, Julie Elliott, F. Javier Ibarrondo, Peter A. Anton, Leonard H. Rome, Heather D. Maynard, Timothy Deming, <span class="NLM_string-name hlFld-ContribAuthor">Otto O. Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (8)
                                     , 2216-2227. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00451" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00451%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DHuman%252BVault%252BNanoparticle%252BTargeted%252BDelivery%252Bof%252BAntiretroviral%252BDrugs%252Bto%252BInhibit%252BHuman%252BImmunodeficiency%252BVirus%252BType%252B1%252BInfection%26aulast%3DFulcher%26aufirst%3DJennifer%2BA.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27062019%26date%3D16072019%26date%3D02072019%26volume%3D30%26issue%3D8%26spage%3D2216%26epage%3D2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tak Ian Chio, Han Gu, Kamalika Mukherjee, L. Nathan Tumey, <span class="NLM_string-name hlFld-ContribAuthor">Susan L. Bane</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific Bioconjugation and Multi-Bioorthogonal Labeling via Rapid Formation of a Boron–Nitrogen Heterocycle. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (5)
                                     , 1554-1564. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00246" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00246</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00246%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSite-Specific%252BBioconjugation%252Band%252BMulti-Bioorthogonal%252BLabeling%252Bvia%252BRapid%252BFormation%252Bof%252Ba%252BBoron%2525E2%252580%252593Nitrogen%252BHeterocycle%26aulast%3DChio%26aufirst%3DTak%2BIan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04042019%26date%3D03052019%26date%3D26042019%26volume%3D30%26issue%3D5%26spage%3D1554%26epage%3D1564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Suvi-Katriina Ruokonen, Filip S. Ekholm, <span class="NLM_string-name hlFld-ContribAuthor">Susanne K. Wiedmer</span>. </span><span class="cited-content_cbyCitation_article-title">Assessing the Interactions of Auristatin Derivatives with Mixed Phospholipid–Sodium Dodecyl Sulfate Aggregate Dispersions. </span><span class="cited-content_cbyCitation_journal-name">Langmuir</span><span> <strong>2019,</strong> <em>35 </em>
                                    (15)
                                     , 5232-5240. <a href="https://doi.org/10.1021/acs.langmuir.9b00116" title="DOI URL">https://doi.org/10.1021/acs.langmuir.9b00116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.langmuir.9b00116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.langmuir.9b00116%26sid%3Dliteratum%253Aachs%26jtitle%3DLangmuir%26atitle%3DAssessing%252Bthe%252BInteractions%252Bof%252BAuristatin%252BDerivatives%252Bwith%252BMixed%252BPhospholipid%2525E2%252580%252593Sodium%252BDodecyl%252BSulfate%252BAggregate%252BDispersions%26aulast%3DRuokonen%26aufirst%3DSuvi-Katriina%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12012019%26date%3D09032019%26date%3D03042019%26date%3D19032019%26volume%3D35%26issue%3D15%26spage%3D5232%26epage%3D5240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jakob
W. Buecheler, Matthias Winzer, Jason Tonillo, Christian Weber, <span class="NLM_string-name hlFld-ContribAuthor">Henning Gieseler</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Payload Hydrophobicity on the Stability of Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (7)
                                     , 2656-2664. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00177" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00177</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00177%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DImpact%252Bof%252BPayload%252BHydrophobicity%252Bon%252Bthe%252BStability%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DBuecheler%26aufirst%3DJakob%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17022018%26date%3D29052018%26date%3D24052018%26date%3D06062018%26date%3D29052018%26volume%3D15%26issue%3D7%26spage%3D2656%26epage%3D2664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madduri  Srinivasarao</span> and <span class="hlFld-ContribAuthor ">Philip S.  Low</span>  . </span><span class="cited-content_cbyCitation_article-title">Ligand-Targeted Drug Delivery. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2017,</strong> <em>117 </em>
                                    (19)
                                     , 12133-12164. <a href="https://doi.org/10.1021/acs.chemrev.7b00013" title="DOI URL">https://doi.org/10.1021/acs.chemrev.7b00013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.7b00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.7b00013%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DLigand-Targeted%252BDrug%252BDelivery%26aulast%3DSrinivasarao%26aufirst%3DMadduri%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07012017%26date%3D12092017%26date%3D11102017%26volume%3D117%26issue%3D19%26spage%3D12133%26epage%3D12164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuxia  Sun</span>, <span class="hlFld-ContribAuthor ">Jose F.  Ponte</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Yoder</span>, <span class="hlFld-ContribAuthor ">Rassol  Laleau</span>, <span class="hlFld-ContribAuthor ">Jennifer  Coccia</span>, <span class="hlFld-ContribAuthor ">Leanne  Lanieri</span>, <span class="hlFld-ContribAuthor ">Qifeng  Qiu</span>, <span class="hlFld-ContribAuthor ">Rui  Wu</span>, <span class="hlFld-ContribAuthor ">Erica  Hong</span>, <span class="hlFld-ContribAuthor ">Megan  Bogalhas</span>, <span class="hlFld-ContribAuthor ">Lintao  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Dong</span>, <span class="hlFld-ContribAuthor ">Yulius  Setiady</span>, <span class="hlFld-ContribAuthor ">Erin K.  Maloney</span>, <span class="hlFld-ContribAuthor ">Olga  Ab</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jan  Pinkas</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Keating</span>, <span class="hlFld-ContribAuthor ">Ravi  Chari</span>, <span class="hlFld-ContribAuthor ">Hans K.  Erickson</span>, and <span class="hlFld-ContribAuthor ">John M.  Lambert</span>  . </span><span class="cited-content_cbyCitation_article-title">Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (5)
                                     , 1371-1381. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00062" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00062%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DEffects%252Bof%252BDrug%2525E2%252580%252593Antibody%252BRatio%252Bon%252BPharmacokinetics%25252C%252BBiodistribution%25252C%252BEfficacy%25252C%252Band%252BTolerability%252Bof%252BAntibody%2525E2%252580%252593Maytansinoid%252BConjugates%26aulast%3DSun%26aufirst%3DXiuxia%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D03022017%26date%3D31032017%26date%3D13042017%26date%3D17052017%26date%3D07042017%26volume%3D28%26issue%3D5%26spage%3D1371%26epage%3D1381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian A.  Mendelsohn</span>, <span class="hlFld-ContribAuthor ">Stuart D.  Barnscher</span>, <span class="hlFld-ContribAuthor ">Josh T.  Snyder</span>, <span class="hlFld-ContribAuthor ">Zili  An</span>, <span class="hlFld-ContribAuthor ">Jennifer M.  Dodd</span>, and <span class="hlFld-ContribAuthor ">Julien  Dugal-Tessier</span>  . </span><span class="cited-content_cbyCitation_article-title">Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 371-381. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00530" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00530%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DInvestigation%252Bof%252BHydrophilic%252BAuristatin%252BDerivatives%252Bfor%252BUse%252Bin%252BAntibody%252BDrug%252BConjugates%26aulast%3DMendelsohn%26aufirst%3DBrian%2BA.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D15092016%26date%3D16122016%26date%3D06012017%26date%3D15022017%26volume%3D28%26issue%3D2%26spage%3D371%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Haiyin  He</span>, <span class="hlFld-ContribAuthor ">Ken  Dirico</span>, <span class="hlFld-ContribAuthor ">Michael  Green</span>, <span class="hlFld-ContribAuthor ">Jesse  Teske</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Frank  Koehn</span>, <span class="hlFld-ContribAuthor ">Robert  Veneziale</span>, <span class="hlFld-ContribAuthor ">Hadi  Falahaptisheh</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Chakrapani  Subramanyam</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>, <span class="hlFld-ContribAuthor ">Hans Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Dangshe  Ma</span>, and <span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>  . </span><span class="cited-content_cbyCitation_article-title">Natural Product Splicing Inhibitors: A New Class of Antibody–Drug Conjugate (ADC) Payloads. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (8)
                                     , 1880-1888. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00291" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00291%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DNatural%252BProduct%252BSplicing%252BInhibitors%25253A%252BA%252BNew%252BClass%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252B%252528ADC%252529%252BPayloads%26aulast%3DPuthenveetil%26aufirst%3DSujiet%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D08062016%26date%3D11072016%26date%3D28072016%26date%3D17082016%26date%3D14072016%26volume%3D27%26issue%3D8%26spage%3D1880%26epage%3D1888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey C.  Kern</span>, <span class="hlFld-ContribAuthor ">Mark  Cancilla</span>, <span class="hlFld-ContribAuthor ">Deborah  Dooney</span>, <span class="hlFld-ContribAuthor ">Kristen  Kwasnjuk</span>, <span class="hlFld-ContribAuthor ">Rena  Zhang</span>, <span class="hlFld-ContribAuthor ">Maribel  Beaumont</span>, <span class="hlFld-ContribAuthor ">Isabel  Figueroa</span>, <span class="hlFld-ContribAuthor ">SuChun  Hsieh</span>, <span class="hlFld-ContribAuthor ">Linda  Liang</span>, <span class="hlFld-ContribAuthor ">Daniela  Tomazela</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Zhang</span>, <span class="hlFld-ContribAuthor ">Philip E.  Brandish</span>, <span class="hlFld-ContribAuthor ">Anthony  Palmieri</span>, <span class="hlFld-ContribAuthor ">Peter  Stivers</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Guo  Feng</span>, <span class="hlFld-ContribAuthor ">Prasanthi  Geda</span>, <span class="hlFld-ContribAuthor ">Sanjiv  Shah</span>, <span class="hlFld-ContribAuthor ">Andrew  Beck</span>, <span class="hlFld-ContribAuthor ">Damien  Bresson</span>, <span class="hlFld-ContribAuthor ">Juhi  Firdos</span>, <span class="hlFld-ContribAuthor ">Dennis  Gately</span>, <span class="hlFld-ContribAuthor ">Nick  Knudsen</span>, <span class="hlFld-ContribAuthor ">Anthony  Manibusan</span>, <span class="hlFld-ContribAuthor ">Peter G.  Schultz</span>, <span class="hlFld-ContribAuthor ">Ying  Sun</span>, and <span class="hlFld-ContribAuthor ">Robert M.  Garbaccio</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2016,</strong> <em>138 </em>
                                    (4)
                                     , 1430-1445. <a href="https://doi.org/10.1021/jacs.5b12547" title="DOI URL">https://doi.org/10.1021/jacs.5b12547</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.5b12547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.5b12547%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDiscovery%252Bof%252BPyrophosphate%252BDiesters%252Bas%252BTunable%25252C%252BSoluble%25252C%252Band%252BBioorthogonal%252BLinkers%252Bfor%252BSite-Specific%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DKern%26aufirst%3DJeffrey%2BC.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D06122015%26date%3D25012016%26date%3D03022016%26date%3D08012016%26volume%3D138%26issue%3D4%26spage%3D1430%26epage%3D1445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paulin L.  Salomon</span> and <span class="hlFld-ContribAuthor ">Rajeeva  Singh</span>  . </span><span class="cited-content_cbyCitation_article-title">Sensitive ELISA Method for the Measurement of Catabolites of Antibody–Drug Conjugates (ADCs) in Target Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1752-1761. <a href="https://doi.org/10.1021/acs.molpharmaceut.5b00028" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.5b00028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.5b00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.5b00028%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSensitive%252BELISA%252BMethod%252Bfor%252Bthe%252BMeasurement%252Bof%252BCatabolites%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADCs%252529%252Bin%252BTarget%252BCancer%252BCells%26aulast%3DSalomon%26aufirst%3DPaulin%2BL.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D12012015%26date%3D04032015%26date%3D19022015%26date%3D17032015%26date%3D01062015%26date%3D04032015%26volume%3D12%26issue%3D6%26spage%3D1752%26epage%3D1761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John F.  Valliere-Douglass</span>, <span class="hlFld-ContribAuthor ">Shawna M.  Hengel</span>, and <span class="hlFld-ContribAuthor ">Lucy Y.  Pan</span>  . </span><span class="cited-content_cbyCitation_article-title">Approaches to Interchain Cysteine-Linked ADC Characterization by Mass Spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1774-1783. <a href="https://doi.org/10.1021/mp500614p" title="DOI URL">https://doi.org/10.1021/mp500614p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp500614p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp500614p%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DApproaches%252Bto%252BInterchain%252BCysteine-Linked%252BADC%252BCharacterization%252Bby%252BMass%252BSpectrometry%26aulast%3DValliere-Douglass%26aufirst%3DJohn%2BF.%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D12092014%26date%3D04122014%26date%3D26112014%26date%3D17122014%26date%3D01062015%26date%3D04122014%26volume%3D12%26issue%3D6%26spage%3D1774%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wayne  Widdison</span>, <span class="hlFld-ContribAuthor ">Sharon  Wilhelm</span>, <span class="hlFld-ContribAuthor ">Karen  Veale</span>, <span class="hlFld-ContribAuthor ">Juliet  Costoplus</span>, <span class="hlFld-ContribAuthor ">Gregory  Jones</span>, <span class="hlFld-ContribAuthor ">Charlene  Audette</span>, <span class="hlFld-ContribAuthor ">Barbara  Leece</span>, <span class="hlFld-ContribAuthor ">Laura  Bartle</span>, <span class="hlFld-ContribAuthor ">Yelena  Kovtun</span>, and <span class="hlFld-ContribAuthor ">Ravi  Chari</span>  . </span><span class="cited-content_cbyCitation_article-title">Metabolites of Antibody–Maytansinoid Conjugates: Characteristics and in Vitro Potencies. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1762-1773. <a href="https://doi.org/10.1021/mp5007757" title="DOI URL">https://doi.org/10.1021/mp5007757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp5007757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp5007757%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DMetabolites%252Bof%252BAntibody%2525E2%252580%252593Maytansinoid%252BConjugates%25253A%252BCharacteristics%252Band%252Bin%252BVitro%252BPotencies%26aulast%3DWiddison%26aufirst%3DWayne%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D19112014%26date%3D31032015%26date%3D20032015%26date%3D08042015%26date%3D01062015%26date%3D31032015%26volume%3D12%26issue%3D6%26spage%3D1762%26epage%3D1773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raffaella  Rossin</span>, <span class="hlFld-ContribAuthor ">Sander M. J.  van Duijnhoven</span>, <span class="hlFld-ContribAuthor ">Tilman  Läppchen</span>, <span class="hlFld-ContribAuthor ">Sandra M.  van den Bosch</span>, and <span class="hlFld-ContribAuthor ">Marc S.  Robillard</span>  . </span><span class="cited-content_cbyCitation_article-title">Trans-Cyclooctene Tag with Improved Properties for Tumor Pretargeting with the Diels–Alder Reaction. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2014,</strong> <em>11 </em>
                                    (9)
                                     , 3090-3096. <a href="https://doi.org/10.1021/mp500275a" title="DOI URL">https://doi.org/10.1021/mp500275a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp500275a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp500275a%26sid%3Dliteratum%253Aachs%26aulast%3DRossin%26jtitle%3DJ%2520Nucl%2520Med.%26date%3D2013%26volume%3D54%26spage%3D1989%26epage%3D1995%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DTrans-Cyclooctene%252BTag%252Bwith%252BImproved%252BProperties%252Bfor%252BTumor%252BPretargeting%252Bwith%252Bthe%252BDiels%2525E2%252580%252593Alder%252BReaction%26aulast%3DRossin%26aufirst%3DRaffaella%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D15042014%26date%3D31072014%26date%3D21072014%26date%3D13082014%26date%3D02092014%26date%3D31072014%26volume%3D11%26issue%3D9%26spage%3D3090%26epage%3D3096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shawna Mae  Hengel</span>, <span class="hlFld-ContribAuthor ">Russell  Sanderson</span>, <span class="hlFld-ContribAuthor ">John  Valliere-Douglass</span>, <span class="hlFld-ContribAuthor ">Nicole  Nicholas</span>, <span class="hlFld-ContribAuthor ">Chris  Leiske</span>, and <span class="hlFld-ContribAuthor ">Stephen C.  Alley</span>  . </span><span class="cited-content_cbyCitation_article-title">Measurement of in Vivo Drug Load Distribution of Cysteine-Linked Antibody–Drug Conjugates Using Microscale Liquid Chromatography Mass Spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2014,</strong> <em>86 </em>
                                    (7)
                                     , 3420-3425. <a href="https://doi.org/10.1021/ac403860c" title="DOI URL">https://doi.org/10.1021/ac403860c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ac403860c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fac403860c%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DMeasurement%252Bof%252Bin%252BVivo%252BDrug%252BLoad%252BDistribution%252Bof%252BCysteine-Linked%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BUsing%252BMicroscale%252BLiquid%252BChromatography%252BMass%252BSpectrometry%26aulast%3DHengel%26aufirst%3DShawna%2BMae%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D27112013%26date%3D27022014%26date%3D14032014%26date%3D01042014%26date%3D27022014%26volume%3D86%26issue%3D7%26spage%3D3420%26epage%3D3425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qun  Zhou</span>, <span class="hlFld-ContribAuthor ">James E.  Stefano</span>, <span class="hlFld-ContribAuthor ">Charlene  Manning</span>, <span class="hlFld-ContribAuthor ">Josephine  Kyazike</span>, <span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Diego A.  Gianolio</span>, <span class="hlFld-ContribAuthor ">Anna  Park</span>, <span class="hlFld-ContribAuthor ">Michelle  Busch</span>, <span class="hlFld-ContribAuthor ">Julie  Bird</span>, <span class="hlFld-ContribAuthor ">Xiaoyang  Zheng</span>, <span class="hlFld-ContribAuthor ">Helene  Simonds-Mannes</span>, <span class="hlFld-ContribAuthor ">Jennifer  Kim</span>, <span class="hlFld-ContribAuthor ">Rick C.  Gregory</span>, <span class="hlFld-ContribAuthor ">Robert J.  Miller</span>, <span class="hlFld-ContribAuthor ">William H.  Brondyk</span>, <span class="hlFld-ContribAuthor ">Pradeep K.  Dhal</span>, and <span class="hlFld-ContribAuthor ">Clark Q.  Pan</span>  . </span><span class="cited-content_cbyCitation_article-title">Site-Specific Antibody–Drug Conjugation through Glycoengineering. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2014,</strong> <em>25 </em>
                                    (3)
                                     , 510-520. <a href="https://doi.org/10.1021/bc400505q" title="DOI URL">https://doi.org/10.1021/bc400505q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bc400505q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbc400505q%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSite-Specific%252BAntibody%2525E2%252580%252593Drug%252BConjugation%252Bthrough%252BGlycoengineering%26aulast%3DZhou%26aufirst%3DQun%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D2014%26date%3D29102013%26date%3D14022014%26date%3D28022014%26date%3D19032014%26date%3D17022014%26volume%3D25%26issue%3D3%26spage%3D510%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert Yongxin  Zhao</span>, <span class="hlFld-ContribAuthor ">Hans K.  Erickson</span>, <span class="hlFld-ContribAuthor ">Barbara A.  Leece</span>, <span class="hlFld-ContribAuthor ">Emily E.  Reid</span>, <span class="hlFld-ContribAuthor ">Victor S.  Goldmacher</span>, <span class="hlFld-ContribAuthor ">John M.  Lambert</span>, and <span class="hlFld-ContribAuthor ">Ravi V. J.  Chari</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (2)
                                     , 766-782. <a href="https://doi.org/10.1021/jm201284m" title="DOI URL">https://doi.org/10.1021/jm201284m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201284m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201284m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BAntibody%252BConjugates%252Bof%252BPhosphate%252BProdrugs%252Bof%252BCytotoxic%252BDNA%252BAlkylators%252Bfor%252Bthe%252BTargeted%252BTreatment%252Bof%252BCancer%26aulast%3DZhao%26aufirst%3DRobert%2BYongxin%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D26092011%26date%3D05012012%26date%3D26012012%26date%3D08122011%26volume%3D55%26issue%3D2%26spage%3D766%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T.  Tedeschini</span>, <span class="hlFld-ContribAuthor ">B.  Campara</span>, <span class="hlFld-ContribAuthor ">A.  Grigoletto</span>, <span class="hlFld-ContribAuthor ">M.  Bellini</span>, <span class="hlFld-ContribAuthor ">M.  Salvalaio</span>, <span class="hlFld-ContribAuthor ">Y.  Matsuno</span>, <span class="hlFld-ContribAuthor ">A.  Suzuki</span>, <span class="hlFld-ContribAuthor ">H.  Yoshioka</span>, <span class="hlFld-ContribAuthor ">G.  Pasut</span>. </span><span class="cited-content_cbyCitation_article-title">Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2021,</strong> <em>337 </em>, 431-447. <a href="https://doi.org/10.1016/j.jconrel.2021.07.041" title="DOI URL">https://doi.org/10.1016/j.jconrel.2021.07.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2021.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2021.07.041%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DPolyethylene%252Bglycol-based%252Blinkers%252Bas%252Bhydrophilicity%252Breservoir%252Bfor%252Bantibody-drug%252Bconjugates%26aulast%3DTedeschini%26aufirst%3DT.%26date%3D2021%26volume%3D337%26spage%3D431%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Kaempffe</span>, <span class="hlFld-ContribAuthor ">Stephan  Dickgiesser</span>, <span class="hlFld-ContribAuthor ">Nicolas  Rasche</span>, <span class="hlFld-ContribAuthor ">Andrea  Paoletti</span>, <span class="hlFld-ContribAuthor ">Elisa  Bertotti</span>, <span class="hlFld-ContribAuthor ">Ilse  De Salve</span>, <span class="hlFld-ContribAuthor ">Federico Riccardi  Sirtori</span>, <span class="hlFld-ContribAuthor ">Roland  Kellner</span>, <span class="hlFld-ContribAuthor ">Doreen  Könning</span>, <span class="hlFld-ContribAuthor ">Stefan  Hecht</span>, <span class="hlFld-ContribAuthor ">Jan  Anderl</span>, <span class="hlFld-ContribAuthor ">Harald  Kolmar</span>, <span class="hlFld-ContribAuthor ">Christian  Schröter</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of conjugation site and technique on the stability and pharmacokinetics of antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2021,</strong> <em>22 </em><a href="https://doi.org/10.1016/j.xphs.2021.08.002" title="DOI URL">https://doi.org/10.1016/j.xphs.2021.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2021.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2021.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DEffect%252Bof%252Bconjugation%252Bsite%252Band%252Btechnique%252Bon%252Bthe%252Bstability%252Band%252Bpharmacokinetics%252Bof%252Bantibody-drug%252Bconjugates%26aulast%3DKaempffe%26aufirst%3DAnna%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abhilash  Rana</span>, <span class="hlFld-ContribAuthor ">Seema  Bhatnagar</span>. </span><span class="cited-content_cbyCitation_article-title">Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104946. <a href="https://doi.org/10.1016/j.bioorg.2021.104946" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104946%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAdvancements%252Bin%252Bfolate%252Breceptor%252Btargeting%252Bfor%252Banti-cancer%252Btherapy%25253A%252BA%252Bsmall%252Bmolecule-drug%252Bconjugate%252Bapproach%26aulast%3DRana%26aufirst%3DAbhilash%26date%3D2021%26volume%3D112%26spage%3D104946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandeep Surendra  Panikar</span>, <span class="hlFld-ContribAuthor ">Nehla  Banu</span>, <span class="hlFld-ContribAuthor ">Jesse  Haramati</span>, <span class="hlFld-ContribAuthor ">Susana  del Toro-Arreola</span>, <span class="hlFld-ContribAuthor ">Annie  Riera Leal</span>, <span class="hlFld-ContribAuthor ">Pedro  Salas</span>. </span><span class="cited-content_cbyCitation_article-title">Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2021,</strong> <em>334 </em>, 389-412. <a href="https://doi.org/10.1016/j.jconrel.2021.05.004" title="DOI URL">https://doi.org/10.1016/j.jconrel.2021.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2021.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2021.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DNanobodies%252Bas%252Befficient%252Bdrug-carriers%25253A%252BProgress%252Band%252Btrends%252Bin%252Bchemotherapy%26aulast%3DPanikar%26aufirst%3DSandeep%2BSurendra%26date%3D2021%26volume%3D334%26spage%3D389%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie  Baah</span>, <span class="hlFld-ContribAuthor ">Mark  Laws</span>, <span class="hlFld-ContribAuthor ">Khondaker Miraz  Rahman</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates—A Tutorial Review. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (10)
                                     , 2943. <a href="https://doi.org/10.3390/molecules26102943" title="DOI URL">https://doi.org/10.3390/molecules26102943</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26102943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26102943%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%2525E2%252580%252594A%252BTutorial%252BReview%26aulast%3DBaah%26aufirst%3DStephanie%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D10%26spage%3D2943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Su</span>, <span class="hlFld-ContribAuthor ">Dian  Xiao</span>, <span class="hlFld-ContribAuthor ">Fei  Xie</span>, <span class="hlFld-ContribAuthor ">Lianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Yanming  Wang</span>, <span class="hlFld-ContribAuthor ">Shiyong  Fan</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>, <span class="hlFld-ContribAuthor ">Song  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugates: Recent advances in linker chemistry. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1016/j.apsb.2021.03.042" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.03.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.03.042%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugates%25253A%252BRecent%252Badvances%252Bin%252Blinker%252Bchemistry%26aulast%3DSu%26aufirst%3DZheng%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephan  Dickgiesser</span>, <span class="hlFld-ContribAuthor ">Marcel  Rieker</span>, <span class="hlFld-ContribAuthor ">Nicolas  Rasche</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 189-214. <a href="https://doi.org/10.1007/978-3-030-54630-4_8" title="DOI URL">https://doi.org/10.1007/978-3-030-54630-4_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-54630-4_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-54630-4_8%26sid%3Dliteratum%253Aachs%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DDickgiesser%26aufirst%3DStephan%26date%3D2021%26date%3D2020%26spage%3D189%26epage%3D214%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DIntroduction%252Bto%252BAntibody%252BEngineering%26aulast%3DR%25C3%25BCker%26aufirst%3DFlorian%26date%3D2021%26volume%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Viswas Raja  Solomon</span>, <span class="hlFld-ContribAuthor ">Elahe  Alizadeh</span>, <span class="hlFld-ContribAuthor ">Wendy  Bernhard</span>, <span class="hlFld-ContribAuthor ">Amal  Makhlouf</span>, <span class="hlFld-ContribAuthor ">Siddesh V.  Hartimath</span>, <span class="hlFld-ContribAuthor ">Wayne  Hill</span>, <span class="hlFld-ContribAuthor ">Ayman  El-Sayed</span>, <span class="hlFld-ContribAuthor ">Kris  Barreto</span>, <span class="hlFld-ContribAuthor ">Clarence Ronald  Geyer</span>, <span class="hlFld-ContribAuthor ">Humphrey  Fonge</span>. </span><span class="cited-content_cbyCitation_article-title">Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-75279-z" title="DOI URL">https://doi.org/10.1038/s41598-020-75279-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-75279-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-75279-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDevelopment%252Band%252Bpreclinical%252Bevaluation%252Bof%252Bcixutumumab%252Bdrug%252Bconjugates%252Bin%252Ba%252Bmodel%252Bof%252Binsulin%252Bgrowth%252Bfactor%252Breceptor%252BI%252B%252528IGF-1R%252529%252Bpositive%252Bcancer%26aulast%3DSolomon%26aufirst%3DViswas%2BRaja%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurence  Gauzy-Lazo</span>, <span class="hlFld-ContribAuthor ">Ingrid  Sassoon</span>, <span class="hlFld-ContribAuthor ">Marie-Priscille  Brun</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (8)
                                     , 843-868. <a href="https://doi.org/10.1177/2472555220912955" title="DOI URL">https://doi.org/10.1177/2472555220912955</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555220912955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555220912955%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DAdvances%252Bin%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BDesign%25253A%252BCurrent%252BClinical%252BLandscape%252Band%252BFuture%252BInnovations%26aulast%3DGauzy-Lazo%26aufirst%3DLaurence%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D8%26spage%3D843%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nagavendra  Kommineni</span>, <span class="hlFld-ContribAuthor ">Palpandi  Pandi</span>, <span class="hlFld-ContribAuthor ">Naveen  Chella</span>, <span class="hlFld-ContribAuthor ">Abraham J.  Domb</span>, <span class="hlFld-ContribAuthor ">Wahid  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody drug conjugates: Development, characterization, and regulatory considerations. </span><span class="cited-content_cbyCitation_journal-name">Polymers for Advanced Technologies</span><span> <strong>2020,</strong> <em>31 </em>
                                    (6)
                                     , 1177-1193. <a href="https://doi.org/10.1002/pat.4789" title="DOI URL">https://doi.org/10.1002/pat.4789</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pat.4789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpat.4789%26sid%3Dliteratum%253Aachs%26jtitle%3DPolymers%2520for%2520Advanced%2520Technologies%26atitle%3DAntibody%252Bdrug%252Bconjugates%25253A%252BDevelopment%25252C%252Bcharacterization%25252C%252Band%252Bregulatory%252Bconsiderations%26aulast%3DKommineni%26aufirst%3DNagavendra%26date%3D2020%26date%3D2019%26volume%3D31%26issue%3D6%26spage%3D1177%26epage%3D1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Chao  Gao</span>, <span class="hlFld-ContribAuthor ">Jun  Tian</span>, <span class="hlFld-ContribAuthor ">Yu-Zhu  Shang</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Steric and stereoscopic disulfide construction for cross-linkage
              via N
              -dithiophthalimides. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (15)
                                     , 3903-3908. <a href="https://doi.org/10.1039/D0SC01060J" title="DOI URL">https://doi.org/10.1039/D0SC01060J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC01060J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC01060J%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DSteric%252Band%252Bstereoscopic%252Bdisulfide%252Bconstruction%252Bfor%252Bcross-linkage%252Bvia%252BN%252B-dithiophthalimides%26aulast%3DGao%26aufirst%3DWen-Chao%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D15%26spage%3D3903%26epage%3D3908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nooshafarin  Amani</span>, <span class="hlFld-ContribAuthor ">Farid Abedin  Dorkoosh</span>, <span class="hlFld-ContribAuthor ">Hamid  Mobedi</span>. </span><span class="cited-content_cbyCitation_article-title">ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Delivery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (1)
                                     , 23-51. <a href="https://doi.org/10.2174/1567201816666191121145109" title="DOI URL">https://doi.org/10.2174/1567201816666191121145109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1567201816666191121145109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1567201816666191121145109%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Delivery%26atitle%3DADCs%25252C%252Bas%252BNovel%252BRevolutionary%252BWeapons%252Bfor%252BProviding%252Ba%252BStep%252BForward%252Bin%252BTargeted%252BTherapy%252Bof%252BMalignancies%26aulast%3DAmani%26aufirst%3DNooshafarin%26date%3D2020%26volume%3D17%26issue%3D1%26spage%3D23%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">An Overview of the Current ADC Discovery Landscape. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-22. <a href="https://doi.org/10.1007/978-1-4939-9929-3_1" title="DOI URL">https://doi.org/10.1007/978-1-4939-9929-3_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-9929-3_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-9929-3_1%26sid%3Dliteratum%253Aachs%26atitle%3DAn%252BOverview%252Bof%252Bthe%252BCurrent%252BADC%252BDiscovery%252BLandscape%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2020%26date%3D2019%26spage%3D1%26epage%3D22%26pub%3DSpringer%2520US%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2020%26volume%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feroz  Jameel</span>, <span class="hlFld-ContribAuthor ">Brittney J.  Mills</span>, <span class="hlFld-ContribAuthor ">Ehab M.  Moussa</span>, <span class="hlFld-ContribAuthor ">Vikram  Sisodiya</span>, <span class="hlFld-ContribAuthor ">Tony  Cano</span>, <span class="hlFld-ContribAuthor ">Anthony R.  Haight</span>. </span><span class="cited-content_cbyCitation_article-title">Chapter 2: Challenges and Considerations in the Design of Antibody-Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 27-48. <a href="https://doi.org/10.1007/978-3-030-31415-6_2" title="DOI URL">https://doi.org/10.1007/978-3-030-31415-6_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-31415-6_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-31415-6_2%26sid%3Dliteratum%253Aachs%26atitle%3DChapter%252B2%25253A%252BChallenges%252Band%252BConsiderations%252Bin%252Bthe%252BDesign%252Bof%252BAntibody-Drug%252BConjugates%26aulast%3DJameel%26aufirst%3DFeroz%26date%3D2020%26date%3D2020%26spage%3D27%26epage%3D48%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDevelopment%252Bof%252BBiopharmaceutical%252BDrug-Device%252BProducts%26aulast%3DJameel%26aufirst%3DFeroz%26date%3D2020%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dennis R.  Goulet</span>, <span class="hlFld-ContribAuthor ">William M.  Atkins</span>. </span><span class="cited-content_cbyCitation_article-title">Considerations for the Design of Antibody-Based Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>109 </em>
                                    (1)
                                     , 74-103. <a href="https://doi.org/10.1016/j.xphs.2019.05.031" title="DOI URL">https://doi.org/10.1016/j.xphs.2019.05.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2019.05.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2019.05.031%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DConsiderations%252Bfor%252Bthe%252BDesign%252Bof%252BAntibody-Based%252BTherapeutics%26aulast%3DGoulet%26aufirst%3DDennis%2BR.%26date%3D2020%26volume%3D109%26issue%3D1%26spage%3D74%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jakob W.  Buecheler</span>, <span class="hlFld-ContribAuthor ">Matthias  Winzer</span>, <span class="hlFld-ContribAuthor ">Christian  Weber</span>, <span class="hlFld-ContribAuthor ">Henning  Gieseler</span>. </span><span class="cited-content_cbyCitation_article-title">Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>109 </em>
                                    (1)
                                     , 161-168. <a href="https://doi.org/10.1016/j.xphs.2019.08.006" title="DOI URL">https://doi.org/10.1016/j.xphs.2019.08.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2019.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2019.08.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DAlteration%252Bof%252BPhysicochemical%252BProperties%252Bfor%252BAntibody-Drug%252BConjugates%252Band%252BTheir%252BImpact%252Bon%252BStability%26aulast%3DBuecheler%26aufirst%3DJakob%2BW.%26date%3D2020%26volume%3D109%26issue%3D1%26spage%3D161%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sajad  Yaghoubi</span>, <span class="hlFld-ContribAuthor ">Mohammad Hossein  Karimi</span>, <span class="hlFld-ContribAuthor ">Majid  Lotfinia</span>, <span class="hlFld-ContribAuthor ">Tohid  Gharibi</span>, <span class="hlFld-ContribAuthor ">Motahare  Mahi‐Birjand</span>, <span class="hlFld-ContribAuthor ">Esmaeil  Kavi</span>, <span class="hlFld-ContribAuthor ">Fahimeh  Hosseini</span>, <span class="hlFld-ContribAuthor ">Koushan  Sineh Sepehr</span>, <span class="hlFld-ContribAuthor ">Mehrdad  Khatami</span>, <span class="hlFld-ContribAuthor ">Nader  Bagheri</span>, <span class="hlFld-ContribAuthor ">Meghdad  Abdollahpour‐Alitappeh</span>. </span><span class="cited-content_cbyCitation_article-title">Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2020,</strong> <em>235 </em>
                                    (1)
                                     , 31-64. <a href="https://doi.org/10.1002/jcp.28967" title="DOI URL">https://doi.org/10.1002/jcp.28967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.28967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.28967%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DPotential%252Bdrugs%252Bused%252Bin%252Bthe%252Bantibody%2525E2%252580%252593drug%252Bconjugate%252B%252528ADC%252529%252Barchitecture%252Bfor%252Bcancer%252Btherapy%26aulast%3DYaghoubi%26aufirst%3DSajad%26date%3D2020%26date%3D2019%26volume%3D235%26issue%3D1%26spage%3D31%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuyu  Xu</span>, <span class="hlFld-ContribAuthor ">Dandan  Guo</span>, <span class="hlFld-ContribAuthor ">Zhongliang  Jiang</span>, <span class="hlFld-ContribAuthor ">Rongsheng  Tong</span>, <span class="hlFld-ContribAuthor ">Peidu  Jiang</span>, <span class="hlFld-ContribAuthor ">Lan  Bai</span>, <span class="hlFld-ContribAuthor ">Lu  Chen</span>, <span class="hlFld-ContribAuthor ">Yuxuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Chun  Guo</span>, <span class="hlFld-ContribAuthor ">Jianyou  Shi</span>, <span class="hlFld-ContribAuthor ">Dongke  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111682. <a href="https://doi.org/10.1016/j.ejmech.2019.111682" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111682</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111682%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BHER2-Targeting%252BAntibody-Drug%252BConjugates%252Bof%252BTrastuzumab%252BBeyond%252BT-DM1%252Bin%252BBreast%252BCancer%25253A%252BTrastuzumab%252BDeruxtecan%252528DS-8201a%252529%252Band%252B%252528Vic-%252529Trastuzumab%252BDuocarmazine%252B%252528SYD985%252529%26aulast%3DXu%26aufirst%3DZhuyu%26date%3D2019%26volume%3D183%26spage%3D111682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mehri  Abedi</span>, <span class="hlFld-ContribAuthor ">Reza Ahangari  Cohan</span>, <span class="hlFld-ContribAuthor ">Fereidoun  Mahboudi</span>, <span class="hlFld-ContribAuthor ">Mohammad Ali  Faramarzi</span>, <span class="hlFld-ContribAuthor ">Ramin  Fazel</span>, <span class="hlFld-ContribAuthor ">Narges  Damavandi</span>, <span class="hlFld-ContribAuthor ">Mehdi Shafiee  Ardestani</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Davami</span>. </span><span class="cited-content_cbyCitation_article-title">Novel trastuzumab‐DM1 conjugate: Synthesis and bio‐evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2019,</strong> <em>234 </em>
                                    (10)
                                     , 18206-18213. <a href="https://doi.org/10.1002/jcp.28453" title="DOI URL">https://doi.org/10.1002/jcp.28453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.28453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.28453%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DNovel%252Btrastuzumab%2525E2%252580%252590DM1%252Bconjugate%25253A%252BSynthesis%252Band%252Bbio%2525E2%252580%252590evaluation%26aulast%3DAbedi%26aufirst%3DMehri%26date%3D2019%26date%3D2019%26volume%3D234%26issue%3D10%26spage%3D18206%26epage%3D18213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanwen  Yang</span>, <span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Diego A.  Gianolio</span>, <span class="hlFld-ContribAuthor ">James E.  Stefano</span>, <span class="hlFld-ContribAuthor ">Michelle  Busch</span>, <span class="hlFld-ContribAuthor ">Charlene  Manning</span>, <span class="hlFld-ContribAuthor ">Kim  Alving</span>, <span class="hlFld-ContribAuthor ">Richard C.  Gregory</span>, <span class="hlFld-ContribAuthor ">William H.  Brondyk</span>, <span class="hlFld-ContribAuthor ">Robert J.  Miller</span>, <span class="hlFld-ContribAuthor ">Pradeep K.  Dhal</span>. </span><span class="cited-content_cbyCitation_article-title">Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (35)
                                     , 8115-8124. <a href="https://doi.org/10.1039/C9OB01639B" title="DOI URL">https://doi.org/10.1039/C9OB01639B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01639B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01639B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConvergent%252Bsynthesis%252Bof%252Bhydrophilic%252Bmonomethyl%252Bdolastatin%252B10%252Bbased%252Bdrug%252Blinkers%252Bfor%252Bantibody%2525E2%252580%252593drug%252Bconjugation%26aulast%3DYang%26aufirst%3DKanwen%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D35%26spage%3D8115%26epage%3D8124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Qiu</span>, <span class="hlFld-ContribAuthor ">Wujian  Mao</span>, <span class="hlFld-ContribAuthor ">Hongyan  Yin</span>, <span class="hlFld-ContribAuthor ">Hui  Tan</span>, <span class="hlFld-ContribAuthor ">Dengfeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Hongcheng  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Pretargeted Nuclear Imaging and Radioimmunotherapy Based on the Inverse Electron-Demand Diels–Alder Reaction and Key Factors in the Pretargeted Synthetic Design. </span><span class="cited-content_cbyCitation_journal-name">Contrast Media & Molecular Imaging</span><span> <strong>2019,</strong> <em>2019 </em>, 1-12. <a href="https://doi.org/10.1155/2019/9182476" title="DOI URL">https://doi.org/10.1155/2019/9182476</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2019/9182476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2019%2F9182476%26sid%3Dliteratum%253Aachs%26jtitle%3DContrast%2520Media%2520%2526%2520Molecular%2520Imaging%26atitle%3DPretargeted%252BNuclear%252BImaging%252Band%252BRadioimmunotherapy%252BBased%252Bon%252Bthe%252BInverse%252BElectron-Demand%252BDiels%2525E2%252580%252593Alder%252BReaction%252Band%252BKey%252BFactors%252Bin%252Bthe%252BPretargeted%252BSynthetic%252BDesign%26aulast%3DQiu%26aufirst%3DLin%26date%3D2019%26volume%3D2019%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc‐André  Kasper</span>, <span class="hlFld-ContribAuthor ">Andreas  Stengl</span>, <span class="hlFld-ContribAuthor ">Philipp  Ochtrop</span>, <span class="hlFld-ContribAuthor ">Marcus  Gerlach</span>, <span class="hlFld-ContribAuthor ">Tina  Stoschek</span>, <span class="hlFld-ContribAuthor ">Dominik  Schumacher</span>, <span class="hlFld-ContribAuthor ">Jonas  Helma</span>, <span class="hlFld-ContribAuthor ">Martin  Penkert</span>, <span class="hlFld-ContribAuthor ">Eberhard  Krause</span>, <span class="hlFld-ContribAuthor ">Heinrich  Leonhardt</span>, <span class="hlFld-ContribAuthor ">Christian P. R.  Hackenberger</span>. </span><span class="cited-content_cbyCitation_article-title">Ethynylphosphonamidates for the Rapid and Cysteine‐Selective Generation of Efficacious Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2019,</strong> <em>131 </em>
                                    (34)
                                     , 11757-11762. <a href="https://doi.org/10.1002/ange.201904193" title="DOI URL">https://doi.org/10.1002/ange.201904193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201904193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201904193%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEthynylphosphonamidates%252Bfor%252Bthe%252BRapid%252Band%252BCysteine%2525E2%252580%252590Selective%252BGeneration%252Bof%252BEfficacious%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DKasper%26aufirst%3DMarc%25E2%2580%2590Andr%25C3%25A9%26date%3D2019%26date%3D2019%26volume%3D131%26issue%3D34%26spage%3D11757%26epage%3D11762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc‐André  Kasper</span>, <span class="hlFld-ContribAuthor ">Andreas  Stengl</span>, <span class="hlFld-ContribAuthor ">Philipp  Ochtrop</span>, <span class="hlFld-ContribAuthor ">Marcus  Gerlach</span>, <span class="hlFld-ContribAuthor ">Tina  Stoschek</span>, <span class="hlFld-ContribAuthor ">Dominik  Schumacher</span>, <span class="hlFld-ContribAuthor ">Jonas  Helma</span>, <span class="hlFld-ContribAuthor ">Martin  Penkert</span>, <span class="hlFld-ContribAuthor ">Eberhard  Krause</span>, <span class="hlFld-ContribAuthor ">Heinrich  Leonhardt</span>, <span class="hlFld-ContribAuthor ">Christian P. R.  Hackenberger</span>. </span><span class="cited-content_cbyCitation_article-title">Ethynylphosphonamidates for the Rapid and Cysteine‐Selective Generation of Efficacious Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2019,</strong> <em>58 </em>
                                    (34)
                                     , 11631-11636. <a href="https://doi.org/10.1002/anie.201904193" title="DOI URL">https://doi.org/10.1002/anie.201904193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201904193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201904193%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DEthynylphosphonamidates%252Bfor%252Bthe%252BRapid%252Band%252BCysteine%2525E2%252580%252590Selective%252BGeneration%252Bof%252BEfficacious%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DKasper%26aufirst%3DMarc%25E2%2580%2590Andr%25C3%25A9%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3D34%26spage%3D11631%26epage%3D11636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siddesh V.  Hartimath</span>, <span class="hlFld-ContribAuthor ">Elahe  Alizadeh</span>, <span class="hlFld-ContribAuthor ">Viswas Raja  Solomon</span>, <span class="hlFld-ContribAuthor ">Rufael  Chekol</span>, <span class="hlFld-ContribAuthor ">Wendy  Bernhard</span>, <span class="hlFld-ContribAuthor ">Wayne  Hill</span>, <span class="hlFld-ContribAuthor ">Angel Casaco  Parada</span>, <span class="hlFld-ContribAuthor ">Kris  Barreto</span>, <span class="hlFld-ContribAuthor ">Clarence Ronald  Geyer</span>, <span class="hlFld-ContribAuthor ">Humphrey  Fonge</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Evaluation of
              111
              In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Nuclear Medicine</span><span> <strong>2019,</strong> <em>60 </em>
                                    (8)
                                     , 1103-1110. <a href="https://doi.org/10.2967/jnumed.118.220095" title="DOI URL">https://doi.org/10.2967/jnumed.118.220095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2967/jnumed.118.220095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2967%2Fjnumed.118.220095%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Nuclear%2520Medicine%26atitle%3DPreclinical%252BEvaluation%252Bof%252B111%252BIn-Labeled%252BPEGylated%252BMaytansine%252BNimotuzumab%252BDrug%252BConjugates%252Bin%252BEGFR-Positive%252BCancer%252BModels%26aulast%3DHartimath%26aufirst%3DSiddesh%2BV.%26date%3D2019%26date%3D2019%26volume%3D60%26issue%3D8%26spage%3D1103%26epage%3D1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Corinna  Duerr</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Friess</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-drug conjugates- stability and formulation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutics and Biopharmaceutics</span><span> <strong>2019,</strong> <em>139 </em>, 168-176. <a href="https://doi.org/10.1016/j.ejpb.2019.03.021" title="DOI URL">https://doi.org/10.1016/j.ejpb.2019.03.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejpb.2019.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejpb.2019.03.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutics%2520and%2520Biopharmaceutics%26atitle%3DAntibody-drug%252Bconjugates-%252Bstability%252Band%252Bformulation%26aulast%3DDuerr%26aufirst%3DCorinna%26date%3D2019%26volume%3D139%26spage%3D168%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel P.  Petrylak</span>, <span class="hlFld-ContribAuthor ">Philip  Kantoff</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Vogelzang</span>, <span class="hlFld-ContribAuthor ">Anthony  Mega</span>, <span class="hlFld-ContribAuthor ">Mark T.  Fleming</span>, <span class="hlFld-ContribAuthor ">Joe J.  Stephenson</span>, <span class="hlFld-ContribAuthor ">Richard  Frank</span>, <span class="hlFld-ContribAuthor ">Neal D.  Shore</span>, <span class="hlFld-ContribAuthor ">Robert  Dreicer</span>, <span class="hlFld-ContribAuthor ">Edward F.  McClay</span>, <span class="hlFld-ContribAuthor ">William R.  Berry</span>, <span class="hlFld-ContribAuthor ">Manish  Agarwal</span>, <span class="hlFld-ContribAuthor ">Vincent A.  DiPippo</span>, <span class="hlFld-ContribAuthor ">Yakov  Rotshteyn</span>, <span class="hlFld-ContribAuthor ">Nancy  Stambler</span>, <span class="hlFld-ContribAuthor ">William C.  Olson</span>, <span class="hlFld-ContribAuthor ">Stephen A.  Morris</span>, <span class="hlFld-ContribAuthor ">Robert J.  Israel</span>. </span><span class="cited-content_cbyCitation_article-title">Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">The Prostate</span><span> <strong>2019,</strong> <em>79 </em>
                                    (6)
                                     , 604-613. <a href="https://doi.org/10.1002/pros.23765" title="DOI URL">https://doi.org/10.1002/pros.23765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pros.23765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpros.23765%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Prostate%26atitle%3DPhase%252B1%252Bstudy%252Bof%252BPSMA%252BADC%25252C%252Ban%252Bantibody%2525E2%252580%252590drug%252Bconjugate%252Btargeting%252Bprostate%2525E2%252580%252590specific%252Bmembrane%252Bantigen%25252C%252Bin%252Bchemotherapy%2525E2%252580%252590refractory%252Bprostate%252Bcancer%26aulast%3DPetrylak%26aufirst%3DDaniel%2BP.%26date%3D2019%26date%3D2019%26volume%3D79%26issue%3D6%26spage%3D604%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maxine  Bauzon</span>, <span class="hlFld-ContribAuthor ">Penelope M.  Drake</span>, <span class="hlFld-ContribAuthor ">Robyn M.  Barfield</span>, <span class="hlFld-ContribAuthor ">Brandon M.  Cornali</span>, <span class="hlFld-ContribAuthor ">Igor  Rupniewski</span>, <span class="hlFld-ContribAuthor ">David  Rabuka</span>. </span><span class="cited-content_cbyCitation_article-title">Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. </span><span class="cited-content_cbyCitation_journal-name">OncoImmunology</span><span> <strong>2019,</strong> <em>8 </em>
                                    (4)
                                     , e1565859. <a href="https://doi.org/10.1080/2162402X.2019.1565859" title="DOI URL">https://doi.org/10.1080/2162402X.2019.1565859</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/2162402X.2019.1565859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F2162402X.2019.1565859%26sid%3Dliteratum%253Aachs%26jtitle%3DOncoImmunology%26atitle%3DMaytansine-bearing%252Bantibody-drug%252Bconjugates%252Binduce%252Bin%252Bvitro%252Bhallmarks%252Bof%252Bimmunogenic%252Bcell%252Bdeath%252Bselectively%252Bin%252Bantigen-positive%252Btarget%252Bcells%26aulast%3DBauzon%26aufirst%3DMaxine%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D4%26spage%3De1565859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Filip  Ekholm</span>, <span class="hlFld-ContribAuthor ">Suvi-Katriina  Ruokonen</span>, <span class="hlFld-ContribAuthor ">Marina  Redón</span>, <span class="hlFld-ContribAuthor ">Virve  Pitkänen</span>, <span class="hlFld-ContribAuthor ">Anja  Vilkman</span>, <span class="hlFld-ContribAuthor ">Juhani  Saarinen</span>, <span class="hlFld-ContribAuthor ">Jari  Helin</span>, <span class="hlFld-ContribAuthor ">Tero  Satomaa</span>, <span class="hlFld-ContribAuthor ">Susanne  Wiedmer</span>. </span><span class="cited-content_cbyCitation_article-title">Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Separations</span><span> <strong>2019,</strong> <em>6 </em>
                                    (1)
                                     , 1. <a href="https://doi.org/10.3390/separations6010001" title="DOI URL">https://doi.org/10.3390/separations6010001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/separations6010001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fseparations6010001%26sid%3Dliteratum%253Aachs%26jtitle%3DSeparations%26atitle%3DHydrophilic%252BMonomethyl%252BAuristatin%252BE%252BDerivatives%252Bas%252BNovel%252BCandidates%252Bfor%252Bthe%252BDesign%252Bof%252BAntibody-Drug%252BConjugates%26aulast%3DEkholm%26aufirst%3DFilip%26date%3D2019%26date%3D2018%26volume%3D6%26issue%3D1%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ke  Xie</span>, <span class="hlFld-ContribAuthor ">Shanshan  Song</span>, <span class="hlFld-ContribAuthor ">Liqian  Zhou</span>, <span class="hlFld-ContribAuthor ">Jianqin  Wan</span>, <span class="hlFld-ContribAuthor ">Yiting  Qiao</span>, <span class="hlFld-ContribAuthor ">Min  Wang</span>, <span class="hlFld-ContribAuthor ">Haiyang  Xie</span>, <span class="hlFld-ContribAuthor ">Lin  Zhou</span>, <span class="hlFld-ContribAuthor ">Shusen  Zheng</span>, <span class="hlFld-ContribAuthor ">Hangxiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2019,</strong> <em>556 </em>, 159-171. <a href="https://doi.org/10.1016/j.ijpharm.2018.12.017" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2018.12.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2018.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2018.12.017%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DRevival%252Bof%252Ba%252Bpotent%252Btherapeutic%252Bmaytansinoid%252Bagent%252Busing%252Ba%252Bstrategy%252Bthat%252Bcombines%252Bcovalent%252Bdrug%252Bconjugation%252Bwith%252Bsequential%252Bnanoparticle%252Bassembly%26aulast%3DXie%26aufirst%3DKe%26date%3D2019%26volume%3D556%26spage%3D159%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siddesh V.  Hartimath</span>, <span class="hlFld-ContribAuthor ">Ayman  El-Sayed</span>, <span class="hlFld-ContribAuthor ">Amal  Makhlouf</span>, <span class="hlFld-ContribAuthor ">Wendy  Bernhard</span>, <span class="hlFld-ContribAuthor ">Carolina  Gonzalez</span>, <span class="hlFld-ContribAuthor ">Wayne  Hill</span>, <span class="hlFld-ContribAuthor ">Angel Casaco  Parada</span>, <span class="hlFld-ContribAuthor ">Kris  Barreto</span>, <span class="hlFld-ContribAuthor ">Clarence Ronald  Geyer</span>, <span class="hlFld-ContribAuthor ">Humphrey  Fonge</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1031-1044. <a href="https://doi.org/10.18632/oncotarget.26613" title="DOI URL">https://doi.org/10.18632/oncotarget.26613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26613%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DTherapeutic%252Bpotential%252Bof%252Bnimotuzumab%252BPEGylated-maytansine%252Bantibody%252Bdrug%252Bconjugates%252Bagainst%252BEGFR%252Bpositive%252Bxenograft%26aulast%3DHartimath%26aufirst%3DSiddesh%2BV.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D10%26spage%3D1031%26epage%3D1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathan J  Alves</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody conjugation and formulation. </span><span class="cited-content_cbyCitation_journal-name">Antibody Therapeutics</span><span> <strong>2019,</strong> <em>2 </em>
                                    (1)
                                     , 33-39. <a href="https://doi.org/10.1093/abt/tbz002" title="DOI URL">https://doi.org/10.1093/abt/tbz002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/abt/tbz002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fabt%2Ftbz002%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibody%2520Therapeutics%26atitle%3DAntibody%252Bconjugation%252Band%252Bformulation%26aulast%3DAlves%26aufirst%3DNathan%2BJ%26date%3D2019%26date%3D2019%26volume%3D2%26issue%3D1%26spage%3D33%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naresh  Goli</span>, <span class="hlFld-ContribAuthor ">Pradeep Kumar  Bolla</span>, <span class="hlFld-ContribAuthor ">Venu  Talla</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Delivery Science and Technology</span><span> <strong>2018,</strong> <em>48 </em>, 106-117. <a href="https://doi.org/10.1016/j.jddst.2018.08.022" title="DOI URL">https://doi.org/10.1016/j.jddst.2018.08.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jddst.2018.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jddst.2018.08.022%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Delivery%2520Science%2520and%2520Technology%26atitle%3DAntibody-drug%252Bconjugates%252B%252528ADCs%252529%25253A%252BPotent%252Bbiopharmaceuticals%252Bto%252Btarget%252Bsolid%252Band%252Bhematological%252Bcancers-%252Ban%252Boverview%26aulast%3DGoli%26aufirst%3DNaresh%26date%3D2018%26volume%3D48%26spage%3D106%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sylvain  Ursuegui</span>, <span class="hlFld-ContribAuthor ">Jérémy P.  Schneider</span>, <span class="hlFld-ContribAuthor ">Claire  Imbs</span>, <span class="hlFld-ContribAuthor ">Florian  Lauvoisard</span>, <span class="hlFld-ContribAuthor ">Marta  Dudek</span>, <span class="hlFld-ContribAuthor ">Michel  Mosser</span>, <span class="hlFld-ContribAuthor ">Alain  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Expedient synthesis of trifunctional oligoethyleneglycol-amine linkers and their use in the preparation of PEG-based branched platforms. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (44)
                                     , 8579-8584. <a href="https://doi.org/10.1039/C8OB02097C" title="DOI URL">https://doi.org/10.1039/C8OB02097C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02097C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02097C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DExpedient%252Bsynthesis%252Bof%252Btrifunctional%252Boligoethyleneglycol-amine%252Blinkers%252Band%252Btheir%252Buse%252Bin%252Bthe%252Bpreparation%252Bof%252BPEG-based%252Bbranched%252Bplatforms%26aulast%3DUrsuegui%26aufirst%3DSylvain%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D44%26spage%3D8579%26epage%3D8584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hadi  Nasiri</span>, <span class="hlFld-ContribAuthor ">Zahra  Valedkarimi</span>, <span class="hlFld-ContribAuthor ">Leili  Aghebati‐Maleki</span>, <span class="hlFld-ContribAuthor ">Jafar  Majidi</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2018,</strong> <em>233 </em>
                                    (9)
                                     , 6441-6457. <a href="https://doi.org/10.1002/jcp.26435" title="DOI URL">https://doi.org/10.1002/jcp.26435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.26435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.26435%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DAntibody%2525E2%252580%252590drug%252Bconjugates%25253A%252BPromising%252Band%252Befficient%252Btools%252Bfor%252Btargeted%252Bcancer%252Btherapy%26aulast%3DNasiri%26aufirst%3DHadi%26date%3D2018%26date%3D2018%26volume%3D233%26issue%3D9%26spage%3D6441%26epage%3D6457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dattatraya H.  Dethe</span>, <span class="hlFld-ContribAuthor ">Aparna  Srivastava</span>, <span class="hlFld-ContribAuthor ">Balu D.  Dherange</span>, <span class="hlFld-ContribAuthor ">B. Vijay  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Unsymmetrical Disulfide Synthesis through Photoredox Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2018,</strong> <em>360 </em>
                                    (16)
                                     , 3020-3025. <a href="https://doi.org/10.1002/adsc.201800405" title="DOI URL">https://doi.org/10.1002/adsc.201800405</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201800405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201800405%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DUnsymmetrical%252BDisulfide%252BSynthesis%252Bthrough%252BPhotoredox%252BCatalysis%26aulast%3DDethe%26aufirst%3DDattatraya%2BH.%26date%3D2018%26date%3D2018%26volume%3D360%26issue%3D16%26spage%3D3020%26epage%3D3025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nirnoy  Dan</span>, <span class="hlFld-ContribAuthor ">Saini  Setua</span>, <span class="hlFld-ContribAuthor ">Vivek  Kashyap</span>, <span class="hlFld-ContribAuthor ">Sheema  Khan</span>, <span class="hlFld-ContribAuthor ">Meena  Jaggi</span>, <span class="hlFld-ContribAuthor ">Murali  Yallapu</span>, <span class="hlFld-ContribAuthor ">Subhash  Chauhan</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2018,</strong> <em>11 </em>
                                    (2)
                                     , 32. <a href="https://doi.org/10.3390/ph11020032" title="DOI URL">https://doi.org/10.3390/ph11020032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph11020032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph11020032%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DAntibody-Drug%252BConjugates%252Bfor%252BCancer%252BTherapy%25253A%252BChemistry%252Bto%252BClinical%252BImplications%26aulast%3DDan%26aufirst%3DNirnoy%26date%3D2018%26date%3D2018%26volume%3D11%26issue%3D2%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>, <span class="hlFld-ContribAuthor ">Angelina V.  Biitseva</span>, <span class="hlFld-ContribAuthor ">Serhii  Zhersh</span>. </span><span class="cited-content_cbyCitation_article-title">Amino sulfonic acids, peptidosulfonamides and other related compounds. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2018,</strong> <em>74 </em>
                                    (13)
                                     , 1355-1421. <a href="https://doi.org/10.1016/j.tet.2018.01.033" title="DOI URL">https://doi.org/10.1016/j.tet.2018.01.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.01.033%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAmino%252Bsulfonic%252Bacids%25252C%252Bpeptidosulfonamides%252Band%252Bother%252Brelated%252Bcompounds%26aulast%3DGrygorenko%26aufirst%3DOleksandr%2BO.%26date%3D2018%26volume%3D74%26issue%3D13%26spage%3D1355%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tayo  Adekiya</span>, <span class="hlFld-ContribAuthor ">Raphael  Aruleba</span>, <span class="hlFld-ContribAuthor ">Sbonelo  Khanyile</span>, <span class="hlFld-ContribAuthor ">Priscilla  Masamba</span>, <span class="hlFld-ContribAuthor ">Babatunji  Oyinloye</span>, <span class="hlFld-ContribAuthor ">Abidemi  Kappo</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development. </span><span class="cited-content_cbyCitation_journal-name">Vaccines</span><span> <strong>2018,</strong> <em>6 </em>
                                    (1)
                                     , 1. <a href="https://doi.org/10.3390/vaccines6010001" title="DOI URL">https://doi.org/10.3390/vaccines6010001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/vaccines6010001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fvaccines6010001%26sid%3Dliteratum%253Aachs%26jtitle%3DVaccines%26atitle%3DStructural%252BAnalysis%252Band%252BEpitope%252BPrediction%252Bof%252BMHC%252BClass-1-Chain%252BRelated%252BProtein-A%252Bfor%252BCancer%252BVaccine%252BDevelopment%26aulast%3DAdekiya%26aufirst%3DTayo%26date%3D2018%26date%3D2017%26volume%3D6%26issue%3D1%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jorge  Verkade</span>, <span class="hlFld-ContribAuthor ">Marloes  Wijdeven</span>, , <span class="hlFld-ContribAuthor ">Brian  Janssen</span>, , . </span><span class="cited-content_cbyCitation_article-title">A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2018,</strong> <em>7 </em>
                                    (1)
                                     , 12. <a href="https://doi.org/10.3390/antib7010012" title="DOI URL">https://doi.org/10.3390/antib7010012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib7010012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib7010012%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DA%252BPolar%252BSulfamide%252BSpacer%252BSignificantly%252BEnhances%252Bthe%252BManufacturability%25252C%252BStability%25252C%252Band%252BTherapeutic%252BIndex%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DVerkade%26aufirst%3DJorge%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D1%26spage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Lambert</span>, <span class="hlFld-ContribAuthor ">Anna  Berkenblit</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Medicine</span><span> <strong>2018,</strong> <em>69 </em>
                                    (1)
                                     , 191-207. <a href="https://doi.org/10.1146/annurev-med-061516-121357" title="DOI URL">https://doi.org/10.1146/annurev-med-061516-121357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-med-061516-121357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-med-061516-121357%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Medicine%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%252Bfor%252BCancer%252BTreatment%26aulast%3DLambert%26aufirst%3DJohn%2BM.%26date%3D2018%26volume%3D69%26issue%3D1%26spage%3D191%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olivier  Marcq</span>. </span><span class="cited-content_cbyCitation_article-title">Outlook on Next Generation Technologies and Strategy Considerations for ADC Process Development and Manufacturing. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 113-161. <a href="https://doi.org/10.1007/978-3-319-78154-9_6" title="DOI URL">https://doi.org/10.1007/978-3-319-78154-9_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-78154-9_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-78154-9_6%26sid%3Dliteratum%253Aachs%26atitle%3DOutlook%252Bon%252BNext%252BGeneration%252BTechnologies%252Band%252BStrategy%252BConsiderations%252Bfor%252BADC%252BProcess%252BDevelopment%252Band%252BManufacturing%26aulast%3DMarcq%26aufirst%3DOlivier%26date%3D2018%26date%3D2018%26spage%3D113%26epage%3D161%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DInnovations%252Bfor%252BNext-Generation%252BAntibody-Drug%252BConjugates%26aulast%3DDamelin%26aufirst%3DMarc%26date%3D2018%26volume%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">Next Generation Payloads for ADCs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 187-214. <a href="https://doi.org/10.1007/978-3-319-78154-9_8" title="DOI URL">https://doi.org/10.1007/978-3-319-78154-9_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-78154-9_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-78154-9_8%26sid%3Dliteratum%253Aachs%26atitle%3DNext%252BGeneration%252BPayloads%252Bfor%252BADCs%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2018%26date%3D2018%26spage%3D187%26epage%3D214%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DInnovations%252Bfor%252BNext-Generation%252BAntibody-Drug%252BConjugates%26aulast%3DDamelin%26aufirst%3DMarc%26date%3D2018%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyoji  Tsuchikama</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  An</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-drug conjugates: recent advances in conjugation and linker chemistries. </span><span class="cited-content_cbyCitation_journal-name">Protein & Cell</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     , 33-46. <a href="https://doi.org/10.1007/s13238-016-0323-0" title="DOI URL">https://doi.org/10.1007/s13238-016-0323-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13238-016-0323-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13238-016-0323-0%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520%2526%2520Cell%26atitle%3DAntibody-drug%252Bconjugates%25253A%252Brecent%252Badvances%252Bin%252Bconjugation%252Band%252Blinker%252Bchemistries%26aulast%3DTsuchikama%26aufirst%3DKyoji%26date%3D2018%26date%3D2016%26volume%3D9%26issue%3D1%26spage%3D33%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Bryden</span>, <span class="hlFld-ContribAuthor ">Camille  Martin</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Letast</span>, <span class="hlFld-ContribAuthor ">Eva  Lles</span>, <span class="hlFld-ContribAuthor ">Inmaculada  Viéitez-Villemin</span>, <span class="hlFld-ContribAuthor ">Anaïs  Rousseau</span>, <span class="hlFld-ContribAuthor ">Cyril  Colas</span>, <span class="hlFld-ContribAuthor ">Marie  Brachet-Botineau</span>, <span class="hlFld-ContribAuthor ">Emilie  Allard-Vannier</span>, <span class="hlFld-ContribAuthor ">Christel  Larbouret</span>, <span class="hlFld-ContribAuthor ">Marie-Claude  Viaud-Massuard</span>, <span class="hlFld-ContribAuthor ">Nicolas  Joubert</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of cathepsin B-sensitive triggers and hydrophilic linkers on
              in vitro
              efficacy of novel site-specific antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (11)
                                     , 1882-1889. <a href="https://doi.org/10.1039/C7OB02780J" title="DOI URL">https://doi.org/10.1039/C7OB02780J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB02780J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB02780J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DImpact%252Bof%252Bcathepsin%252BB-sensitive%252Btriggers%252Band%252Bhydrophilic%252Blinkers%252Bon%252Bin%252Bvitro%252Befficacy%252Bof%252Bnovel%252Bsite-specific%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DBryden%26aufirst%3DFrancesca%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D11%26spage%3D1882%26epage%3D1889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Malik</span>, <span class="hlFld-ContribAuthor ">Colin  Phipps</span>, <span class="hlFld-ContribAuthor ">Andrea  Edginton</span>, <span class="hlFld-ContribAuthor ">Jonathan  Blay</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2017,</strong> <em>34 </em>
                                    (12)
                                     , 2579-2595. <a href="https://doi.org/10.1007/s11095-017-2259-3" title="DOI URL">https://doi.org/10.1007/s11095-017-2259-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-017-2259-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-017-2259-3%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DPharmacokinetic%252BConsiderations%252Bfor%252BAntibody-Drug%252BConjugates%252Bagainst%252BCancer%26aulast%3DMalik%26aufirst%3DPaul%26date%3D2017%26date%3D2017%26volume%3D34%26issue%3D12%26spage%3D2579%26epage%3D2595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Zongtao  Lin</span>, <span class="hlFld-ContribAuthor ">Kinsie  Arnst</span>, <span class="hlFld-ContribAuthor ">Duane  Miller</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (8)
                                     , 1281. <a href="https://doi.org/10.3390/molecules22081281" title="DOI URL">https://doi.org/10.3390/molecules22081281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22081281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22081281%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTubulin%252BInhibitor-Based%252BAntibody-Drug%252BConjugates%252Bfor%252BCancer%252BTherapy%26aulast%3DChen%26aufirst%3DHao%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D8%26spage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Fengping  Li</span>, <span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, <span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, <span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Casavant</span>, <span class="hlFld-ContribAuthor ">Kimberly  Marquette</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Jack  Bikker</span>, <span class="hlFld-ContribAuthor ">Eric M.  Bennett</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Nicole  Piche-Nicholas</span>, <span class="hlFld-ContribAuthor ">Amy  Tam</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, <span class="hlFld-ContribAuthor ">Hans Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Lioudmila  Tchistiakova</span>. </span><span class="cited-content_cbyCitation_article-title">Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2017,</strong> <em>19 </em>
                                    (4)
                                     , 1123-1135. <a href="https://doi.org/10.1208/s12248-017-0083-7" title="DOI URL">https://doi.org/10.1208/s12248-017-0083-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-017-0083-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-017-0083-7%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DSite%252BSelection%25253A%252Ba%252BCase%252BStudy%252Bin%252Bthe%252BIdentification%252Bof%252BOptimal%252BCysteine%252BEngineered%252BAntibody%252BDrug%252BConjugates%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D4%26spage%3D1123%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arianna  Pina</span>, <span class="hlFld-ContribAuthor ">A.  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Michele  Caruso</span>, <span class="hlFld-ContribAuthor ">Laura  Belvisi</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Simone  Zanella</span>, <span class="hlFld-ContribAuthor ">Fabio  Gasparri</span>, <span class="hlFld-ContribAuthor ">Clara  Albanese</span>, <span class="hlFld-ContribAuthor ">Ulisse  Cucchi</span>, <span class="hlFld-ContribAuthor ">Ivan  Fraietta</span>, <span class="hlFld-ContribAuthor ">Aurelio  Marsiglio</span>, <span class="hlFld-ContribAuthor ">Luca  Pignataro</span>, <span class="hlFld-ContribAuthor ">Daniele  Donati</span>, <span class="hlFld-ContribAuthor ">Cesare  Gennari</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Integrin α
              V
              β
              3
              with Theranostic RGD-Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2017,</strong> <em>2 </em>
                                    (17)
                                     , 4759-4766. <a href="https://doi.org/10.1002/slct.201701052" title="DOI URL">https://doi.org/10.1002/slct.201701052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201701052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201701052%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DTargeting%252BIntegrin%252B%2525CE%2525B1%252BV%252B%2525CE%2525B2%252B3%252Bwith%252BTheranostic%252BRGD-Camptothecin%252BConjugates%252BBearing%252Ba%252BDisulfide%252BLinker%25253A%252BBiological%252BEvaluation%252BReveals%252Ba%252BComplex%252BScenario%26aulast%3DPina%26aufirst%3DArianna%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D17%26spage%3D4759%26epage%3D4766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renpeng  Liu</span>, <span class="hlFld-ContribAuthor ">Xuan  Chen</span>, <span class="hlFld-ContribAuthor ">Junia  Dushime</span>, <span class="hlFld-ContribAuthor ">Megan  Bogalhas</span>, <span class="hlFld-ContribAuthor ">Alexandru C.  Lazar</span>, <span class="hlFld-ContribAuthor ">Thomas  Ryll</span>, <span class="hlFld-ContribAuthor ">Lintao  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2017,</strong> <em>9 </em>
                                    (3)
                                     , 490-497. <a href="https://doi.org/10.1080/19420862.2017.1285478" title="DOI URL">https://doi.org/10.1080/19420862.2017.1285478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/19420862.2017.1285478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F19420862.2017.1285478%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DThe%252Bimpact%252Bof%252Btrisulfide%252Bmodification%252Bof%252Bantibodies%252Bon%252Bthe%252Bproperties%252Bof%252Bantibody-drug%252Bconjugates%252Bmanufactured%252Busing%252Bthiol%252Bchemistry%26aulast%3DLiu%26aufirst%3DRenpeng%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D3%26spage%3D490%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Yang</span>, <span class="hlFld-ContribAuthor ">Wen  Wang</span>, <span class="hlFld-ContribAuthor ">Kaidi  Li</span>, <span class="hlFld-ContribAuthor ">Weili  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaochun  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient one-pot construction of unsymmetrical disulfide bonds with TCCA. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (3)
                                     , 218-222. <a href="https://doi.org/10.1016/j.tetlet.2016.12.007" title="DOI URL">https://doi.org/10.1016/j.tetlet.2016.12.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2016.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2016.12.007%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DEfficient%252Bone-pot%252Bconstruction%252Bof%252Bunsymmetrical%252Bdisulfide%252Bbonds%252Bwith%252BTCCA%26aulast%3DYang%26aufirst%3DFeng%26date%3D2017%26volume%3D58%26issue%3D3%26spage%3D218%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Yan  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao-Ling  Lu</span>, <span class="hlFld-ContribAuthor ">Xin  Cao</span>, <span class="hlFld-ContribAuthor ">Bing-Hua  Jiao</span>. </span><span class="cited-content_cbyCitation_article-title">Marine Antibody–Drug Conjugates: Design Strategies and Research Progress. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2017,</strong> <em>15 </em>
                                    (1)
                                     , 18. <a href="https://doi.org/10.3390/md15010018" title="DOI URL">https://doi.org/10.3390/md15010018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md15010018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd15010018%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DMarine%252BAntibody%2525E2%252580%252593Drug%252BConjugates%25253A%252BDesign%252BStrategies%252Band%252BResearch%252BProgress%26aulast%3DWang%26aufirst%3DYu-Jie%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D1%26spage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrick G.  Holder</span>, <span class="hlFld-ContribAuthor ">David  Rabuka</span>. </span><span class="cited-content_cbyCitation_article-title">Technologies for Antibody-Drug Conjugation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 591-640. <a href="https://doi.org/10.1002/9781118940648.ch22" title="DOI URL">https://doi.org/10.1002/9781118940648.ch22</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118940648.ch22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118940648.ch22%26sid%3Dliteratum%253Aachs%26atitle%3DTechnologies%252Bfor%252BAntibody-Drug%252BConjugation%26aulast%3DHolder%26aufirst%3DPatrick%2BG.%26date%3D2016%26date%3D2016%26spage%3D591%26epage%3D640%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DBiosimilars%252Bof%252BMonoclonal%252BAntibodies%26aulast%3DLiu%26aufirst%3DCheng%26date%3D2016%26date%3D2016%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leanna R.  Staben</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Koenig</span>, <span class="hlFld-ContribAuthor ">Sophie M.  Lehar</span>, <span class="hlFld-ContribAuthor ">Richard  Vandlen</span>, <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Josefa  Chuh</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Carl  Ng</span>, <span class="hlFld-ContribAuthor ">Jun  Guo</span>, <span class="hlFld-ContribAuthor ">Yanzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Aimee  Fourie-O'Donohue</span>, <span class="hlFld-ContribAuthor ">MaryAnn  Go</span>, <span class="hlFld-ContribAuthor ">Xin  Linghu</span>, <span class="hlFld-ContribAuthor ">Nathaniel L.  Segraves</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Jinhua  Chen</span>, <span class="hlFld-ContribAuthor ">BinQing  Wei</span>, <span class="hlFld-ContribAuthor ">Gail D. Lewis  Phillips</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Sanjeev  Mariathasan</span>, <span class="hlFld-ContribAuthor ">John A.  Flygare</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Pillow</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (12)
                                     , 1112-1119. <a href="https://doi.org/10.1038/nchem.2635" title="DOI URL">https://doi.org/10.1038/nchem.2635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchem.2635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchem.2635%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemistry%26atitle%3DTargeted%252Bdrug%252Bdelivery%252Bthrough%252Bthe%252Btraceless%252Brelease%252Bof%252Btertiary%252Band%252Bheteroaryl%252Bamines%252Bfrom%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DStaben%26aufirst%3DLeanna%2BR.%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D12%26spage%3D1112%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Filip S.  Ekholm</span>, <span class="hlFld-ContribAuthor ">Henna  Pynnönen</span>, <span class="hlFld-ContribAuthor ">Anja  Vilkman</span>, <span class="hlFld-ContribAuthor ">Virve  Pitkänen</span>, <span class="hlFld-ContribAuthor ">Jari  Helin</span>, <span class="hlFld-ContribAuthor ">Juhani  Saarinen</span>, <span class="hlFld-ContribAuthor ">Tero  Satomaa</span>. </span><span class="cited-content_cbyCitation_article-title">Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (22)
                                     , 2501-2505. <a href="https://doi.org/10.1002/cmdc.201600372" title="DOI URL">https://doi.org/10.1002/cmdc.201600372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201600372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201600372%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DIntroducing%252BGlycolinkers%252Bfor%252Bthe%252BFunctionalization%252Bof%252BCytotoxic%252BDrugs%252Band%252BApplications%252Bin%252BAntibody-Drug%252BConjugation%252BChemistry%26aulast%3DEkholm%26aufirst%3DFilip%2BS.%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D22%26spage%3D2501%26epage%3D2505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">Typical Antibody-Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 1-32. <a href="https://doi.org/10.1002/9781119060727.ch1" title="DOI URL">https://doi.org/10.1002/9781119060727.ch1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119060727.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119060727.ch1%26sid%3Dliteratum%253Aachs%26atitle%3DTypical%252BAntibody-Drug%252BConjugates%26aulast%3DLambert%26aufirst%3DJohn%2BM.%26date%3D2016%26date%3D2016%26spage%3D1%26epage%3D32%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DOlivier%26aufirst%3DKenneth%2BJ.%26date%3D2016%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip L.  Ross</span>, <span class="hlFld-ContribAuthor ">Janet  Wolfe</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-Drug Conjugates: An Overview of the CMC and Characterization Process. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 59-83. <a href="https://doi.org/10.1002/9781119060727.ch3" title="DOI URL">https://doi.org/10.1002/9781119060727.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119060727.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119060727.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DAntibody-Drug%252BConjugates%25253A%252BAn%252BOverview%252Bof%252Bthe%252BCMC%252Band%252BCharacterization%252BProcess%26aulast%3DRoss%26aufirst%3DPhilip%2BL.%26date%3D2016%26date%3D2016%26spage%3D59%26epage%3D83%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DOlivier%26aufirst%3DKenneth%2BJ.%26date%3D2016%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riley  Ennis</span>, <span class="hlFld-ContribAuthor ">Sourav  Sinha</span>. </span><span class="cited-content_cbyCitation_article-title">Linker and Conjugation Technology; and Improvements. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 85-103. <a href="https://doi.org/10.1002/9781119060727.ch4" title="DOI URL">https://doi.org/10.1002/9781119060727.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119060727.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119060727.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DLinker%252Band%252BConjugation%252BTechnology%25253B%252Band%252BImprovements%26aulast%3DEnnis%26aufirst%3DRiley%26date%3D2016%26date%3D2016%26spage%3D85%26epage%3D103%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DOlivier%26aufirst%3DKenneth%2BJ.%26date%3D2016%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao Hong.  Chen</span>, <span class="hlFld-ContribAuthor ">Mate  Tolnay</span>. </span><span class="cited-content_cbyCitation_article-title">QC Assay Development. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 131-149. <a href="https://doi.org/10.1002/9781119060727.ch6" title="DOI URL">https://doi.org/10.1002/9781119060727.ch6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119060727.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119060727.ch6%26sid%3Dliteratum%253Aachs%26atitle%3DQC%252BAssay%252BDevelopment%26aulast%3DChen%26aufirst%3DXiao%2BHong.%26date%3D2016%26date%3D2016%26spage%3D131%26epage%3D149%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DOlivier%26aufirst%3DKenneth%2BJ.%26date%3D2016%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Ponraj  Prabakaran</span>, <span class="hlFld-ContribAuthor ">Weizao  Chen</span>, <span class="hlFld-ContribAuthor ">Zhongyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Yang  Feng</span>, <span class="hlFld-ContribAuthor ">Dimiter  Dimitrov</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody Aggregation: Insights from Sequence and Structure. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2016,</strong> <em>5 </em>
                                    (3)
                                     , 19. <a href="https://doi.org/10.3390/antib5030019" title="DOI URL">https://doi.org/10.3390/antib5030019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib5030019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib5030019%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DAntibody%252BAggregation%25253A%252BInsights%252Bfrom%252BSequence%252Band%252BStructure%26aulast%3DLi%26aufirst%3DWei%26date%3D2016%26date%3D2016%26volume%3D5%26issue%3D3%26spage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael L.  Miller</span>, <span class="hlFld-ContribAuthor ">Nathan E.  Fishkin</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Kathleen R.  Whiteman</span>, <span class="hlFld-ContribAuthor ">Yelena  Kovtun</span>, <span class="hlFld-ContribAuthor ">Emily E.  Reid</span>, <span class="hlFld-ContribAuthor ">Katie E.  Archer</span>, <span class="hlFld-ContribAuthor ">Erin K.  Maloney</span>, <span class="hlFld-ContribAuthor ">Charlene A.  Audette</span>, <span class="hlFld-ContribAuthor ">Michele F.  Mayo</span>, <span class="hlFld-ContribAuthor ">Alan  Wilhelm</span>, <span class="hlFld-ContribAuthor ">Holly A.  Modafferi</span>, <span class="hlFld-ContribAuthor ">Rajeeva  Singh</span>, <span class="hlFld-ContribAuthor ">Jan  Pinkas</span>, <span class="hlFld-ContribAuthor ">Victor  Goldmacher</span>, <span class="hlFld-ContribAuthor ">John M.  Lambert</span>, <span class="hlFld-ContribAuthor ">Ravi V.J.  Chari</span>. </span><span class="cited-content_cbyCitation_article-title">A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2016,</strong> <em>15 </em>
                                    (8)
                                     , 1870-1878. <a href="https://doi.org/10.1158/1535-7163.MCT-16-0184" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-16-0184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-16-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-16-0184%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DA%252BNew%252BClass%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Bwith%252BPotent%252BDNA%252BAlkylating%252BActivity%26aulast%3DMiller%26aufirst%3DMichael%2BL.%26date%3D2016%26date%3D2016%26volume%3D15%26issue%3D8%26spage%3D1870%26epage%3D1878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anish  Thomas</span>, <span class="hlFld-ContribAuthor ">Beverly A  Teicher</span>, <span class="hlFld-ContribAuthor ">Raffit  Hassan</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugates for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Oncology</span><span> <strong>2016,</strong> <em>17 </em>
                                    (6)
                                     , e254-e262. <a href="https://doi.org/10.1016/S1470-2045(16)30030-4" title="DOI URL">https://doi.org/10.1016/S1470-2045(16)30030-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1470-2045(16)30030-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1470-2045%2816%2930030-4%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Oncology%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugates%252Bfor%252Bcancer%252Btherapy%26aulast%3DThomas%26aufirst%3DAnish%26date%3D2016%26volume%3D17%26issue%3D6%26spage%3De254%26epage%3De262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajeeva  Singh</span>, <span class="hlFld-ContribAuthor ">Yulius Y.  Setiady</span>, <span class="hlFld-ContribAuthor ">Jose  Ponte</span>, <span class="hlFld-ContribAuthor ">Yelena V.  Kovtun</span>, <span class="hlFld-ContribAuthor ">Katharine C.  Lai</span>, <span class="hlFld-ContribAuthor ">E. Erica  Hong</span>, <span class="hlFld-ContribAuthor ">Nathan  Fishkin</span>, <span class="hlFld-ContribAuthor ">Ling  Dong</span>, <span class="hlFld-ContribAuthor ">Gregory E.  Jones</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Coccia</span>, <span class="hlFld-ContribAuthor ">Leanne  Lanieri</span>, <span class="hlFld-ContribAuthor ">Karen  Veale</span>, <span class="hlFld-ContribAuthor ">Juliet A.  Costoplus</span>, <span class="hlFld-ContribAuthor ">Anna  Skaletskaya</span>, <span class="hlFld-ContribAuthor ">Rabih  Gabriel</span>, <span class="hlFld-ContribAuthor ">Paulin  Salomon</span>, <span class="hlFld-ContribAuthor ">Rui  Wu</span>, <span class="hlFld-ContribAuthor ">Qifeng  Qiu</span>, <span class="hlFld-ContribAuthor ">Hans K.  Erickson</span>, <span class="hlFld-ContribAuthor ">John M.  Lambert</span>, <span class="hlFld-ContribAuthor ">Ravi V.J.  Chari</span>, <span class="hlFld-ContribAuthor ">Wayne C.  Widdison</span>. </span><span class="cited-content_cbyCitation_article-title">A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2016,</strong> <em>15 </em>
                                    (6)
                                     , 1311-1320. <a href="https://doi.org/10.1158/1535-7163.MCT-16-0021" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-16-0021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-16-0021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-16-0021%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DA%252BNew%252BTriglycyl%252BPeptide%252BLinker%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADCs%252529%252Bwith%252BImproved%252BTargeted%252BKilling%252Bof%252BCancer%252BCells%26aulast%3DSingh%26aufirst%3DRajeeva%26date%3D2016%26date%3D2016%26volume%3D15%26issue%3D6%26spage%3D1311%26epage%3D1320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominik  Schumacher</span>, <span class="hlFld-ContribAuthor ">Christian P. R.  Hackenberger</span>, <span class="hlFld-ContribAuthor ">Heinrich  Leonhardt</span>, <span class="hlFld-ContribAuthor ">Jonas  Helma</span>. </span><span class="cited-content_cbyCitation_article-title">Current Status: Site-Specific Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Immunology</span><span> <strong>2016,</strong> <em>36 </em>
                                    (S1)
                                     , 100-107. <a href="https://doi.org/10.1007/s10875-016-0265-6" title="DOI URL">https://doi.org/10.1007/s10875-016-0265-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10875-016-0265-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10875-016-0265-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Immunology%26atitle%3DCurrent%252BStatus%25253A%252BSite-Specific%252BAntibody%252BDrug%252BConjugates%26aulast%3DSchumacher%26aufirst%3DDominik%26date%3D2016%26date%3D2016%26volume%3D36%26issue%3DS1%26spage%3D100%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad Sajid Hamid  Akash</span>, <span class="hlFld-ContribAuthor ">Kanwal  Rehman</span>, <span class="hlFld-ContribAuthor ">Amna  Parveen</span>, <span class="hlFld-ContribAuthor ">Muhammad  Ibrahim</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-drug conjugates as drug carrier systems for bioactive agents. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Polymeric Materials and Polymeric Biomaterials</span><span> <strong>2016,</strong> <em>65 </em>
                                    (1)
                                     , 1-10. <a href="https://doi.org/10.1080/00914037.2015.1038818" title="DOI URL">https://doi.org/10.1080/00914037.2015.1038818</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00914037.2015.1038818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00914037.2015.1038818%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Polymeric%2520Materials%2520and%2520Polymeric%2520Biomaterials%26atitle%3DAntibody-drug%252Bconjugates%252Bas%252Bdrug%252Bcarrier%252Bsystems%252Bfor%252Bbioactive%252Bagents%26aulast%3DAkash%26aufirst%3DMuhammad%2BSajid%2BHamid%26date%3D2016%26date%3D2015%26volume%3D65%26issue%3D1%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Padma  Akkapeddi</span>, <span class="hlFld-ContribAuthor ">Saara-Anne  Azizi</span>, <span class="hlFld-ContribAuthor ">Allyson M.  Freedy</span>, <span class="hlFld-ContribAuthor ">Pedro M. S. D.  Cal</span>, <span class="hlFld-ContribAuthor ">Pedro M. P.  Gois</span>, <span class="hlFld-ContribAuthor ">Gonçalo J. L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2016,</strong> <em>7 </em>
                                    (5)
                                     , 2954-2963. <a href="https://doi.org/10.1039/C6SC00170J" title="DOI URL">https://doi.org/10.1039/C6SC00170J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6SC00170J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6SC00170J%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DConstruction%252Bof%252Bhomogeneous%252Bantibody%2525E2%252580%252593drug%252Bconjugates%252Busing%252Bsite-selective%252Bprotein%252Bchemistry%26aulast%3DAkkapeddi%26aufirst%3DPadma%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D5%26spage%3D2954%26epage%3D2963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin J.  Hamblett</span>, <span class="hlFld-ContribAuthor ">Allison P.  Jacob</span>, <span class="hlFld-ContribAuthor ">Jesse L.  Gurgel</span>, <span class="hlFld-ContribAuthor ">Mark E.  Tometsko</span>, <span class="hlFld-ContribAuthor ">Brooke M.  Rock</span>, <span class="hlFld-ContribAuthor ">Sonal K.  Patel</span>, <span class="hlFld-ContribAuthor ">Robert R.  Milburn</span>, <span class="hlFld-ContribAuthor ">Sophia  Siu</span>, <span class="hlFld-ContribAuthor ">Seamus P.  Ragan</span>, <span class="hlFld-ContribAuthor ">Dan A.  Rock</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Borths</span>, <span class="hlFld-ContribAuthor ">Jason W.  O'Neill</span>, <span class="hlFld-ContribAuthor ">Wesley S.  Chang</span>, <span class="hlFld-ContribAuthor ">Margaret F.  Weidner</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Bio</span>, <span class="hlFld-ContribAuthor ">Kim C.  Quon</span>, <span class="hlFld-ContribAuthor ">William C.  Fanslow</span>. </span><span class="cited-content_cbyCitation_article-title">SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2015,</strong> <em>75 </em>
                                    (24)
                                     , 5329-5340. <a href="https://doi.org/10.1158/0008-5472.CAN-15-1610" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-15-1610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-15-1610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-15-1610%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DSLC46A3%252BIs%252BRequired%252Bto%252BTransport%252BCatabolites%252Bof%252BNoncleavable%252BAntibody%252BMaytansine%252BConjugates%252Bfrom%252Bthe%252BLysosome%252Bto%252Bthe%252BCytoplasm%26aulast%3DHamblett%26aufirst%3DKevin%2BJ.%26date%3D2015%26date%3D2015%26volume%3D75%26issue%3D24%26spage%3D5329%26epage%3D5340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satish K.  Singh</span>, <span class="hlFld-ContribAuthor ">Donna L.  Luisi</span>, <span class="hlFld-ContribAuthor ">Roger H.  Pak</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2015,</strong> <em>32 </em>
                                    (11)
                                     , 3541-3571. <a href="https://doi.org/10.1007/s11095-015-1704-4" title="DOI URL">https://doi.org/10.1007/s11095-015-1704-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-015-1704-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-015-1704-4%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DAntibody-Drug%252BConjugates%25253A%252BDesign%25252C%252BFormulation%252Band%252BPhysicochemical%252BStability%26aulast%3DSingh%26aufirst%3DSatish%2BK.%26date%3D2015%26date%3D2015%26volume%3D32%26issue%3D11%26spage%3D3541%26epage%3D3571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vesela  Kostova</span>, <span class="hlFld-ContribAuthor ">Estelle  Dransart</span>, <span class="hlFld-ContribAuthor ">Michel  Azoulay</span>, <span class="hlFld-ContribAuthor ">Laura  Brulle</span>, <span class="hlFld-ContribAuthor ">Siau-Kun  Bai</span>, <span class="hlFld-ContribAuthor ">Jean-Claude  Florent</span>, <span class="hlFld-ContribAuthor ">Ludger  Johannes</span>, <span class="hlFld-ContribAuthor ">Frédéric  Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Shiga toxin–drug conjugates prepared via Cu-free click chemistry. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (22)
                                     , 7150-7157. <a href="https://doi.org/10.1016/j.bmc.2015.10.010" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.10.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.10.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BShiga%252Btoxin%2525E2%252580%252593drug%252Bconjugates%252Bprepared%252Bvia%252BCu-free%252Bclick%252Bchemistry%26aulast%3DKostova%26aufirst%3DVesela%26date%3D2015%26volume%3D23%26issue%3D22%26spage%3D7150%26epage%3D7157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eunhee G.  Kim</span>, <span class="hlFld-ContribAuthor ">Kristine M.  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules & Therapeutics</span><span> <strong>2015,</strong> <em>23 </em>
                                    (6)
                                     , 493-509. <a href="https://doi.org/10.4062/biomolther.2015.116" title="DOI URL">https://doi.org/10.4062/biomolther.2015.116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4062/biomolther.2015.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4062%2Fbiomolther.2015.116%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%2520%2526%2520Therapeutics%26atitle%3DStrategies%252Band%252BAdvancement%252Bin%252BAntibody-Drug%252BConjugate%252BOptimization%252Bfor%252BTargeted%252BCancer%252BTherapeutics%26aulast%3DKim%26aufirst%3DEunhee%2BG.%26date%3D2015%26volume%3D23%26issue%3D6%26spage%3D493%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John J  Walsh</span>, <span class="hlFld-ContribAuthor ">Gary D  Stack</span>. </span><span class="cited-content_cbyCitation_article-title">Linker technologies and release mechanisms for antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 40-55. <a href="https://doi.org/10.4155/fseb2013.14.48" title="DOI URL">https://doi.org/10.4155/fseb2013.14.48</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fseb2013.14.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffseb2013.14.48%26sid%3Dliteratum%253Aachs%26atitle%3DLinker%252Btechnologies%252Band%252Brelease%252Bmechanisms%252Bfor%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DWalsh%26aufirst%3DJohn%2BJ%26date%3D2015%26date%3D2015%26spage%3D40%26epage%3D55%26pub%3DFuture%2520Science%2520Ltd%26atitle%3DOptimizing%252BAntibody-Drug%252BConjugates%252Bfor%252BTargeted%252BDelivery%252Bof%252BTherapeutics%26aulast%3DSewald%26aufirst%3DNorbert%26date%3D2015%26date%3D2015%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Fracassetti</span>, <span class="hlFld-ContribAuthor ">A.  Tirelli</span>. </span><span class="cited-content_cbyCitation_article-title">Monitoring of glutathione concentration during winemaking by a reliable high-performance liquid chromatography analytical method. </span><span class="cited-content_cbyCitation_journal-name">Australian Journal of Grape and Wine Research</span><span> <strong>2015,</strong> <em>21 </em>
                                    (3)
                                     , 389-395. <a href="https://doi.org/10.1111/ajgw.12139" title="DOI URL">https://doi.org/10.1111/ajgw.12139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ajgw.12139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fajgw.12139%26sid%3Dliteratum%253Aachs%26jtitle%3DAustralian%2520Journal%2520of%2520Grape%2520and%2520Wine%2520Research%26atitle%3DMonitoring%252Bof%252Bglutathione%252Bconcentration%252Bduring%252Bwinemaking%252Bby%252Ba%252Breliable%252Bhigh-performance%252Bliquid%252Bchromatography%252Banalytical%252Bmethod%26aulast%3DFracassetti%26aufirst%3DD.%26date%3D2015%26date%3D2015%26volume%3D21%26issue%3D3%26spage%3D389%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert P  Lyon</span>, <span class="hlFld-ContribAuthor ">Tim D  Bovee</span>, <span class="hlFld-ContribAuthor ">Svetlana O  Doronina</span>, <span class="hlFld-ContribAuthor ">Patrick J  Burke</span>, <span class="hlFld-ContribAuthor ">Joshua H  Hunter</span>, <span class="hlFld-ContribAuthor ">Haley D  Neff-LaFord</span>, <span class="hlFld-ContribAuthor ">Mechthild  Jonas</span>, <span class="hlFld-ContribAuthor ">Martha E  Anderson</span>, <span class="hlFld-ContribAuthor ">Jocelyn R  Setter</span>, <span class="hlFld-ContribAuthor ">Peter D  Senter</span>. </span><span class="cited-content_cbyCitation_article-title">Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. </span><span class="cited-content_cbyCitation_journal-name">Nature Biotechnology</span><span> <strong>2015,</strong> <em>33 </em>
                                    (7)
                                     , 733-735. <a href="https://doi.org/10.1038/nbt.3212" title="DOI URL">https://doi.org/10.1038/nbt.3212</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nbt.3212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnbt.3212%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Biotechnology%26atitle%3DReducing%252Bhydrophobicity%252Bof%252Bhomogeneous%252Bantibody-drug%252Bconjugates%252Bimproves%252Bpharmacokinetics%252Band%252Btherapeutic%252Bindex%26aulast%3DLyon%26aufirst%3DRobert%2BP%26date%3D2015%26date%3D2015%26volume%3D33%26issue%3D7%26spage%3D733%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olga  Ab</span>, <span class="hlFld-ContribAuthor ">Kathleen R.  Whiteman</span>, <span class="hlFld-ContribAuthor ">Laura M.  Bartle</span>, <span class="hlFld-ContribAuthor ">Xiuxia  Sun</span>, <span class="hlFld-ContribAuthor ">Rajeeva  Singh</span>, <span class="hlFld-ContribAuthor ">Daniel  Tavares</span>, <span class="hlFld-ContribAuthor ">Alyssa  LaBelle</span>, <span class="hlFld-ContribAuthor ">Gillian  Payne</span>, <span class="hlFld-ContribAuthor ">Robert J.  Lutz</span>, <span class="hlFld-ContribAuthor ">Jan  Pinkas</span>, <span class="hlFld-ContribAuthor ">Victor S.  Goldmacher</span>, <span class="hlFld-ContribAuthor ">Thomas  Chittenden</span>, <span class="hlFld-ContribAuthor ">John M.  Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2015,</strong> <em>14 </em>
                                    (7)
                                     , 1605-1613. <a href="https://doi.org/10.1158/1535-7163.MCT-14-1095" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-14-1095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-14-1095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-14-1095%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DIMGN853%25252C%252Ba%252BFolate%252BReceptor-%2525CE%2525B1%252B%252528FR%2525CE%2525B1%252529%2525E2%252580%252593Targeting%252BAntibody%2525E2%252580%252593Drug%252BConjugate%25252C%252BExhibits%252BPotent%252BTargeted%252BAntitumor%252BActivity%252Bagainst%252BFR%2525CE%2525B1-Expressing%252BTumors%26aulast%3DAb%26aufirst%3DOlga%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D7%26spage%3D1605%26epage%3D1613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo
              biotransformations of antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2015,</strong> <em>7 </em>
                                    (13)
                                     , 1649-1664. <a href="https://doi.org/10.4155/bio.15.84" title="DOI URL">https://doi.org/10.4155/bio.15.84</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio.15.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio.15.84%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DIn%252Bvivo%252Bbiotransformations%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DTumey%26aufirst%3DL%2BNathan%26date%3D2015%26volume%3D7%26issue%3D13%26spage%3D1649%26epage%3D1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cornélie  Batisse</span>, <span class="hlFld-ContribAuthor ">Estelle  Dransart</span>, <span class="hlFld-ContribAuthor ">Rafik  Ait Sarkouh</span>, <span class="hlFld-ContribAuthor ">Laura  Brulle</span>, <span class="hlFld-ContribAuthor ">Siau-Kun  Bai</span>, <span class="hlFld-ContribAuthor ">Sylvie  Godefroy</span>, <span class="hlFld-ContribAuthor ">Ludger  Johannes</span>, <span class="hlFld-ContribAuthor ">Frédéric  Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">A new delivery system for auristatin in STxB-drug conjugate therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>95 </em>, 483-491. <a href="https://doi.org/10.1016/j.ejmech.2015.03.047" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.047%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnew%252Bdelivery%252Bsystem%252Bfor%252Bauristatin%252Bin%252BSTxB-drug%252Bconjugate%252Btherapy%26aulast%3DBatisse%26aufirst%3DCorn%25C3%25A9lie%26date%3D2015%26volume%3D95%26spage%3D483%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francisco J.  Esteva</span>, <span class="hlFld-ContribAuthor ">Kathy D.  Miller</span>, <span class="hlFld-ContribAuthor ">Beverly A.  Teicher</span>. </span><span class="cited-content_cbyCitation_article-title">What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. </span><span class="cited-content_cbyCitation_journal-name">American Society of Clinical Oncology Educational Book</span><span> <strong>2015,</strong> <em> </em>
                                    (35)
                                     , e117-e125. <a href="https://doi.org/10.14694/EdBook_AM.2015.35.e117" title="DOI URL">https://doi.org/10.14694/EdBook_AM.2015.35.e117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14694/EdBook_AM.2015.35.e117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14694%2FEdBook_AM.2015.35.e117%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%2520Educational%2520Book%26atitle%3DWhat%252BCan%252BWe%252BLearn%252Babout%252BAntibody-Drug%252BConjugates%252Bfrom%252Bthe%252BT-DM1%252BExperience%25253F%26aulast%3DEsteva%26aufirst%3DFrancisco%2BJ.%26date%3D2015%26issue%3D35%26spage%3De117%26epage%3De125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica R.  McCombs</span>, <span class="hlFld-ContribAuthor ">Shawn C.  Owen</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2015,</strong> <em>17 </em>
                                    (2)
                                     , 339-351. <a href="https://doi.org/10.1208/s12248-014-9710-8" title="DOI URL">https://doi.org/10.1208/s12248-014-9710-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-014-9710-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-014-9710-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DAntibody%252BDrug%252BConjugates%25253A%252BDesign%252Band%252BSelection%252Bof%252BLinker%25252C%252BPayload%252Band%252BConjugation%252BChemistry%26aulast%3DMcCombs%26aufirst%3DJessica%2BR.%26date%3D2015%26date%3D2015%26volume%3D17%26issue%3D2%26spage%3D339%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. Erica  Hong</span>, <span class="hlFld-ContribAuthor ">Ravi  Chari</span>. </span><span class="cited-content_cbyCitation_article-title">Linker Design for Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 49-76. <a href="https://doi.org/10.1007/978-3-319-13081-1_4" title="DOI URL">https://doi.org/10.1007/978-3-319-13081-1_4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-13081-1_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-13081-1_4%26sid%3Dliteratum%253Aachs%26atitle%3DLinker%252BDesign%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DHong%26aufirst%3DE.%2BErica%26date%3D2015%26date%3D2015%26spage%3D49%26epage%3D76%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DWang%26aufirst%3DJeffrey%26date%3D2015%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm2002958&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm2002958%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-10%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=134&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Structures of Some Antibody–Cytotoxic Drug Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>The linkers used for each drug are indicated in parentheses, and the labile bonds are in circles.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Original Strategy for Synthesis of the Sulfonate Hydrophilic Linker Starting from Lipoic Acid<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) [O]; (b) NHS/EDC; (c) mAb; (d) drug–SH.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Disulfide-Linked Antibody–Cytotoxic Agent Conjugates via a Sulfonate Soluble Linker<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) HSAc, DIPEA, THF, −20 °C, 96%; (b) H<sub>2</sub>O<sub>2</sub>/HOAc, 90%; (c) HSAc, DIPEA, DMA, 90%; (d) NaOH; (e) (SPyR)<sub>2</sub>, pH 7.5; (f) NHS, EDC, DMA, 82%; (g) antibody; (h) maytansinoid–SH.</p></p></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of AMC Bearing a PEGylated Disulfide Linker, 15-(2-Pyridyldithio)-4,7,10,13-tetraoxapentadecanoic Acid <i>N</i>-Hydroxysuccinimide Ester <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) (SPy)<sub>2</sub>, DME, 64%; (b) NHS, EDC, DCM, 38%; (c) antibody; (d) maytansinoid–SH.</p></p></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of a Noncleavable Charged Linker and AMC<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) NaN<sub>3</sub>, DMA, 90%; (b) 1 M HCl, HAc, 100 °C, 95%; (c) H<sub>2</sub>/Pd/C, H<sub>2</sub>O, 95%; (d) maleic anhydride, DMA, 83%; (e) HMDS, ZnCl, DMA, Tol; (f) CH<sub>3</sub>OH, HCl (cat.), 85%; (g) NHS, EDC, DMA, 80%; (h) antibody; (i) maytansinoid–SH.</p></p></figure><figure data-id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Mechanism of the Formation of Five-Membered Ring of Maleimic Compound <b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Succinimidyl 4-<i>N</i>-Maleimido-3-sulfobutyrate <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) NaN<sub>3</sub>, DMF, 0 °C, 80%; (b) HSAc, Et<sub>3</sub>N, THF, 81%; (c)H<sub>2</sub>O<sub>2</sub>, HAc, 93%; (d) HCl, HAc, 110 °C, 85%; (e) Pd/C/H<sub>2</sub>, 90%; (f) maleic anhydride, DMA, 83%; (g) HMDS, ZnCl, DMA, Tol; (h) CH<sub>3</sub>OH, HCl (cat.), 75%; (i) NHS, EDC, DMA, 75%.</p></p></figure><figure data-id="sch8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of (<i>Z</i>)-4-(3-Carboxy-2-sulfopropylamino)-4-oxobut-2-enoic Acid <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) HSAc, DIPEA, THF, 0 °C, 65%; (b) H<sub>2</sub>O<sub>2</sub>, HAc, 93%; (c) Raney Ni, H<sub>2</sub>, BOC<sub>2</sub>O, DMA, 85%; (d) LiOH, 90%; (e) 20% HCl, dioxane; (f) maleic anhydride, DMA, 83%.</p></p></figure><figure data-id="sch9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0014.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Maytansinoid–Linkers for One-Step Antibody Conjugation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) drug–SH (DM4), pH 4.0–6.5; (b) mAb, pH 6.5–8.0; (c) <b>18</b>, DME, 4-methylmorpholine; (d) NHS/EDC, 54%; (e) DM1 or DM4, pH 4.0–6.5.</p></p></figure><figure data-id="fig1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0015.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Binding of huC242-DMx conjugates analysis by flow cytometry on COLO 205 cells at 10 000 cells/well in 3 h at 0 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0001.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Activity of reducible (left) and nonreducible (right) anti-EpCAM-DMx conjugates prepared with hydrophilic linkers from the hydrophilic linker series with similar ∼3.5 ratio of DMx/mAb.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0002.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vitro cytotoxicity of the huC242-DM1 conjugates (3.3–7.3 DAR) toward (a) COLO205 and (b) COLO205-MDR cells upon dilution with 50-fold excess unconjugated huC242 antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/medium/jm-2011-002958_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0003.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo efficacy of anti-EpCAM-DMx conjugates (∼3.5 DMx/Ab) against multidrug resistant COLO205-MDR tumors in SCID mice (single iv injection, 170 μg/kg DMx based dose (10 mg/kg mAb dose)).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-10/jm2002958/production/images/large/jm-2011-002958_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2002958&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Verstappen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimans, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoekman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postma, T. J.</span><span> </span><span class="NLM_article-title">Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1549</span><span class="NLM_x">–</span> <span class="NLM_lpage">1563</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1549-1563&author=C.+C.+Verstappenauthor=J.+J.+Heimansauthor=K.+Hoekmanauthor=T.+J.+Postma&title=Neurotoxic+complications+of+chemotherapy+in+patients+with+cancer%3A+clinical+signs+and+optimal+management"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstappen%26aufirst%3DC.%2BC.%26aulast%3DHeimans%26aufirst%3DJ.%2BJ.%26aulast%3DHoekman%26aufirst%3DK.%26aulast%3DPostma%26aufirst%3DT.%2BJ.%26atitle%3DNeurotoxic%2520complications%2520of%2520chemotherapy%2520in%2520patients%2520with%2520cancer%253A%2520clinical%2520signs%2520and%2520optimal%2520management%26jtitle%3DDrugs%26date%3D2003%26volume%3D63%26spage%3D1549%26epage%3D1563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Kohler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milstein, C.</span><span> </span><span class="NLM_article-title">Continuous cultures of fused cells secreting antibody of predefined specificity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">497</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2F256495a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=1172191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1975&pages=495-497&author=G.+Kohlerauthor=C.+Milstein&title=Continuous+cultures+of+fused+cells+secreting+antibody+of+predefined+specificity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous cultures of fused cells secreting antibody of predefined specificity</span></div><div class="casAuthors">Kohler G; Milstein C</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5517</span>),
    <span class="NLM_cas:pages">495-7</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLHx9X4gieguxsqfvU0ziafW6udTcc2eZMDGTfUCuQN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D&md5=b5003f0bd9ce2870718bc392c40b89eb</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F256495a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F256495a0%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DG.%26aulast%3DMilstein%26aufirst%3DC.%26atitle%3DContinuous%2520cultures%2520of%2520fused%2520cells%2520secreting%2520antibody%2520of%2520predefined%2520specificity%26jtitle%3DNature%26date%3D1975%26volume%3D256%26spage%3D495%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etessami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span> </span><span class="NLM_article-title">Principal therapeutic uses of monoclonal antibodies in oncology</span> <span class="citation_source-journal">Cancer Radiother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">24s</span><span class="NLM_x">–</span> <span class="NLM_lpage">28s</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=24s-28s&issue=Suppl.+1&author=F.+Penault-Llorcaauthor=A.+Etessamiauthor=J.+Bourhis&title=Principal+therapeutic+uses+of+monoclonal+antibodies+in+oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DEtessami%26aufirst%3DA.%26aulast%3DBourhis%26aufirst%3DJ.%26atitle%3DPrincipal%2520therapeutic%2520uses%2520of%2520monoclonal%2520antibodies%2520in%2520oncology%26jtitle%3DCancer%2520Radiother.%26date%3D2002%26volume%3D6%26issue%3DSuppl.%25201%26spage%3D24s%26epage%3D28s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0lhS0YyWegiabA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span> </span><span class="NLM_article-title">Realizing the full potential of immunotoxins</span> <span class="citation_source-journal">Cancer Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=2701364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1989&pages=50-55&author=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=V.+S.+Goldmacher&title=Realizing+the+full+potential+of+immunotoxins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Realizing the full potential of immunotoxins</span></div><div class="casAuthors">Blattler, Walter A.; Lambert, John M.; Goldmacher, Victor S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cells (1989)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">50-5</span>CODEN:
                <span class="NLM_cas:coden">CCELER</span>;
        ISSN:<span class="NLM_cas:issn">1042-2196</span>.
    </div><div class="casAbstract">A review with 51 refs. discussing some of the insights that have come from detailed analyses of the so-called first-generation immunotoxins, and how these insights have prompted ideas for more effective design of second-generation immunotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0w_MAoEvYArVg90H21EOLACvtfcHk0lhS0YyWegiabA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWis7w%253D&md5=b751d65874356ab81be011049a79aa8c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26atitle%3DRealizing%2520the%2520full%2520potential%2520of%2520immunotoxins%26jtitle%3DCancer%2520Cells%26date%3D1989%26volume%3D1%26spage%3D50%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Targeted cancer therapy: conferring specificity to cytotoxic drugs</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700108g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=98-107&author=R.+V.+Chari&title=Targeted+cancer+therapy%3A+conferring+specificity+to+cytotoxic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs</span></div><div class="casAuthors">Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Most anticancer drugs in clin. use today display poor tumor specificity, resulting in high systemic toxicity.  Monoclonal antibodies that recognize specific markers on the surface of tumor cells offer an alternative therapy that is tumor-specific and, thus, less toxic.  Although highly selective, very few monoclonal antibodies are therapeutically useful because they only display modest cell-killing activity.  The tumor selectivity of monoclonal antibodies can be exploited for the targeted delivery of highly cytotoxic drugs that are otherwise too toxic to be used on their own.  This Account provides a brief history of the development of antibody-drug conjugates, followed by a review of recent advances, wherein highly cytotoxic drugs have been linked to tumor-reactive antibodies.  Linkers have been designed such that these monoclonal antibody-drug conjugates are stable in circulation and are virtually nontoxic until they bind to the tumor cell through the antibody component.  Upon binding to the tumor cell and internalization, lysosomal processing releases the potent cytotoxic agents inside the cell.  These conjugates display high target-specific cytotoxicity in vitro and antitumor activity that is superior to that of the antibodies alone or the std. anticancer drugs in human tumor xenograft models.  Several conjugates from this new class of tumor-targeted anticancer agents are currently undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHel9bmmcerVg90H21EOLACvtfcHk0lhS0YyWegiabA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt12isLo%253D&md5=83bb7694ba47151534d9fd5c626edfc2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Far700108g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700108g%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520conferring%2520specificity%2520to%2520cytotoxic%2520drugs%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D98%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2FS0169-409X%2897%2900095-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=10837619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlOjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=89-104&author=R.+V.+Chari&title=Targeted+delivery+of+chemotherapeutics%3A+tumor-activated+prodrug+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy</span></div><div class="casAuthors">Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">89-104</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with 66 refs.  The potential of targeted delivery of chemotherapeutic drugs for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic concns. to the target site.  While in vivo studies in animal tumor models have produced very encouraging results, clin. studies with antibody-drug conjugates have been less successful.  This paper will review the current status of the targeted delivery approach and analyze some of the reasons for the lack of success so far.  Starting with a historical perspective, this review will end with a description of newer, more potent and specific antibody-drug conjugates, which behave like tumor-activated prodrugs that may yet fulfil the promise of the targeted delivery approach for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Bgt9D72i97Vg90H21EOLACvtfcHk0ljbOe8YMtBHNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlOjsrg%253D&md5=c401d630c51432f2f1933644c0b84e51</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2897%2900095-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252897%252900095-1%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DTargeted%2520delivery%2520of%2520chemotherapeutics%253A%2520tumor-activated%2520prodrug%2520therapy%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1998%26volume%3D31%26spage%3D89%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Potent antibody drug conjugates for cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2Fj.cbpa.2009.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=19414278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=235-244&author=P.+D.+Senter&title=Potent+antibody+drug+conjugates+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in the past few years in the area of antibody drug conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors.  Early work in this field incorporated clin. approved drugs and mouse monoclonal antibodies (mAbs), which had modest activities, and were generally immunogenic.  The results of these studies prompted investigation that led to the identity of several key parameters that influenced activity and tolerability.  These included the antigen target, the use of non-immunogenic mAb carriers, the incorporation of highly potent drugs and novel conditionally stable linker technologies, and the specific methods used to attach drugs to mAbs.  As a result of these investigations, new agents with pronounced clin. activities have been developed.  These include SGN-35, an ADC directed against the CD30-pos. malignancies such as Hodgkin's disease and anaplastic large cell lymphoma, and trastuzumab-DM1 which has shown activity in metastatic breast carcinoma.  This review details many of the technol. advancements, and provides examples of promising ADCs that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomJSUUPIrcbVg90H21EOLACvtfcHk0ljbOe8YMtBHNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D&md5=3cf72b412351bae075fab1159c49d8c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DPotent%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanagh, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Semisynthetic maytansine analogues for the targeted treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Blattlerauthor=R.+V.+Chari&title=Semisynthetic+maytansine+analogues+for+the+targeted+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0ljbOe8YMtBHNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DSemisynthetic%2520maytansine%2520analogues%2520for%2520the%2520targeted%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Lambert, J. M.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates: a new strategy for the treatment of cancer</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1358%2Fdof.2010.035.06.1497487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFChur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=471-480&author=J.+M.+Lambert&title=Antibody%E2%80%93maytansinoid+conjugates%3A+a+new+strategy+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer</span></div><div class="casAuthors">Lambert, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">471-480</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Early clin. development in the field of targeted delivery of cytotoxic drugs to tumors using antibodies failed to achieve effective, well-tolerated anticancer products.  In recent years, several new highly potent cell-killing agents, such as thiol derivs. of the potent antimitotic microtubule agent maytansine, developed by ImmunoCen, are being utilized to make a new generation of antibody-drug conjugates (ADCs).  Several antibody-maytansinoid conjugates (AMCs) have shown encouraging efficacy in clin. trials, including trastuzumab-DM1 (T-DM1), which targets HER2+ breast cancer, SAR-3419, which targets CD19 expressed on B-cell malignancies, and IMGN-901, which targets CD56 expressed on both solid tumors (small cell lung cancer and other neuroendocrine tumor types) and hematol. tumors, including multiple myeloma.  Besides their demonstrated efficacy in phase I and/or phase II clin. studies, these AMCs are well tolerated, with no clin. significant myelosuppression, suggesting that AMC compds. are well suited for evaluation in combination treatment regimens.  Maytansinoids are payloads for antibody-mediated delivery that are realizing the promise of ADCs for improved targeted therapy in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwoNcf49xdQrVg90H21EOLACvtfcHk0ljQKIMsNk7swQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFChur3N&md5=b878b5e78355f1e057e25eea9f00c94d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.06.1497487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.06.1497487%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%253A%2520a%2520new%2520strategy%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DDrugs%2520Future%26date%3D2010%26volume%3D35%26spage%3D471%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Damle, N. K.</span><span> </span><span class="NLM_article-title">Tumour-targeted chemotherapy with immunoconjugates of calicheamicin</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">–</span> <span class="NLM_lpage">1452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1517%2F14712598.4.9.1445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=15335312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFOmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1445-1452&author=N.+K.+Damle&title=Tumour-targeted+chemotherapy+with+immunoconjugates+of+calicheamicin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-targeted chemotherapy with immunoconjugates of calicheamicin</span></div><div class="casAuthors">Damle, Nitin K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1445-1452</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Antibody-targeted chemotherapy is a therapeutic strategy in cancer therapy that involves a monoclonal antibody specific for a tumor-assocd. antigen, covalently linked via a suitable linker to a potent cytotoxic agent.  Tumor-targeted delivery of a cytotoxic agent in the form of an immunoconjugate is expected to improve its antitumor activity and safety.  Calicheamicin is a cytotoxic natural product isolated from Micromonospora echinospora that is at least 1000-fold more potent than conventional cytotoxic chemotherapeutics.  Calicheamicin binds DNA in the minor groove and causes double-strand DNA breaks, leading to cell death.  Immunoconjugates of calicheamicin targeted against tumor-assocd. antigens exhibit tumor-specific cytotoxic effects and cause regression of established human tumor xenografts in nude mice.  Gemtuzumab ozogamicin is the first clin. validated cytotoxic immunoconjugate in which a humanized anti-CD33 antibody is linked to a deriv. of calicheamicin.  Gemtuzumab ozogamicin is indicated for the treatment of elderly patients with relapsed acute myeloid leukemia.  A similar conjugate, inotuzumab ozogamicin, is being evaluated at present in Phase I clin. trials in patients with non-Hodgkin's lymphoma.  A no. of tumor-targeted immunoconjugates of calicheamicin are being explored preclinically at present for their therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz7ki0LzNT5LVg90H21EOLACvtfcHk0ljQKIMsNk7swQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFOmtro%253D&md5=33bd35d83fa6b220a2f41b1db67efdc8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F14712598.4.9.1445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.4.9.1445%26sid%3Dliteratum%253Aachs%26aulast%3DDamle%26aufirst%3DN.%2BK.%26atitle%3DTumour-targeted%2520chemotherapy%2520with%2520immunoconjugates%2520of%2520calicheamicin%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2004%26volume%3D4%26spage%3D1445%26epage%3D1452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Hamann, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinman, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shochat, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mountain, A.</span><span> </span><span class="NLM_article-title">A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049794n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=354-360&author=P.+R.+Hamannauthor=L.+M.+Hinmanauthor=C.+F.+Beyerauthor=D.+Lindhauthor=J.+Upeslacisauthor=D.+Shochatauthor=A.+Mountain&title=A+calicheamicin+conjugate+with+a+fully+humanized+anti-MUC1+antibody+shows+potent+antitumor+effects+in+breast+and+ovarian+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A Calicheamicin Conjugate with a Fully Humanized Anti-MUC1 Antibody Shows Potent Antitumor Effects in Breast and Ovarian Tumor Xenografts</span></div><div class="casAuthors">Hamann, Philip R.; Hinman, Lois M.; Beyer, Carl F.; Lindh, Delores; Upeslacis, Janis; Shochat, Dan; Mountain, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-360</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Murine CTM01 is an internalizing murine IgG1 monoclonal antibody that recognizes the MUC1 antigen expressed on many solid tumors of epithelial origin.  Calicheamicin conjugates of this antibody have previously been shown to be potent, selective antitumor agents in preclin. models.  A conjugate has now been made with a genetically engineered human version of this antibody, hCTM01.  The hCTM01 is an IgG4 isotype, has an immunoaffinity approx. 30% higher than mCTM01 by competitive RIA, and is efficiently internalized into target cells.  The hCTM01-NAc-gamma calicheamicin DM amide conjugate, referred to as CMB-401, shows targeted killing of MUC1-expressing cells in vitro and produces pronounced dose-related antitumor effects over an 8-fold dose range against a MUC1-expressing, ovarian xenograft tumor, OvCar-3.  The specificity of CMB-401 was confirmed by comparing its antitumor effects with those of an isotype-matched nonspecific conjugate against the MX-1 breast carcinoma.  CMB-401, given either i.p. or iv, was highly active in these models in single and multiple dose regimens and gave complete regressions at the highest doses examd. with good overall therapeutic ratios.  CMB-401 also gave good antitumor effects at similar doses with a cisplatin-resistant MUC1-expressing cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpohk2Pfsj8-rVg90H21EOLACvtfcHk0ljQKIMsNk7swQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7Y%253D&md5=24504bade5fee83d49b9a7431c37c1ac</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fbc049794n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049794n%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DBeyer%26aufirst%3DC.%2BF.%26aulast%3DLindh%26aufirst%3DD.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DShochat%26aufirst%3DD.%26aulast%3DMountain%26aufirst%3DA.%26atitle%3DA%2520calicheamicin%2520conjugate%2520with%2520a%2520fully%2520humanized%2520anti-MUC1%2520antibody%2520shows%2520potent%2520antitumor%2520effects%2520in%2520breast%2520and%2520ovarian%2520tumor%2520xenografts%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D354%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Zhao, R. Y.; Sun, D.; Cavanagh, E.; Miller, M.; Leece, B.; Erickson, H.; Singh, R.; Kovtun, Y.; Goldmacher, V.; Chari, R.</span><span> </span><span class="NLM_article-title">Design and Synthesis of PEG-Containing CC-1065 Analogs for Targeted Therapy of Cancer</span>. Presented at the 233rd National Meeting of the American Chemical Society, Chicago, IL, U.S.,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>No. 38, Medicinal Chemistry Section.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+Y.+Zhao&author=D.+Sun&author=E.+Cavanagh&author=M.+Miller&author=B.+Leece&author=H.+Erickson&author=R.+Singh&author=Y.+Kovtun&author=V.+Goldmacher&author=R.+Chari&title=Design+and+Synthesis+of+PEG-Containing+CC-1065+Analogs+for+Targeted+Therapy+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%2BY.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520PEG-Containing%2520CC-1065%2520Analogs%2520for%2520Targeted%2520Therapy%2520of%2520Cancer%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourret, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derr, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadayoni, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattocks, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span> </span><span class="NLM_article-title">Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4079</span><span class="NLM_x">–</span> <span class="NLM_lpage">4084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=7545085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK2MXotV2mtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=4079-4084&author=R.+V.+Chariauthor=K.+A.+Jackelauthor=L.+A.+Bourretauthor=S.+M.+Derrauthor=B.+M.+Tadayoniauthor=K.+M.+Mattocksauthor=S.+A.+Shahauthor=C.+Liuauthor=W.+A.+Blattlerauthor=V.+S.+Goldmacher&title=Enhancement+of+the+selectivity+and+antitumor+efficacy+of+a+CC-1065+analogue+through+immunoconjugate+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of the selectivity and antitumor efficacy of a CC-1065 analog through immunoconjugate formation</span></div><div class="casAuthors">Chari, Ravi V. J.; Jackel, Kristine A.; Bourret, Lizabeth A.; Derr, Susan M.; Tadayoni, B. Mitra; Mattocks, Kristin M.; Shah, Sudhir A.; Liu, Changnian; Blattler, Walter A.; Goldmacher, Victor S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4079-84</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Bis-indolyl-(seco)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one compds. are synthetic analogs of CC-1065 that are highly cytotoxic toward a broad spectrum of tumor cell lines.  One of these compds., called DC1 (I), was conjugated to antibodies via novel cleavable disulfide linkers.  Conjugates of DC1 with murine mAbs anti-B4 and N901 directed against tumor-assocd. antigens CD19 and CD56, resp., proved to be extremely potent and antigen selective in killing target cells in culture.  DC1 conjugates with humanized versions of anti-B4 and N901 antibodies were also constructed and demonstrated to be as cytotoxic and selective as the resp. murine antibody conjugates.  The anti-B4-DC1 conjugate showed antitumor efficacy in an aggressive metastatic human B-cell lymphoma survival model in SCID mice and completely cured animals bearing large tumors.  Anti-B4-DC1 was considerably more effective in this tumor model than doxorubicin, cyclophosphamide, etoposide, or vincristine at their max. tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfKcvk5pnoe7Vg90H21EOLACvtfcHk0lhmssuhj9G6Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotV2mtrY%253D&md5=0ce1107615cef0d96494217ef4281864</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DJackel%26aufirst%3DK.%2BA.%26aulast%3DBourret%26aufirst%3DL.%2BA.%26aulast%3DDerr%26aufirst%3DS.%2BM.%26aulast%3DTadayoni%26aufirst%3DB.%2BM.%26aulast%3DMattocks%26aufirst%3DK.%2BM.%26aulast%3DShah%26aufirst%3DS.%2BA.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26atitle%3DEnhancement%2520of%2520the%2520selectivity%2520and%2520antitumor%2520efficacy%2520of%2520a%2520CC-1065%2520analogue%2520through%2520immunoconjugate%2520formation%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D4079%26epage%3D4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugates: targeted drug delivery for cancer</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2Fj.cbpa.2010.06.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=20643572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=529-537&author=S.+C.+Alleyauthor=N.+M.+Okeleyauthor=P.+D.+Senter&title=Antibody%E2%80%93drug+conjugates%3A+targeted+drug+delivery+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: Targeted drug delivery for cancer</span></div><div class="casAuthors">Alley, Stephen C.; Okeley, Nicole M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technol., and the stoichiometry and placement of conjugated drugs.  The underlying reason for this was obtained in pre-clin. biodistribution and pharmacokinetics studies showing that targeted delivery leads to high intratumoral free drug concns., while non-target tissues are largely spared from chemotherapeutic exposure.  Recent developments in the field have led to an increase in the no. of ADCs being tested clin., with 3 in late stage clin. trials: Brentuximab vedotin (also referred to as SGN-35) for Hodgkin lymphoma; Trastuzumab-DM1 for breast cancer; and Inotuzumab ozogamicin for non-Hodgkin lymphoma.  This review highlights the recent pre-clin. and clin. advances that have been made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-9ugy8pi8C7Vg90H21EOLACvtfcHk0lhmssuhj9G6Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D&md5=ace266066ea07d49d0e0b4338b48eeb3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.170%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%253A%2520targeted%2520drug%2520delivery%2520for%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D529%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oflazoglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc0502917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=114-124&author=S.+O.+Doroninaauthor=B.+A.+Mendelsohnauthor=T.+D.+Boveeauthor=C.+G.+Cervenyauthor=S.+C.+Alleyauthor=D.+L.+Meyerauthor=E.+Oflazogluauthor=B.+E.+Tokiauthor=R.+J.+Sandersonauthor=R.+F.+Zabinskiauthor=A.+F.+Wahlauthor=P.+D.+Senter&title=Enhanced+activity+of+monomethylauristatin+F+through+monoclonal+antibody+delivery%3A+effects+of+linker+technology+on+efficacy+and+toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity</span></div><div class="casAuthors">Doronina, Svetlana O.; Mendelsohn, Brian A.; Bovee, Tim D.; Cerveny, Charles G.; Alley, Stephen C.; Meyer, Damon L.; Oflazoglu, Ezogelin; Toki, Brian E.; Sanderson, Russell J.; Zabinski, Roger F.; Wahl, Alan F.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against antigen pos. tumor models.  MMAF is a new antimitotic auristatin deriv. with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE, most likely due to impaired intracellular access.  In vitro cytotoxicity studies indicated that mAb-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-MMAF (mAb-L1-MMAF) conjugates were >2200-fold more potent than free MMAF on a large panel of CD30 pos. hematol. cell lines.  As with cAC10-L1-MMAE, the corresponding MMAF ADC induced cures and regressions of established xenograft tumors at well tolerated doses.  To further optimize the ADC, several new linkers were generated in which various components within the L1 linker were either altered or deleted.  One of the most promising linkers contained a noncleavable maleimidocaproyl (L4) spacer between the drug and the mAb.  CAC10-L4-MMAF was approx. as potent in vitro as cAC10-L1-MMAF against a large panel of cell lines and was equally potent in vivo.  Importantly, cAC10-L4-MMAF was tolerated at >3 times the MTD of cAC10-L1-MMAF.  LCMS studies indicated that drug released from cAC10-L4-MMAF was the cysteine-L4-MMAF adduct, which likely arises from mAb degrdn. within the lysosomes of target cells.  This new linker technol. appears to be ideally suited for drugs that are both relatively cell-impermeable and tolerant of substitution with amino acids.  Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwQJyn8sp0LVg90H21EOLACvtfcHk0lhmssuhj9G6Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL&md5=92da0266f0a83c7680006ef94956c879</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fbc0502917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0502917%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DOflazoglu%26aufirst%3DE.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DEnhanced%2520activity%2520of%2520monomethylauristatin%2520F%2520through%2520monoclonal%2520antibody%2520delivery%253A%2520effects%2520of%2520linker%2520technology%2520on%2520efficacy%2520and%2520toxicity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D114%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hamann, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinman, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menendez, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durr, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span> </span><span class="NLM_article-title">An anti-MUC1 antibody–calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">353</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049795f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=346-353&author=P.+R.+Hamannauthor=L.+M.+Hinmanauthor=C.+F.+Beyerauthor=L.+M.+Greenbergerauthor=C.+Linauthor=D.+Lindhauthor=A.+T.+Menendezauthor=R.+Wallaceauthor=F.+E.+Durrauthor=J.+Upeslacis&title=An+anti-MUC1+antibody%E2%80%93calicheamicin+conjugate+for+treatment+of+solid+tumors.+Choice+of+linker+and+overcoming+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An Anti-MUC1 Antibody-Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance</span></div><div class="casAuthors">Hamann, Philip R.; Hinman, Lois M.; Beyer, Carl F.; Greenberger, Lee M.; Lin, Clara; Lindh, Delores; Menendez, Ana T.; Wallace, Rosalyn; Durr, Frederick E.; Upeslacis, Janis</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">346-353</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anti-MUC1 antibody, CTM01, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to solid tumors of epithelial origin that express this antigen.  Earlier calicheamicin conjugates relied on the attachment of a hydrazide deriv. to the oxidized carbohydrates that occur naturally on antibodies.  This produced a "carbohydrate conjugate" capable of releasing active drug by hydrolysis in the lysosomes where the pH is low.  Conjugates have now been made that are formed by reacting a calicheamicin deriv. contg. an activated ester with the lysines of antibodies.  This gives an "amide conjugate" that is stable to hydrolysis, leaving the disulfide that is present in all calicheamicin conjugates as the only likely site of drug release from the conjugate.  As previously shown for the carbohydrate conjugate, this amide conjugate of CTM01 produces complete regressions of xenograft tumors at doses of 300 μg/kg (calicheamicin equiv.) given three times.  This indicates that hydrolytic drug release is not necessary for potent, selective cytotoxicity for calicheamicin conjugates of CTM01.  Although the unconjugated calicheamicins are in general less active in cells expressing the multidrug resistance phenotype, both in vitro and in vivo results of studies reported here suggest that the efficacy of the calicheamicins toward such tumors is unexpectedly enhanced by antibody conjugation, esp. for the "amide conjugate".  These hydrolytically stable conjugates are also active toward cisplatin-resistant ovarian carcinoma cells as well.  Such studies indicate that the calicheamicin amide conjugate of CTM01 may have potential for the treatment of MUC1-pos. solid tumors, including some types of resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWx1KbzV6eYLVg90H21EOLACvtfcHk0lhvtP1i02jaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCju7c%253D&md5=2a8c7e5d7d8fe237dac2de3090b06765</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc049795f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049795f%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DBeyer%26aufirst%3DC.%2BF.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLindh%26aufirst%3DD.%26aulast%3DMenendez%26aufirst%3DA.%2BT.%26aulast%3DWallace%26aufirst%3DR.%26aulast%3DDurr%26aufirst%3DF.%2BE.%26aulast%3DUpeslacis%26aufirst%3DJ.%26atitle%3DAn%2520anti-MUC1%2520antibody%25E2%2580%2593calicheamicin%2520conjugate%2520for%2520treatment%2520of%2520solid%2520tumors.%2520Choice%2520of%2520linker%2520and%2520overcoming%2520drug%2520resistance%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D346%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">King, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubowchik, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestone, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4336</span><span class="NLM_x">–</span> <span class="NLM_lpage">4343</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020149g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4336-4343&author=H.+D.+Kingauthor=G.+M.+Dubowchikauthor=H.+Mastalerzauthor=D.+Willnerauthor=S.+J.+Hofsteadauthor=R.+A.+Firestoneauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Monoclonal+antibody+conjugates+of+doxorubicin+prepared+with+branched+peptide+linkers%3A+inhibition+of+aggregation+by+methoxytriethyleneglycol+chains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibody conjugates of doxorubicin Prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains</span></div><div class="casAuthors">King, H. Dalton; Dubowchik, Gene M.; Mastalerz, Harold; Willner, David; Hofstead, Sandra J.; Firestone, Raymond A.; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4336-4343</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High mole ratio BR96 immunoconjugates were synthesized using branched peptide-doxorubicin linkers designed to liberate doxorubicin following antigen-specific internalization into lysosomes. However, these immunoconjugates are highly prone to noncovalent, dimeric aggregation.  We hypothesize that this is due to (1) the hydrophobic nature of the peptides, (2) the loss of pos. charge upon amide formation at the 3'-amino group of doxorubicin, and (3) the proximity of the peptide hydrophobic residues to form efficient intermol. stacking interactions.  By introducing a hydrophilic methoxytriethylene glycol chain onto the doxorubicin portion of the branched peptide linkers, aggregation has been eliminated or greatly reduced in the immunoconjugate products.  The methoxytriethylene glycol chain was linked to the doxorubicin moiety of the linker via a hydrazone bond that is stable at pH 7 but hydrolyzes rapidly at pH 5 to release free drug. BR96 immunoconjugates synthesized from methoxytriethylene glycol-modified branched peptide-doxorubicin linkers are highly potent and immunospecific in vitro.  The data suggest that the methoxytriethylene glycol chain hydrolyzes as designed upon antigen-specific internalization into tumor lysosomes in vitro, where enzymic degrdn. of the peptide linker releases free doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr70hWG3Du_3rVg90H21EOLACvtfcHk0lhvtP1i02jaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVCntbs%253D&md5=2769f58125d9dcb895529a30aaa6debb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm020149g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020149g%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DH.%2BD.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DMonoclonal%2520antibody%2520conjugates%2520of%2520doxorubicin%2520prepared%2520with%2520branched%2520peptide%2520linkers%253A%2520inhibition%2520of%2520aggregation%2520by%2520methoxytriethyleneglycol%2520chains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4336%26epage%3D4343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Contribution of linker stability to the activities of anticancer immunoconjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc7004329" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=759-765&author=S.+C.+Alleyauthor=D.+R.+Benjaminauthor=S.+C.+Jeffreyauthor=N.+M.+Okeleyauthor=D.+L.+Meyerauthor=R.+J.+Sandersonauthor=P.+D.+Senter&title=Contribution+of+linker+stability+to+the+activities+of+anticancer+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates</span></div><div class="casAuthors">Alley, Stephen C.; Benjamin, Dennis R.; Jeffrey, Scott C.; Okeley, Nicole M.; Meyer, Damon L.; Sanderson, Russell J.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">759-765</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are highly active at well tolerated doses.  For maximal intratumoral drug delivery, linkers are required that are highly stable in the systemic circulation, yet allow for efficient drug release at the target site.  In this respect, amide bond-based technologies constitute a technol. advancement, since the linker half-lives in circulation (t1/2 ∼ 7 days) are much longer than earlier generation linkers that break down within 1-2 days.  The amide linkers, some of which contain peptides, are appended to the mAb carriers through thioether/maleimide adducts.  Here, we describe that use of a bromoacetamidecaproyl (bac) in place of the maleimidocaproyl (mc) increases the plasma stability of resulting thioether ADCs.  One such ADC, 1F6-C4v2-bac-MMAF, which is directed against the CD70 antigen on lymphomas and renal cell carcinoma, was prepd. contg. a bac thioether spacer between the drug (MMAF) and the mAb carrier (1F6-C4v2).  There was no measurable systemic drug release from this ADC for 2 wk postadministration in mice.  In order to assess the impact of improving linker stability beyond mc contg. ADCs, a series of mc and bac-linked 1F6-MMAF conjugates were compared for tolerability, intratumoral drug delivery, and therapeutic efficacy in nude mice with renal cell carcinoma xenografts.  There were no statistically significant efficacy differences between sets of mc and bac contg. ADCs, although the bac linker technol. led to 25% higher intratumoral drug exposure over a 7 day period compared to the corresponding mc linker.  The mechanism of drug release from maleimide-adducts likely involves a retro-Michael reaction that takes place in plasma, based on in vitro studies demonstrating that some of the released drug-maleimide deriv. became covalently bound to cysteine-34 of serum albumin.  In summary, the data indicate that new linkers can be obtained with improved in vivo stability by replacing the maleimide with an acetamide, but the resulting ADCs had similar tolerability and activity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAEuKHrhYzvrVg90H21EOLACvtfcHk0lhvtP1i02jaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislemurk%253D&md5=62abdec871dda99c160a9b989c12f6f0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbc7004329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc7004329%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DContribution%2520of%2520linker%2520stability%2520to%2520the%2520activities%2520of%2520anticancer%2520immunoconjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D759%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Blättler, W. A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">B., S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">New heterobifunctional protein cross-linking reagent that forms an acid labile link</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1524</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00327a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1985&pages=1517-1524&author=W.+A.+K.+Bl%C3%A4ttlerauthor=S.+B.author=J.+M.+Lambertauthor=P.+D.+Senter&title=New+heterobifunctional+protein+cross-linking+reagent+that+forms+an+acid+labile+link"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbi00327a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00327a034%26sid%3Dliteratum%253Aachs%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%2BK.%26aulast%3DB.%26aufirst%3DS.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DNew%2520heterobifunctional%2520protein%2520cross-linking%2520reagent%2520that%2520forms%2520an%2520acid%2520labile%2520link%26jtitle%3DBiochemistry%26date%3D1985%26volume%3D24%26spage%3D1517%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody%E2%80%93cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody%25E2%2580%2593cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, P. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">4426</span><span class="NLM_x">–</span> <span class="NLM_lpage">4433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4426-4433&author=H.+K.+Ericksonauthor=P.+U.+Parkauthor=W.+C.+Widdisonauthor=Y.+V.+Kovtunauthor=L.+M.+Garrettauthor=K.+Hoffmanauthor=R.+J.+Lutzauthor=V.+S.+Goldmacherauthor=W.+A.+Blattler&title=Antibody%E2%80%93maytansinoid+conjugates+are+activated+in+targeted+cancer+cells+by+lysosomal+degradation+and+linker-dependent+intracellular+processing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DGarrett%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%2520are%2520activated%2520in%2520targeted%2520cancer%2520cells%2520by%2520lysosomal%2520degradation%2520and%2520linker-dependent%2520intracellular%2520processing%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4426%26epage%3D4433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, P. R.</span><span> </span><span class="NLM_article-title">Selection of reaction additives used in the preparation of monomeric antibody–calicheamicin conjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc700321z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yrur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=358-361&author=I.+Hollanderauthor=A.+Kunzauthor=P.+R.+Hamann&title=Selection+of+reaction+additives+used+in+the+preparation+of+monomeric+antibody%E2%80%93calicheamicin+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selection of Reaction Additives Used in the Preparation of Monomeric Antibody-Calicheamicin Conjugates</span></div><div class="casAuthors">Hollander, Irwin; Kunz, Arthur; Hamann, Philip. R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">358-361</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The formation of protein aggregates can be a major problem during the prepn. of antibody-drug conjugates.  Herein is described the methods by which reaction additives were selected, which reduce the tendency of antibodies to aggregate during the attachment of the cytotoxic agent calicheamicin to form an immunoconjugate.  Reaction conditions were delineated that produced optimized yields of monomeric conjugates.  These conditions were used in the preclin. prepns. of gemtuzumab ozogamicin (Mylotarg), the first com. available chemotherapeutic immunoconjugate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg3Cw6oqJgr7Vg90H21EOLACvtfcHk0li4JgrbavhHmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yrur3M&md5=0811ce169312ba1da792bb8d1c3655e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc700321z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc700321z%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DKunz%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26atitle%3DSelection%2520of%2520reaction%2520additives%2520used%2520in%2520the%2520preparation%2520of%2520monomeric%2520antibody%25E2%2580%2593calicheamicin%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D358%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manikumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of antibody–drug conjugates comprised of potent camptothecin analogues</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1242</span><span class="NLM_x">–</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc9001097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlKjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=1242-1250&author=P.+J.+Burkeauthor=P.+D.+Senterauthor=D.+W.+Meyerauthor=J.+B.+Miyamotoauthor=M.+Andersonauthor=B.+E.+Tokiauthor=G.+Manikumarauthor=M.+C.+Waniauthor=D.+J.+Krollauthor=S.+C.+Jeffrey&title=Design%2C+synthesis%2C+and+biological+evaluation+of+antibody%E2%80%93drug+conjugates+comprised+of+potent+camptothecin+analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues</span></div><div class="casAuthors">Burke, Patrick J.; Senter, Peter D.; Meyer, David W.; Miyamoto, Jamie B.; Anderson, Martha; Toki, Brian E.; Manikumar, Govindarajan; Wani, Mansukh C.; Kroll, David J.; Jeffrey, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1242-1250</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) were prepd. with potent camptothecin analogs attached to monoclonal antibodies (mAbs) via dipeptide or glucuronide-based linkers.  Aniline-contg. camptothecin analogs were employed to provide a site of linker attachment via carbamate bonds that would be stable in circulation.  The camptothecin analogs, 7-butyl-10-amino-camptothecin and 7-butyl-9-amino-10,11-methylenedioxy-camptothecin, are generally 10-1000 times more potent than camptothecin.  Dipeptide and glucuronide drug linkers were employed contg. self-immolative spacers that release drug following lysosomal degrdn. upon ADC internalization into antigen-pos. cell lines.  The camptothecin drug linkers were conjugated to three antibodies: chimeric BR96, chimeric AC10, and humanized 1F6, which bind to the Lewis-Y antigen on carcinomas, CD30 on hematol. malignancies, and CD70 present on hematol. malignancies and renal cell carcinoma, resp.  ADCs bearing the potent camptothecin analog, 7-butyl-9-amino-10,11-methylenedioxy-camptothecin, were highly potent and immunol. specific on a panel of cancer cell lines in vitro, and efficacious at well-tolerated doses in a renal cell carcinoma xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN96RaueGbDrVg90H21EOLACvtfcHk0li4JgrbavhHmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlKjtro%253D&md5=c9eb87cd5a7e0e947c75f4d9a18a7503</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fbc9001097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9001097%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DManikumar%26aufirst%3DG.%26aulast%3DWani%26aufirst%3DM.%2BC.%26aulast%3DKroll%26aufirst%3DD.%2BJ.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%2520comprised%2520of%2520potent%2520camptothecin%2520analogues%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26spage%3D1242%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">King, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurgaitis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestone, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellstrom, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc980100i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK1MXht1Kisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=279-288&author=H.+D.+Kingauthor=D.+Yurgaitisauthor=D.+Willnerauthor=R.+A.+Firestoneauthor=M.+B.+Yangauthor=S.+J.+Laschauthor=K.+E.+Hellstromauthor=P.+A.+Trail&title=Monoclonal+antibody+conjugates+of+doxorubicin+prepared+with+branched+linkers%3A+a+novel+method+for+increasing+the+potency+of+doxorubicin+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates</span></div><div class="casAuthors">King, H. Dalton; Yurgaitis, Derek; Willner, David; Firestone, Raymond A.; Yang, Michael B.; Lasch, Shirley J.; Hellstroem, Karl Erik; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-288</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Immunoconjugates of monoclonal antibody BR96 and Doxorubicin have been prepd. using a novel series of branched hydrazone linkers.  Since each linker bound to the mAb carries two DOX mols., the DOX/mAb molar ratios of these conjugates were approx. 16, twice that of those previously prepd. with single-chain hydrazone linkers.  The conjugates were stable at a physiol. pH of 7, but released DOX rapidly at lysosomal pH 5.  The branched series of BR96 conjugates demonstrated antigen-specific cytotoxicity, and were more potent in vitro than the single-chain conjugate on both a DOX (4-14-fold) and mAb (7-23-fold) basis.  The results suggest that, by using the branched linker methodol., it is possible to significantly reduce the amt. of mAb required to achieve antigen-specific cytotoxic activity.  In this paper, the synthesis and in vitro biol. of branched chain immunoconjugates are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSIvOo_ta5LVg90H21EOLACvtfcHk0lhrFYwR4OCx3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1Kisb8%253D&md5=3816d461f60a77f179300b0da40a2ca2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbc980100i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc980100i%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DH.%2BD.%26aulast%3DYurgaitis%26aufirst%3DD.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DM.%2BB.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DHellstrom%26aufirst%3DK.%2BE.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DMonoclonal%2520antibody%2520conjugates%2520of%2520doxorubicin%2520prepared%2520with%2520branched%2520linkers%253A%2520a%2520novel%2520method%2520for%2520increasing%2520the%2520potency%2520of%2520doxorubicin%2520immunoconjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D1999%26volume%3D10%26spage%3D279%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Hamblett, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chace, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenox, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissler, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopcha, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francisco, J. A.</span><span> </span><span class="NLM_article-title">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">7063</span><span class="NLM_x">–</span> <span class="NLM_lpage">7070</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1158%2F1078-0432.CCR-04-0789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=15501986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7063-7070&author=K.+J.+Hamblettauthor=P.+D.+Senterauthor=D.+F.+Chaceauthor=M.+M.+Sunauthor=J.+Lenoxauthor=C.+G.+Cervenyauthor=K.+M.+Kisslerauthor=S.+X.+Bernhardtauthor=A.+K.+Kopchaauthor=R.+F.+Zabinskiauthor=D.+L.+Meyerauthor=J.+A.+Francisco&title=Effects+of+drug+loading+on+the+antitumor+activity+of+a+monoclonal+antibody+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span></div><div class="casAuthors">Hamblett, Kevin J.; Senter, Peter D.; Chace, Dana F.; Sun, Michael M. C.; Lenox, Joel; Cerveny, Charles G.; Kissler, Kim M.; Bernhardt, Starr X.; Kopcha, Anastasia K.; Zabinski, Roger F.; Meyer, Damon L.; Francisco, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7063-7070</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE) conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties per mAb, was previously shown to have potent cytotoxic activity against CD30+ malignant cells.  To det. the effect of drug loading on antibody-drug conjugate therapeutic potential, we assessed cAC10 antibody-drug conjugates contg. different drug-mAb ratios in vitro and in vivo.  Coupling MMAE to the cysteines that comprise the interchain disulfides of cAC10 created an antibody-drug conjugate population, which was purified using hydrophobic interaction chromatog. to yield antibody-drug conjugates with two, four, and eight drugs per antibody (E2, E4, and E8, resp.).  Antibody-drug conjugate potency was tested in vitro against CD30+ lines followed by in vivo xenograft models.  The max.-tolerated dose and pharmacokinetic profiles of the antibody-drug conjugates were investigated in mice.  Although antibody-drug conjugate potency in vitro was directly dependent on drug loading (IC50 values E8<E4<E2), the in vivo antitumor activity of E4 was comparable with E8 at equal mAb doses, although the E4 contained half the amt. of MMAE per mAb.  E2 was also an active antitumor agent but required higher doses.  The max.-tolerated dose of E2 in mice was at least double that of E4, which in turn was twice that of E8.  MMAE loading affected plasma clearance, as E8 cleared 3-fold faster than E4 and 5-fold faster than E2.  By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCAEfk7W0KNbVg90H21EOLACvtfcHk0lhrFYwR4OCx3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D&md5=2d2dd7a498d1181a57dcd3ab8b931e65</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0789%26sid%3Dliteratum%253Aachs%26aulast%3DHamblett%26aufirst%3DK.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DSun%26aufirst%3DM.%2BM.%26aulast%3DLenox%26aufirst%3DJ.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKopcha%26aufirst%3DA.%2BK.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520drug%2520loading%2520on%2520the%2520antitumor%2520activity%2520of%2520a%2520monoclonal%2520antibody%2520drug%2520conjugate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7063%26epage%3D7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Takeshita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinjo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamakage, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigeno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, R.</span><span> </span><span class="NLM_article-title">CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1111%2Fj.1365-2141.2009.07701.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=19388933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlWgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2009&pages=34-43&author=A.+Takeshitaauthor=K.+Shinjoauthor=N.+Yamakageauthor=T.+Onoauthor=I.+Hiranoauthor=H.+Matsuiauthor=K.+Shigenoauthor=S.+Nakamuraauthor=T.+Tobitaauthor=M.+Maekawaauthor=K.+Ohnishiauthor=Y.+Sugimotoauthor=H.+Kiyoiauthor=T.+Naoeauthor=R.+Ohno&title=CMC-544+%28inotuzumab+ozogamicin%29+shows+less+effect+on+multidrug+resistant+cells%3A+analyses+in+cell+lines+and+cells+from+patients+with+B-cell+chronic+lymphocytic+leukaemia+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma</span></div><div class="casAuthors">Takeshita, Akihiro; Shinjo, Kaori; Yamakage, Nozomi; Ono, Takaaki; Hirano, Isao; Matsui, Hirotaka; Shigeno, Kazuyuki; Nakamura, Satoki; Tobita, Tadasu; Maekawa, Masato; Ohnishi, Kazunori; Sugimoto, Yoshikazu; Kiyoi, Hitoshi; Naoe, Tomoki; Ohno, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analyzed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro.  The cell lines used were CD22-pos. parental Daudi and Raji, and their P-gp pos. sublines, Daudi/MDR and Raji/MDR.  Cells obtained from 19 patients with B-cell CLL or NHL were also used.  The effect of CMC-544 was analyzed by viable cell count, morphol., annexin-V staining, and cell cycle distribution.  A dose-dependent, selective cytotoxic effect of CMC-544 was obsd. in cell lines that expressed CD22.  CMC-544 was not effective on Daudi/MDR and Raji/MDR cells compared with their parental cells.  The MDR modifiers, PSC833 and MS209, restored the cytotoxic effect of CMC-544 in P-gp-expressing sublines.  In clin. samples, the cytotoxic effect of CMC-544 was inversely related to the amt. of P-gp (p = 0.003), and to intracellular rhodamine-123 accumulation (P < 0.001).  On the other hand, the effect pos. correlated with the amt. of CD22 (P = 0.010).  The effect of CMC-544 depends on the levels of CD22 and P-gp.  Our findings will help to predict the clin. effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNU682oM1owbVg90H21EOLACvtfcHk0lhrFYwR4OCx3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlWgsb0%253D&md5=a3e0b7e363b730afb39b9e6d2f57ccb7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2009.07701.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2009.07701.x%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DShinjo%26aufirst%3DK.%26aulast%3DYamakage%26aufirst%3DN.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DHirano%26aufirst%3DI.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DShigeno%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DTobita%26aufirst%3DT.%26aulast%3DMaekawa%26aufirst%3DM.%26aulast%3DOhnishi%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DOhno%26aufirst%3DR.%26atitle%3DCMC-544%2520%2528inotuzumab%2520ozogamicin%2529%2520shows%2520less%2520effect%2520on%2520multidrug%2520resistant%2520cells%253A%2520analyses%2520in%2520cell%2520lines%2520and%2520cells%2520from%2520patients%2520with%2520B-cell%2520chronic%2520lymphocytic%2520leukaemia%2520and%2520lymphoma%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2009%26volume%3D146%26spage%3D34%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Szakacs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth-Genthe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Targeting multidrug resistance in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2Fnrd1984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=16518375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=219-234&author=G.+Szakacsauthor=J.+K.+Patersonauthor=J.+A.+Ludwigauthor=C.+Booth-Gentheauthor=M.+M.+Gottesman&title=Targeting+multidrug+resistance+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting multidrug resistance in cancer</span></div><div class="casAuthors">Szakacs, Gergely; Paterson, Jill K.; Ludwig, Joseph A.; Booth-Genthe, Catherine; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy.  In most cases, multiple drugs are used, as resistance to single agents occurs almost universally.  For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chem. structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years.  Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters.  We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7LUp3JikHr7Vg90H21EOLACvtfcHk0lhq4bWVG6-4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D&md5=67ca376f65aa58a71288167f6815a896</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrd1984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1984%26sid%3Dliteratum%253Aachs%26aulast%3DSzakacs%26aufirst%3DG.%26aulast%3DPaterson%26aufirst%3DJ.%2BK.%26aulast%3DLudwig%26aufirst%3DJ.%2BA.%26aulast%3DBooth-Genthe%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520multidrug%2520resistance%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D219%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Mechanisms of cancer drug resistance</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1146%2Fannurev.med.53.082901.103929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=11818492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2002&pages=615-627&author=M.+M.+Gottesman&title=Mechanisms+of+cancer+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cancer drug resistance</span></div><div class="casAuthors">Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">615-627</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer.  Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin.  Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.  The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance.  Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquuMAtOcoDfbVg90H21EOLACvtfcHk0lhq4bWVG6-4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D&md5=8f442a5c749266ad76ad7c7406a4e611</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.53.082901.103929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.53.082901.103929%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DMechanisms%2520of%2520cancer%2520drug%2520resistance%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2002%26volume%3D53%26spage%3D615%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handley, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Is resistance useless? Multidrug resistance and collateral sensitivity</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2Fj.tips.2009.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=19762091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=546-556&author=M.+D.+Hallauthor=M.+D.+Handleyauthor=M.+M.+Gottesman&title=Is+resistance+useless%3F+Multidrug+resistance+and+collateral+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Is resistance useless? Multidrug resistance and collateral sensitivity</span></div><div class="casAuthors">Hall, Matthew D.; Handley, Misty D.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">546-556</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  When cancer cells develop resistance to chemotherapeutics, it is frequently conferred by the ATP-dependent efflux pump P-glycoprotein (MDR1, P-gp, ABCB1).  P-gp can efflux a wide range of cancer drugs; its expression confers cross-resistance, termed "multidrug resistance" (MDR), to a wide range of drugs.  Strategies to overcome this resistance have been actively sought for more than 30 years, yet clin. solns. do not exist.  A less understood aspect of MDR is the hypersensitivity of resistant cancer cells to other drugs, a phenomenon known as "collateral sensitivity" (CS).  This review highlights the extent of this effect for the first time, and discusses hypotheses (e.g. generation of reactive oxygen species) to account for the underlying generality of this phenomenon, and proposes exploitation of CS as a strategy to improve response to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqXXX0g-kpErVg90H21EOLACvtfcHk0lhq4bWVG6-4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3J&md5=eec04be9cc6fd699383bbd1e72ea7aa6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DHandley%26aufirst%3DM.%2BD.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DIs%2520resistance%2520useless%253F%2520Multidrug%2520resistance%2520and%2520collateral%2520sensitivity%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D546%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Saito, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, S.</span><span> </span><span class="NLM_article-title">Studies on the oxidation products of lipoic acid</span> <span class="citation_source-journal">J. Vitaminol. (Kyoto)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.5925%2Fjnsv1954.13.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=4861288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaF2sXkslWgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1967&pages=115-121&author=I.+Saitoauthor=S.+Fukui&title=Studies+on+the+oxidation+products+of+lipoic+acid"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the oxidation products of lipoic acid</span></div><div class="casAuthors">Saito, Isao; Fukui, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Vitaminology</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-21</span>CODEN:
                <span class="NLM_cas:coden">JVITA5</span>;
        ISSN:<span class="NLM_cas:issn">0022-5398</span>.
    </div><div class="casAbstract">Oxidn. of α-lipoic acid (I) in CHCl3 soln. by tert.-butyl hydroperoxide (5 molar ratio) for 1 day at 40° gave a product with an Rf of 0.90 on paper with 2.8% aq. ammonia-satd. n-butanol as the developing agent.  It had an inhibitory effect upon Streptococcus faecalis 10 C 1; and by ir spectrum and chem. analyses, appeared to be the tert-butyl ester of lipoic acid sulfone.  Oxidn. of I with H2O2 (2 molar ratio) in aq. Me2CO for 1 day at room temp. produced β-lipoic acid and a lipoic acid-active product which according to ir and uv spectra, appeared to be an isomer of β-lipoic acid with the sulfoxide group in a different position.  Oxidn. of I with H2O2 (10 molar ratio) in HOAc for 2 days at 40° resulted in a white ppt., m.p. 108-110°, which by ir spectrum and elementary analysis, appeared to be lipoic acid disulfone.  It was inactive for S. faecalis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCi8PptV-7mbVg90H21EOLACvtfcHk0lhq4bWVG6-4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXkslWgsr8%253D&md5=9704592478f8005d2374f5ed708ce6eb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.5925%2Fjnsv1954.13.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5925%252Fjnsv1954.13.115%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DI.%26aulast%3DFukui%26aufirst%3DS.%26atitle%3DStudies%2520on%2520the%2520oxidation%2520products%2520of%2520lipoic%2520acid%26jtitle%3DJ.%2520Vitaminol.%2520%2528Kyoto%2529%26date%3D1967%26volume%3D13%26spage%3D115%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kluger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. C.</span><span> </span><span class="NLM_article-title">Carboxylic acid participation in amide hydrolysis. Competition between acid-catalyzed dehydration and anhydride formation</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5921</span><span class="NLM_x">–</span> <span class="NLM_lpage">5925</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00197a062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1989&pages=5921-5925&author=R.+Klugerauthor=J.+C.+Hunt&title=Carboxylic+acid+participation+in+amide+hydrolysis.+Competition+between+acid-catalyzed+dehydration+and+anhydride+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fja00197a062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00197a062%26sid%3Dliteratum%253Aachs%26aulast%3DKluger%26aufirst%3DR.%26aulast%3DHunt%26aufirst%3DJ.%2BC.%26atitle%3DCarboxylic%2520acid%2520participation%2520in%2520amide%2520hydrolysis.%2520Competition%2520between%2520acid-catalyzed%2520dehydration%2520and%2520anhydride%2520formation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1989%26volume%3D111%26spage%3D5921%26epage%3D5925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Garner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandhee, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngs, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, V. O.</span><span> </span><span class="NLM_article-title">Development of an asymmetric approach to the 3,8-diazabicyclo[3.2.1]octane moiety of quinocarcin via intramolecular 1,3-dipolar cycloadditions of photochemically generated azomethine ylides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5893</span><span class="NLM_x">–</span> <span class="NLM_lpage">5903</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00020a035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1991&pages=5893-5903&author=P.+Garnerauthor=W.+B.+Hoauthor=S.+K.+Grandheeauthor=W.+J.+Youngsauthor=V.+O.+Kennedy&title=Development+of+an+asymmetric+approach+to+the+3%2C8-diazabicyclo%5B3.2.1%5Doctane+moiety+of+quinocarcin+via+intramolecular+1%2C3-dipolar+cycloadditions+of+photochemically+generated+azomethine+ylides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo00020a035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00020a035%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DP.%26aulast%3DHo%26aufirst%3DW.%2BB.%26aulast%3DGrandhee%26aufirst%3DS.%2BK.%26aulast%3DYoungs%26aufirst%3DW.%2BJ.%26aulast%3DKennedy%26aufirst%3DV.%2BO.%26atitle%3DDevelopment%2520of%2520an%2520asymmetric%2520approach%2520to%2520the%25203%252C8-diazabicyclo%255B3.2.1%255Doctane%2520moiety%2520of%2520quinocarcin%2520via%2520intramolecular%25201%252C3-dipolar%2520cycloadditions%2520of%2520photochemically%2520generated%2520azomethine%2520ylides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1991%26volume%3D56%26spage%3D5893%26epage%3D5903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Haval, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mhaske, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argade, N. P.</span><span> </span><span class="NLM_article-title">Cyanuric chloride: decent dehydrating agent for an exclusive and efficient synthesis of kinetically controlled isomaleimides</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">942</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=937-942&author=K.+P.+Havalauthor=S.+B.+Mhaskeauthor=N.+P.+Argade&title=Cyanuric+chloride%3A+decent+dehydrating+agent+for+an+exclusive+and+efficient+synthesis+of+kinetically+controlled+isomaleimides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaval%26aufirst%3DK.%2BP.%26aulast%3DMhaske%26aufirst%3DS.%2BB.%26aulast%3DArgade%26aufirst%3DN.%2BP.%26atitle%3DCyanuric%2520chloride%253A%2520decent%2520dehydrating%2520agent%2520for%2520an%2520exclusive%2520and%2520efficient%2520synthesis%2520of%2520kinetically%2520controlled%2520isomaleimides%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26spage%3D937%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lazar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amphlett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span> </span><span class="NLM_article-title">Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1806</span><span class="NLM_x">–</span> <span class="NLM_lpage">1814</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1002%2Frcm.1987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=15945030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVegt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1806-1814&author=A.+C.+Lazarauthor=L.+Wangauthor=W.+A.+Blattlerauthor=G.+Amphlettauthor=J.+M.+Lambertauthor=W.+Zhang&title=Analysis+of+the+composition+of+immunoconjugates+using+size-exclusion+chromatography+coupled+to+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry</span></div><div class="casAuthors">Lazar, Alexandru C.; Wang, Lintao; Blaettler, Walter A.; Amphlett, Godfrey; Lambert, John M.; Zhang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1806-1814</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Recombinant monoclonal antibody drug products play an increasingly important role in the treatment of various diseases.  Antibodies are large, multi-chain proteins and antibody prepns. often contain several mol. variants, which renders them heterogeneous.  The heterogeneity is further increased in immunoconjugates prepd. by covalently linking several drug mols. per antibody mol.  As part of the product characterization, the mol. wts. of the antibodies or their drug conjugates need to be measured.  Electrospray ionization mass spectrometry (ESI-MS) is well suited for the anal. of recombinant antibodies and immunoconjugates.  Sample prepn. is an important element of ESI-MS anal., in particular samples need to be freed of interfering charged species, such as salts and buffer components.  In this paper, Amicon centrifugal filters, reversed-phase high-performance liq. chromatog. (HPLC), and size-exclusion HPLC were evaluated for sample desalting.  Size-exclusion HPLC, using aq. acetonitrile as the mobile phase, directly coupled to ESI-MS provided the best performance and was optimized for the study of immunoconjugates.  The results showed that antibodies carrying covalently linked maytansinoid mols. generated charge envelope profiles that differ from those of the non-conjugated antibody.  For the detn. of the distribution of the various conjugate species in an immunoconjugate sample prepd. by randomly linking in the av. 3.6 drug mols. per antibody mol., the exptl. conditions needed to be carefully selected to allow acquisition of the whole spectrum contg. the charge envelopes of all species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruiBJzbRAMY7Vg90H21EOLACvtfcHk0lgZML5fK2cWQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVegt70%253D&md5=678eee93e086e099fa72f4d2d79e6646</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Frcm.1987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1987%26sid%3Dliteratum%253Aachs%26aulast%3DLazar%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DAmphlett%26aufirst%3DG.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DAnalysis%2520of%2520the%2520composition%2520of%2520immunoconjugates%2520using%2520size-exclusion%2520chromatography%2520coupled%2520to%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2005%26volume%3D19%26spage%3D1806%26epage%3D1814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Sutherland, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreyka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span> </span><span class="NLM_article-title">Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">10540</span><span class="NLM_x">–</span> <span class="NLM_lpage">10547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=10540-10547&author=M.+S.+Sutherlandauthor=R.+J.+Sandersonauthor=K.+A.+Gordonauthor=J.+Andreykaauthor=C.+G.+Cervenyauthor=C.+Yuauthor=T.+S.+Lewisauthor=D.+L.+Meyerauthor=R.+F.+Zabinskiauthor=S.+O.+Doroninaauthor=P.+D.+Senterauthor=C.+L.+Lawauthor=A.+F.+Wahl&title=Lysosomal+trafficking+and+cysteine+protease+metabolism+confer+target-specific+cytotoxicity+by+peptide-linked+anti-CD30-auristatin+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%2BS.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DGordon%26aufirst%3DK.%2BA.%26aulast%3DAndreyka%26aufirst%3DJ.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DT.%2BS.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DLaw%26aufirst%3DC.%2BL.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26atitle%3DLysosomal%2520trafficking%2520and%2520cysteine%2520protease%2520metabolism%2520confer%2520target-specific%2520cytotoxicity%2520by%2520peptide-linked%2520anti-CD30-auristatin%2520conjugates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D10540%26epage%3D10547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Drake, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvain, S. M.</span><span> </span><span class="NLM_article-title">The reaction of organic halides with piperidine. IV. Bromo esters</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1934</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja01318a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1934&pages=697-700&author=W.+V.+Drakeauthor=S.+M.+McElvain&title=The+reaction+of+organic+halides+with+piperidine.+IV.+Bromo+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja01318a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01318a050%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DW.%2BV.%26aulast%3DMcElvain%26aufirst%3DS.%2BM.%26atitle%3DThe%2520reaction%2520of%2520organic%2520halides%2520with%2520piperidine.%2520IV.%2520Bromo%2520esters%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1934%26volume%3D56%26spage%3D697%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Awasthi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhal, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saini, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandya, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pikula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandorowicz-Pikula, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimniak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awasthi, Y. C.</span><span> </span><span class="NLM_article-title">Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">9327</span><span class="NLM_x">–</span> <span class="NLM_lpage">9334</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi992964c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=9327-9334&author=S.+Awasthiauthor=J.+Chengauthor=S.+S.+Singhalauthor=M.+K.+Sainiauthor=U.+Pandyaauthor=S.+Pikulaauthor=J.+Bandorowicz-Pikulaauthor=S.+V.+Singhauthor=P.+Zimniakauthor=Y.+C.+Awasthi&title=Novel+function+of+human+RLIP76%3A+ATP-dependent+transport+of+glutathione+conjugates+and+doxorubicin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi992964c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi992964c%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DSinghal%26aufirst%3DS.%2BS.%26aulast%3DSaini%26aufirst%3DM.%2BK.%26aulast%3DPandya%26aufirst%3DU.%26aulast%3DPikula%26aufirst%3DS.%26aulast%3DBandorowicz-Pikula%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DS.%2BV.%26aulast%3DZimniak%26aufirst%3DP.%26aulast%3DAwasthi%26aufirst%3DY.%2BC.%26atitle%3DNovel%2520function%2520of%2520human%2520RLIP76%253A%2520ATP-dependent%2520transport%2520of%2520glutathione%2520conjugates%2520and%2520doxorubicin%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D9327%26epage%3D9334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0liD_T50w5Ov1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambudkar, S. V.</span><span> </span><span class="NLM_article-title">Overview: ABC transporters and human disease</span> <span class="citation_source-journal">J. Bioenerg. Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1023%2FA%3A1012866803188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=11804186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=453-458&author=M.+M.+Gottesmanauthor=S.+V.+Ambudkar&title=Overview%3A+ABC+transporters+and+human+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Overview: ABC transporters and human disease</span></div><div class="casAuthors">Gottesman, Michael M.; Ambudkar, Suresh V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-458</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">A review.  ABC transporters are found in all known organisms, and approx. 1,100 different transporters belonging to this family have been described in the literature.  The family is defined by homol. within the ATP-binding cassette (ABC) region, which extends outside of the more typical Walker motifs found in all ATP-binding proteins.  Most family members also contain transmembrane domains involved in recognition of substrates, which are transported across, into, and out of cell membranes, but some members utilize ABCs as engines to regulate ion channels.  There are approx. 50 known ABC transporters in the human, and there are currently 13 genetic diseases assocd. with defects in 14 of these transporters.  The most common genetic disease conditions include cystic fibrosis, Stargardt disease, age-related macular degeneration, adrenoleukodystrophy, Tangier disease, Dubin-Johnson syndrome and progressive familial intrahepatic cholestasis.  At least 8 members of this family are involved in the transport of a variety of amphipathic compds., including anticancer drugs, and some appear to contribute to the resistance of cancer cells to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMu6ktbmOQNLVg90H21EOLACvtfcHk0liD_T50w5Ov1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVymuw%253D%253D&md5=86de63d7320866aee7f6e8dd57b9a1de</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012866803188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012866803188%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26atitle%3DOverview%253A%2520ABC%2520transporters%2520and%2520human%2520disease%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2001%26volume%3D33%26spage%3D453%26epage%3D458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Raviv, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggemann, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">3975</span><span class="NLM_x">–</span> <span class="NLM_lpage">3980</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm2002958&amp;key=10.1016%2FS0021-9258%2819%2939690-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm2002958&amp;key=1968065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm2002958&amp;key=1%3ACAS%3A528%3ADyaK3cXhslWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1990&pages=3975-3980&author=Y.+Ravivauthor=H.+B.+Pollardauthor=E.+P.+Bruggemannauthor=I.+Pastanauthor=M.+M.+Gottesman&title=Photosensitized+labeling+of+a+functional+multidrug+transporter+in+living+drug-resistant+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells</span></div><div class="casAuthors">Raviv, Yossef; Pollard, Harvey B.; Bruggemann, Edward P.; Pastan, Ira; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3975-80</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A 170,000-Da glycoprotein (P170 multidrug transporter) becomes specifically labeled in multidrug-resistant human KB carcinoma cells by the photolabile lipophilic membrane probe 5-[125I]iodonaphthalene-1-azide ([125I]INA) when photoactivation of the probe is triggered by energy transfer from intracellular doxorubicin or rhodamine 123.  In contrast, in drug-sensitive cells, drug-induced specific labeling of membrane proteins with [125I]INA was not obsd.  Instead, multiple membrane proteins became labeled in a nonspecific manner.  This phenomenon of drug-induced specific labeling of P170 by [125I]INA is obsd. only in living cells, but not in purified membrane vesicles or lysed cells.  It is generated by doxorubicin and rhodamine 123, drugs that are chromophores and to which the cells exhibit resistance; but it is not obsd. with other drugs or dyes.  Verapamil, a calcium channel blocker which reverses resistance to doxorubicin, also abolishes doxorubicin-induced specific [125I]INA labeling of P170.  These results reveal that a specific interaction between P170 and doxorubicin takes place in living cells and demonstrate that P170 is directly involved in the mechanism of drug resistance in vivo.  They also provide a possible means to label functional domains in the multidrug transporter.  The results demonstrate that photosensitized [125I]INA labeling is a technique which provides sufficient spatial and time resoln. to detect specific intracellular interactions between chromophores and proteins in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphFkvZS77SHbVg90H21EOLACvtfcHk0liD_T50w5Ov1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslWrtbc%253D&md5=20c20a46b0b6b90acb1c2893e3bf55fd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2939690-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252939690-5%26sid%3Dliteratum%253Aachs%26aulast%3DRaviv%26aufirst%3DY.%26aulast%3DPollard%26aufirst%3DH.%2BB.%26aulast%3DBruggemann%26aufirst%3DE.%2BP.%26aulast%3DPastan%26aufirst%3DI.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DPhotosensitized%2520labeling%2520of%2520a%2520functional%2520multidrug%2520transporter%2520in%2520living%2520drug-resistant%2520tumor%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1990%26volume%3D265%26spage%3D3975%26epage%3D3980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates designed to bypass multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2528-2537&author=Y.+V.+Kovtunauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=G.+E.+Jonesauthor=H.+Dohertyauthor=E.+K.+Maloneyauthor=H.+K.+Ericksonauthor=X.+Sunauthor=S.+Wilhelmauthor=O.+Abauthor=K.+C.+Laiauthor=W.+C.+Widdisonauthor=B.+Kelloggauthor=H.+Johnsonauthor=J.+Pinkasauthor=R.+J.+Lutzauthor=R.+Singhauthor=V.+S.+Goldmacherauthor=R.+V.+Chari&title=Antibody%E2%80%93maytansinoid+conjugates+designed+to+bypass+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DDoherty%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKellogg%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DH.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%2520designed%2520to%2520bypass%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a href="/doi/suppl/10.1021/jm2002958">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11478"></div></div></div></div></div><hr /></hr><p class="last">HPLC purity data and UV chromatographic profiles for target compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2002958/suppl_file/jm2002958_si_001.pdf">jm2002958_si_001.pdf (244.7 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm2002958&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm2002958%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-10%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm2002958" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994a81183d3cf4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
